## Brazilian Guidelines for In-office and Out-of-office Blood Pressure Measurement – 2023

**Development:** Brazilian Society of Cardiology, Brazilian Society of Hypertension, Brazilian Society of Nephrology

General coordinator: Audes Diogenes de Magalhães Feitosa

**Coordinators:** Audes Diogenes de Magalhães Feitosa, Celso Amodeo, Decio Mion Junior, Fernando Nobre, Marco Antonio Mota-Gomes, Paulo Cesar Brandão Veiga Jardim, Weimar Kunz Sebba Barroso, Wilson Nadruz Junior

**Guideline Authors:** Audes Diogenes de Magalhães Feitosa,<sup>1,2,3</sup> Weimar Kunz Sebba Barroso,<sup>4</sup> Decio Mion Junior,<sup>5</sup> Fernando Nobre,<sup>6</sup> Marco Antonio Mota-Gomes,<sup>7,8,9</sup> Paulo Cesar Brandão Veiga Jardim,<sup>4</sup> Celso Amodeo,<sup>10</sup> Adriana Camargo Oliveira,<sup>11</sup> Alexandre Alessi,<sup>12</sup> Ana Luiza Lima Sousa,<sup>13</sup> Andréa Araujo Brandão,<sup>14</sup> Andrea Pio-Abreu,<sup>5</sup> Andrei C. Sposito,<sup>15</sup> Angela Maria Geraldo Pierin,<sup>16</sup> Annelise Machado Gomes de Paiva,<sup>7,8</sup> Antonio Carlos de Souza Spinelli,<sup>17</sup> Carlos Alberto Machado,<sup>18</sup> Carlos Eduardo Poli-de-Figueiredo,<sup>19</sup> Cibele Isaac Saad Rodrigues,<sup>20</sup> Claudia Lucia de Moraes Forjaz,<sup>21</sup> Diogo Pereira Santos Sampaio,<sup>22</sup> Eduardo Costa Duarte Barbosa,<sup>23</sup> Elizabete Viana de Freitas,<sup>24</sup> Elizabeth do Espirito Santo Cestario,<sup>25</sup> Elizabeth Silaid Muxfeldt,<sup>26,27</sup> Emilton Lima Júnior,<sup>26</sup> Erika Maria Gonçalves Campana,<sup>14</sup> Fabiana Gomes Aragão Magalhães Feitosa,<sup>1,2,29</sup> Fernanda Marciano Consolim-Colombo,<sup>30</sup> Fernando Antônio de Almeida,<sup>200</sup> Giovanio Vieira da Silva,<sup>56</sup> Heitor Moreno Júnior,<sup>15</sup> Helius Carlos Finimundi,<sup>31</sup> Isabel Cristina Britto Guimarães,<sup>32</sup> João Roberto Gemelli,<sup>33</sup> José Augusto Soares Barreto-Filho,<sup>34</sup> José Fernando Vilela-Martin,<sup>35</sup> José Marcio Ribeiro,<sup>36,37</sup> Juan Carlos Yugar-Toledo,<sup>35</sup> Lucélia Batista Neves Cunha Magalhães,<sup>38</sup> Luciano F. Drager,<sup>56</sup> Luiz Aparecido Bortolotto,<sup>30</sup> Marco Antonio de Melo Alves,<sup>39</sup> Marcus Vinícius Bolívar Malachias,<sup>36,40</sup> Mario Fritsch Toros Neves,<sup>14</sup> Mayara Cedrim Santos,<sup>1,3</sup> Nelson Dinamarco,<sup>41</sup> Osni Moreira Filho,<sup>42</sup> Oswaldo Passarelli Júnior,<sup>43</sup> Priscila Valverde de Oliveira Vitorino,<sup>44</sup> Roberto Dischinger Miranda,<sup>45</sup> Rodrigo Bezerra,<sup>2,46</sup> Rodrigo Pinto Pedrosa,<sup>20</sup> Rogerio Baumgratz de Paula,<sup>47</sup> Rogério Toshiro Passos Okawa,<sup>48</sup> Rui Manuel dos Santos Póvoa,<sup>45</sup> Sandra C. Fuchs,<sup>49</sup> Sandro Gonçalves de Lima,<sup>15</sup> Sayuri Inuzuka,<sup>50</sup> Sebastião Rodrigues Ferreira-Filho,<sup>51</sup> Silvio Hock de Paffer Filho,<sup>52</sup> Thiago de Souza Veiga Jardim,<sup>53</sup> Vanildo da Silva Guimarães Neto,<sup>54</sup> Vera Hermina Kalika Koch,<sup>55</sup> Waléria Dantas

Universidade Federal de Pernambuco (UFPE),<sup>1</sup> Recife, PE – Brazil Pronto Socorro Cardiológico de Pernambuco (PROCAPE),<sup>2</sup> Recife, PE – Brazil Instituto de Assistência, Pesquisa e Ensino em Saúde (IAPES),<sup>3</sup> Recife, PE – Brazil Faculdade de Medicina da Universidade Federal de Goiás (UFG),<sup>4</sup> Goiânia, GO – Brazil Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP),<sup>5</sup> São Paulo, SP – Brazil Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo,<sup>6</sup> Ribeirão Preto, SP – Brazil Centro Universitário CESMAC,7 Maceió, AL – Brazil Hospital do Coração de Alagoas,8 Maceió, AL – Brazil Centro de Pesquisas Clínicas Dr. Marco Mota, Maceió,<sup>9</sup> AL – Brazil Hcor, Associação Beneficente Síria, 10 São Paulo, SP – Brazil Liga de Hipertensão Arterial da Universidade Federal de Goiás (UFG), <sup>11</sup> Goiânia, GO – Brazil Universidade Federal do Paraná (UFPR),12 Curitiba, PR – Brazil Faculdade de Enfermagem da Universidade Federal de Goiás (UFG), <sup>13</sup> Goiânia, GO – Brazil Universidade do Estado do Rio de Janeiro (UERJ),14 Rio de Janeiro, RJ – Brazil Universidade Estadual de Campinas (UNICAMP), 15 Campinas, São Paulo – Brazil Universidade de São Paulo (USP), 16 São Paulo, SP – Brazil Cardiocentro,17 Natal, RN – Brazil Secretaria Municipal de Saúde de Campos do Jordão, 18 Campos do Jordão, SP – Brazil Pontifícia Universidade Católica do Rio Grande do Sul, 19 Porto Alegre, RS – Brazil Pontifícia Universidade Católica de São Paulo, Faculdade de Ciências Médicas e da Saúde,<sup>20</sup> Sorocaba, SP – Brazil Escola de Educação Física e Esporte da Universidade de São Paulo (USP),<sup>21</sup> São Paulo, SP – Brazil Hospital das Clínicas da Universidade Federal de Goiás, 22 Goiânia, GO – Brazil Universidade FEEVALE, 23 Porto Alegre, RS – Brazil

## **DOI:** https://doi.org/10.36660/abc.20240113i

Sociedade Brasileira de Geriatria e Gerontologia,<sup>24</sup> Rio de Janeiro, RJ – Brazil Centro Universitário de Votuporanga (UNIFEV),<sup>25</sup> Votuporanga, SP – Brazil Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho – Programa de Hipertensão Arterial Resistente (ProHArt),<sup>26</sup> Rio de Janeiro, RJ – Brazil Instituto de Educação Médica (IDOMED) - Universidade Estácio de Sá,<sup>27</sup> Rio de Janeiro, RJ – Brazil Pontifícia Universidade Católica do Paraná,28 Curitiba, PR – Brazil Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), 29 Recife, PE – Brazil Instituto do Coração da Faculdade de Medicina da Universidade de São Paulo (Incor/FMUSP), 30 São Paulo, SP – Brazil Universidade de Caxias do Sul (UCS),<sup>31</sup> Caxias do Sul, RS – Brazil Universidade Federal da Bahia (UFBA), 32 Salvador, BA – Brazil Governo do Estado de Rondônia,<sup>33</sup> Porto Velho, RO – Brazil Universidade Federal de Sergipe,<sup>34</sup> São Cristóvão, SE – Brazil Faculdade de Medicina de São José do Rio Preto (FAMERP),35 São José do Rio Preto, SP – Brazil Faculdade Ciências Médicas de Minas Gerais,<sup>36</sup> Belo Horizonte, MG – Brazil Hospital Felício Rocho,37 Belo Horizonte, MG – Brazil Faculdade Zarns,<sup>38</sup> Salvador, BA – Brazil Hospital Esperança Recife, 39 Ilha do Leite, Recife, PE – Brazil Fundação Educacional Lucas Machado (FELUMA),<sup>40</sup> Belo Horizonte, MG – Brazil Colegiado de Medicina – Universidade Estadual de Santa Cruz (UESC),<sup>41</sup> Ilhéus, BA – Brazil Clínica Gapski Moreira,<sup>42</sup> Curitiba, PR – Brazil Instituto Dante Pazzanese de Cardiologia,43 São Paulo, SP – Brazil Pontifícia Universidade Católica de Goiás, 44 Goiânia, GO – Brazil Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP),<sup>45</sup> São Paulo, SP – Brazil Laboratório de Imunopatologia Keizo Asami da Universidade Federal de Pernambuco,46 Recife, PE – Brazil Universidade Federal de Juiz de Fora, 47 Juiz de Fora, MG – Brazil Universidade Estadual de Maringá, <sup>48</sup> Maringá, PR – Brazil Universidade Federal do Rio Grande do Sul (UFRGS),49 Porto Alegre, RS – Brazil Unidade de Hipertensão Arterial – NIPEE – LHA/UFG, 50 Goiânia, GO – Brazil Nefroclinica de Uberlândia, 51 Uberlândia, MG – Brazil Faculdade de Medicina de Olinda.<sup>52</sup> Olinda. PE – Brazil Hospital do Coração de Goiás, 53 Goiânia, GO – Brazil Diagnóstico Cardíaco,54 Recife, PE – Brazil Instituto da Criança e do adolescente do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP),<sup>55</sup> São Paulo, SP – Brazil Universidade Estadual de Ciências da Saúde de Alagoas (UNCISAL),56 Maceió, AL – Brazil

**SBC Clinical Practice Guidelines Committee:** Carisi Anne Polanczyk (Coordinator), Humberto Graner Moreira, Mário de Seixas Rocha, Jose Airton de Arruda, Pedro Gabriel Melo de Barros e Silva – Period 2022-2023

**How to cite this Guideline:** Feitosa ADM, Barroso WKS, Mion Junior D, Nobre F, Mota-Gomes MA, Jardim PCB, et al. Brazilian Guidelines for In-Office and Out-of-Office Blood Pressure Measurement – 2023. Arq Bras Cardiol. 2024;121(4):e20240113

**Note:** These guidelines are for information purposes and should not replace the clinical judgment of a physician, who must ultimately determine the appropriate treatment for each patient.

**Correspondence:** Sociedade Brasileira de Cardiologia – Av. Marechal Câmara, 360/330 – Centro – Rio de Janeiro, Brazil – Postal Code 20020-907. E-mail: diretrizes@cardiol.br

Adriana Camargo Diiveiracontrolling owner, business partner, shareholder or participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Brace Pharms; EMS; Servier; Biolab. Other relationships Funding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Biolab: Bivolet; EMS; Xakilis.Alexandre AlessiNothing to be declaredAna Luiza Lima SousaNothing to be declaredAndréa Araujo BrandãoNothing to be declaredAndréa C. SpositoFunding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novo Nordisk; Novartis.Angela Maria Geraido PierinNothing to be declaredAnnelise Machado Gomes de PaivaNothing to be declaredAntonio Carlos de Souza SpinelliFinancial declaredion - Novo Nordisk; Novartis.Antonio Carlos de Souza SpinelliFinancial declaredion, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novo Nordisk; Ozempic; Dailchi Sankyo: Benicar Tripio; Torrent: Rosucor; Boehringer: Jardiance. Other relations	The report below lists declaration	ons of interest as reported to the SBC by the experts during the period of the development of these	
Financial declaration       A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participant; any payments received for lecture lessons, training instructions, compensation, fees paid for participant; any payments received for lecture deupiment and implants industry:         - Brace Pharma; EMS; Servier; Biolab.         Other relationships         Funding of continuing medical education activities, including travel, accommodation and registratit in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prostness equipment and implants industry:         - Biolab: Bivolet; EMS: Xakiis.         Alexandre Alessi       Nothing to be declared         Andrea Pio-Abreu       Nothing to be declared         Andrea Pio-Abreu       Nothing to be declared         Andrei C. Sposito       Other relationships         Funding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry:         - Novo Nordisk; Novartis.       Nothing to be declared         Andrei C. Sposito       Financial declaration         Anterio Carlos de Souza Sp		statement, 2021-2023.	
A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person in wind with you, (iii) any legal person in wind wind you for base is either a direct or infine lessons, training instructuot, compensation, Ges paid for participant, any payments received for lecture lessons, training instructuotis, compensation, Ges paid for participant, any payments received for lecture equipment and implants industry:	Expert	Type of relationship with industry	
Ana Luiza Lima Sousa         Nothing to be declared           Andréa Araujo Brandão         Nothing to be declared           Andrea Pio-Abreu         Nothing to be declared           Other relationships         Funding of continuing medical education activities, including travel, accommodation and registrativi in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novo Nordisk, Novartis.           Angela Maria Geraldo Pierin         Nothing to be declared           Annelise Machado Gomes de Paiva         Nothing to be declared           Financial declaration         A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prostegioupment and implants industry:           Antonio Carlos de Souza Spinelli         equipment and implants industry:           Antonio Garlos de Souza Spinelli         equipment and implants industry:           Antonio Carlos de Souza Spinelli         equipment and implants industry:           Antonio Carlos de Souza Spinelli         equipment and implants industry:           Antonio Carlos de Souza Spinelli         equipment and implants industry:           Antonio Carlos de Souza Spinelli         equipment and implants industry:	Adriana Camargo Oliveira	<ul> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry:</li> <li>Brace Pharma; EMS; Servier; Biolab.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> </ul>	
Andréa Araujo Brandão         Nothing to be declared           Andréa Pio-Abreu         Nothing to be declared           Andrei C. Sposito         Chter relationships Funding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novo Nordisk; Novartis.           Angela Maria Geraldo Pierin         Nothing to be declared           Annelise Machado Gomes de Paiva         Nothing to be declared           Annelise Machado Gomes de Paiva         Nothing to be declared           Financial declaration         A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships Funding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance.           Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct	Alexandre Alessi	Nothing to be declared	
Andrea Pio-Abreu         Nothing to be declared           Andrei C. Sposito         Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry: - Novo Nordisk; Novartis.           Angela Maria Geraldo Pierin         Nothing to be declared           Annelise Machado Gomes de Paiva         Nothing to be declared           Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance.           Audes Diogenes de Magalhães Feitosa         Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or	Ana Luiza Lima Sousa	Nothing to be declared	
Andrei C. Sposito       Other relationships         Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: <ul> <li>Novo Nordisk; Novartis.</li> </ul> Angela Maria Geraldo Pierin       Nothing to be declared         Annelise Machado Gomes de Paiva       Nothing to be declared         Financial declaration       A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosteguipment and implants industry: <ul> <li>Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry:       <ul> <li>Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance.</li> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participation</li></ul></li></ul>	Andréa Araujo Brandão	Nothing to be declared	
Andrei C. SpositoFunding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry: - Novo Nordisk; Novartis.Angela Maria Geraldo PierinNothing to be declaredAnnelise Machado Gomes de PaivaNothing to be declaredAnnolise Machado Gomes de PaivaNothing to be declaredAnnolise Machado Gomes de PaivaFinancial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participant; any payments received for lecture lessons, training instruction, compensation, fies paid for participant; any payments received for lecture lessons, training instruction, compensation, fies paid for participant; any payments received for lecture lessons, training instruction, compensation, fies paid for participant; any payments received for lecture lessons, training instruction, compensation, fies paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (ii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments recei	Andrea Pio-Abreu	Nothing to be declared	
Annelise Machado Gomes de Paiva         Nothing to be declared           Annelise Machado Gomes de Paiva         Nothing to be declared           Financial declaration         A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosequipment and implants industry:           - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships           Funding of continuing medical education activities, including travel, accommodation and registratic in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry:           - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships           Financial declaration           A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prostesi equipment and implants industry:           - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. </td <td>Andrei C. Sposito</td> <td>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</td>	Andrei C. Sposito	Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:	
Antonio Carlos de Souza Spinelli Antonio Carlos de Souza Spinelli Antonio Carlos de Souza Spinelli Antonio Carlos de Magalhães Financial declaration Antonio Carlos de Souza Spinelli Antonio Carlos de Souz	Angela Maria Geraldo Pierin	Nothing to be declared	
A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships Funding of continuing medical education activities, including travel, accommodation and registratio in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance. Other relationships Funding of continuing medical education activities, including travel, accommodation and registratio in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi equipment and implants industry: - Novonordisk: Ozempic; Daiichi Sankyo: Benicar Triplo; Torrent: Rosucor; Boehringer: Jardiance.Audes Diogenes de Magalhães FeitosaFinancial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Omron Consultant; classes for Omron, Micromed and Cardios. Other relationships Funding	Annelise Machado Gomes de Paiva	Nothing to be declared	
A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indire controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investig boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Omron Consultant; classes for Omron, Micromed and Cardios. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesi	Antonio Carlos de Souza Spinelli	<ul> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indir controlling owner, business partner, shareholder or participant; any payments received for lecture lessons, training instruction, compensation, fees paid for participation in advisory boards, investi boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, pro equipment and implants industry:</li></ul>	
- Omron.		<ul> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry:</li> <li>Omron Consultant; classes for Omron, Micromed and Cardios.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> </ul>	

Carlos Eduardo Poli-de-Figueiredo	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>AstraZeneca/Alexion: HUS and Chronic kidney disease; Bayer: Chronic kidney disease; Fresenius, Life and Baxter: Dialysis. Organization of the MAYOPUCRS 2023 event and other congresses of Medical Societies with support from companies. No conflicts in the area of hypertension.</li> <li>B - Research funding under your direct/personal responsibility (directed to the department or institution) from the Brazilian or international pharmaceutical, orthosis, equipment and implants industry:</li> <li>Researcher at the PUCRS Clinical Research Center. No studies at the moment.</li> <li>Outros relacionamentos</li> <li>Any economically relevant equity interest in companies in the healthcare or education industry or in any companies competing with or supplying to SBC:</li> <li>Doctor's office (Nefromonitoriza).</li> <li>Participation in procurement committees for supplies or drugs in health institutions or any similar roles taken:</li> <li>Head of Nephrology Service at HSL/PUCRS until 2023.</li> <li>Participation in government-related regulatory authorities or advocacy authorities in cardiology:</li> <li>Participation in studies funded by the Ministry of Health, CNPq and CAPES.</li> </ul>	
Celso Amodeo	Nothing to be declared	
Cibele Isaac Saad Rodrigues	rigues Nothing to be declared	
Claudia Lucia de Moraes Forjaz	Nothing to be declared	
Décio Mion Junior	Nothing to be declared	
Diogo Pereira Santos Sampaio	Nothing to be declared	
Eduardo Costa Duarte Barbosa	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>- Cardios: Arteris; Brace Pharma: Olmy Anlo; Servier: Triplixam; EMS: Bramicar.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>- Servier: Triplixam.</li> </ul>	
Elizabete Viana de Freitas	Nothing to be declared	
Elizabeth do Espírito Santo Cestario	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Servier: Triplixam; Torrent: Rosucor.</li> <li>B - Research funding under your direct/personal responsibility (directed to the department or institution) from the Brazilian or international pharmaceutical, orthosis, equipment and implants industry:</li> <li>Servier: Vastarel; Libbs: Hipertensão.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, erosthesis, equipment and implants industry:</li> <li>Servier: Torrent.</li> </ul>	

Elizabeth Silaid Muxfeldt	Nothing to be declared
Emilton Lima Júnior	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Servier: Hypertension; Novo Nordisk: Diabetes/Obesity; Daiichi Sankyo: Liliana; Chiesi: COPD; Novartis: Dyslipidemia.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Servier: Hypertension; Novo Nordisk: Diabetes/Obesity; Daiichi Sankyo: Liliana; Chiesi: COPD; Novartis: Dyslipidemia.</li> </ul>
<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/pail other person living with you, (iii) any legal person in which any of these is either a controlling owner, business partner, shareholder or participant; any payments receively lessons, training instruction, compensation, fees paid for participation in advisory beoards or other committees, etc. From the brazilian or international pharmaceutical, equipment and implants industry:         <ul> <li>Servier: Perindopril/Hypertension; Biolab: Pressplus/Hypertension.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation in conferences and courses, from the brazilian or international pharmaceutical, equipment and implants industry:             <ul></ul></li></ul></li></ul>	
Fabiana Gomes Aragão Magalhães Feitosa	Nothing to be declared
<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or other person living with you, (iii) any legal person in which any of these is either a direct or controlling owner, business partner, shareholder or participant; any payments received for l lessons, training instruction, compensation, fees paid for participation in advisory boards, in boards or other committees, etc. From the brazilian or international pharmaceutical, orthosi equipment and implants industry:</li></ul>	
Fernando Antônio de Almeida	Nothing to be declared
Fernando Nobre	Nothing to be declared
Giovanio Vieira da Silva	Nothing to be declared
Heitor Moreno Júnior	Nothing to be declared
Helius Carlos Finimundi	Nothing to be declared
Isabel Cristina Britto Guimarães	Nothing to be declared
	Financial declaration
João Roberto Gemelli	<ul> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Servier; Boerinhger; AstraZeneca; Libbs.</li> </ul>

lacé Formando Vilala Martin	Nothing to be deployed	
José Fernando Vilela-Martin	Nothing to be declared	
José Marcio Ribeiro	Nothing to be declared	
Juan Carlos Yugar-Toledo	Nothing to be declared	
Lucélia Batista Neves Cunha Magalhães Construities and courses, from the brazilian or international pharmaceutical, orthosis, equipment and implants industry: - AstraZeneca: Selozok; Farmoquímica: Exforge.		
Luciano Ferreira Drager	Nothing to be declared	
Luiz Aparecido Bortolotto	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry:</li> <li>GSK: Shingrix; Servier: Triplicam.</li> </ul>	
Marco Antonio de Melo Alves	Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Torrent: Dyslipidemia/Hypertension.	
Marco Antonio Mota-Gomes	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry:</li> <li>Omron: Equipment; Biolab: Press Plus; Daiichi Sankyo: Benicar Triplo; AstraZeneca: Forxiga; Ache: Edistride.</li> <li>B - Research funding under your direct/personal responsibility (directed to the department or institution from the Brazilian or international pharmaceutical, orthosis, equipment and implants industry:</li> <li>Novartis: Inclisiran; Libbs: Associação Tripla; Servier: Associação Quádrupla.</li> </ul>	
Marcus Vinícius Bolívar Malachias	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry:</li> <li>Boehringer Ingelheim/Lilly: diabetes; Daiichi Sankyo: Hypertension; Libbs: Hypertension, Roche: Biomarkers; Novo Nordisk: Diabetes; Bayer: Diabetes; Novartis: Heart Failure; Viatris: Heart Failure; Servier: Heart Failure.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Boehringer Ingelheim/Lilly: Diabetes; Daiichi Sankyo: Hypertension; Libbs: Hypertension, Novo Nordist, Diabetes; Bayer: Diabetes; Including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Boehringer Ingelheim/Lilly: Diabetes; Daiichi Sankyo: Hypertension; Libbs: Hypertension, Novo Nordist Diabetes; Bayer: Diabetes.</li> <li>Any economically relevant equity interest in companies in the healthcare or education industry or in any companies competing with or supplying to SBC:</li> </ul>	
	- Institute of Arterial Hypertension of Minas Gerais: health services; Cardio Check Up: services in the health sector.	
Mario Fritsch Toros Neves		
Mario Fritsch Toros Neves Mayara Cedrim Santos	health sector.	

Osni Moreira Filho	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Daiichi Sankyo: Benicar Triplo; Servier: Triplixam.</li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry:</li> <li>Torrent: Arterial Hypertension; Servier: Arterial Hypertension.</li> </ul>	
Oswaldo Passarelli Júnior	Nothing to be declared	
Paulo Cesar Brandão Veiga Jardim	Nothing to be declared	
Priscila Valverde de Oliveira Vitorino	Nothing to be declared	
Roberto Dischinger Miranda	Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Ozempic; EMS: Arterial Hypertension and Atrial Fibrillation.	
Rodrigo Bezerra	Nothing to be declared	
Rodrigo Pinto Pedrosa	Nothing to be declared	
Rogério Baumgratz de Paula	Nothing to be declared	
<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or an other person living with you, (iii) any legal person in which any of these is either a direct or in controlling owner, business partner, shareholder or participant; any payments received for lect lessons, training instruction, compensation, fees paid for participation in advisory boards, inveboards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, equipment and implants industry:</li></ul>		
Rui Manuel dos Santos Povoa	Nothing to be declared	
Sandra C. Fuchs	Nothing to be declared	
Sandro Gonçalves de Lima	Nothing to be declared	
Other relationships Funding of continuing medical education activities, including travel, accommodation and regis Sayuri Inuzuka in conferences and courses, from the brazilian or international pharmaceutical, orthosis, pros equipment and implants industry: - Servier; EMS; Daichi Sankyo.		
Sebastião Rodrigues Ferreira-Filho	Nothing to be declared	
Silvio Hock de Paffer Fillho	Nothing to be declared	
Thiago de Souza Veiga Jardim	Nothing to be declared	
Vanildo da Silva Guimarães Neto	Nothing to be declared	
Vera Hermina Kalika Koch	Nothing to be declared	
Waléria Dantas Pereira Gusmão	Nothing to be declared	

Wille Oigman Nothing to be declared	Weimar Kunz Sebba Barroso	<ul> <li>Financial declaration</li> <li>A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. From the brazilian or international pharmaceutical, orthosis, prosthesis equipment and implants industry: <ul> <li>EMS; Brace Pharma; Servier; Biolab; Omron; Cardios.</li> </ul> </li> <li>B - Research funding under your direct/personal responsibility (directed to the department or institution from the Brazilian or international pharmaceutical, orthosis, prosthesis, industry: <ul> <li>Ministry of Health; PROADI SUS; Novartis: Entresto.</li> <li>Personal research funding paid by the Brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: <ul> <li>EMS: RITMO Study; Brace Pharma: BRACE 23 Study.</li> </ul> </li> <li>Other relationships</li> <li>Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: <ul> <li>Servier; European Hypertension Meeting.</li> </ul> </li> </ul></li></ul>
	Wille Oigman	Nothing to be declared

## **Table of contents**

Updates and modifications to the Brazilian Guidelines
for In-Office and Out-of-Office Blood Pressure
Measurement
Part 1 – Blood pressure measurement 10
<b>1. Introduction</b>
2. In-office BP measurement 11
2.1. Auscultatory BP measurement
2.2. Oscillometric BP measurement with automated and
semiautomated devices 11
2.3. Steps for in-office BP measurement
2.4. Wrist and finger BP measurement
2.5. BP measurement in older patients
2.6. BP classification according to in-office measurements
3. Out-of-office BP measurement
3.1. Self-measured blood pressure (SMBP)
3.2. BP measurement in pharmacies
3.3. BP measurement in public spaces
3.4 Ambulatory blood pressure monitoring (ABPM)
3.5. Home blood pressure monitoring (HBPM)
4. Central BP measurement and derived parameters 14
5. BP measurement during exercise
Part 2 – Aspects and concepts common to
ABPM and HBPM
1. Essential aspects for establishing an
ABPM and HBPM service
2. Abnormality thresholds for in-office and out-of-office
BP measurements
2.1. Normotension and controlled hypertension
2.2. Sustained hypertension and sustained
uncontrolled hypertension
2.3. White-coat hypertension and white-coat
uncontrolled hypertension
<b>2.3.1. White-coat effect</b>
<b>2.3.2. Investigation</b>
<b>2.3.3. Prognosis</b>
2.3.4. Follow-up and treatment
2.4. Masked hypertension and masked uncontrolled hypertension 17
2.4.1. Masking effect 17
2.4.2. Investigation
2.4.3. Prognosis
2.4.4. Treatment
2.5 Resistant hypertension 17
3. Indications, advantages, and disadvantages of
ABPM and HBPM
Part 3 – Ambulatory blood pressure monitoring
(ABPM)
1. Definition
2. ABPM protocols
2.1. ABPM reproducibility
3. Guidance for patients and health professionals
3.1. Activity diary during BP measurements
3.2. General instructions
4. Interpretation of results
4.1. Criteria for interpreting BP measurements
4.2. Abnormality thresholds
4.3. BP patterns in transition periods between
daytime and nighttime
4.4. Morning BP surge 22

4.5. BP load, areas under the curves, BP variability, and heart rate	22
4.5.1. BP load	
4.5.2. Areas under the curves	22
4.5.3. BP variability	23
4.5.4. Heart rate	23
5. Interpretation of ABPM and technical report	23
5.1. Technical report	23
5.2. Systolic and diastolic BP patterns over 24 hours,	
daytime, and nighttime	23
5.3. Systolic and diastolic BP patterns in transition periods between	
daytime and nighttime	23
5.4. BP spikes and hypotension	23
5.5. Correlation between activities, medication use, and symptoms	23
5.6. Conclusion	24
6. Clinical applications of ABPM	25
6.1. Assessment of prognosis in patients with hypertension	25
6.2. Assessment of antihypertensive treatment efficacy	25
7. ABPM in special situations	25
7.1. Children and adolescents	25
7.2. Pregnant women	25
7.3. Older people	26
7.4. Diabetes	26
7.5. Chronic kidney disease	26
7.6. Obstructive sleep apnea syndrome	26
7.7 Heart failure	26
7.8. Physical activity	27
8. Cost-effectiveness	27
9. Perspectives	27
Part 4 – Home blood pressure monitoring (HBPM)	
1. Introduction	27
2. Instructions for patients	27
3. HBPM protocol	28
4. Abnormality thresholds	
5. Technical report and interpretation of results	28
6. Applications of HBPM	
6.1. Determination of in-office and out-of-office BP behavior	30
6.2. Assessment of prognosis	30
6.3. Assessment of antihypertensive treatment	30
6.4. In special populations and situations	31
6.4.1. Children and adolescents	31
6.4.2. Pregnant women	31
6.4.3. Older patients	31
6.4.4. Diabetes	31
6.4.5. Chronic kidney disease	31
6.4.6. Obesity	
6.4.7. Arrhythmias	
7. Cost-effectiveness	
8. Perspectives	32
Part 5 – Central blood pressure, pulse wave velocity, an	d
augmentation index	
1. Introduction	32
2. Definitions	32
2.1. Pulse wave velocity	32
2.2. Augmentation index	33
2.3. Central blood pressure	
3. Indications	
4. Advantages of measuring CBP, Alx, and PWV	33
5. Limitations of measuring CBP, Alx, and PWV	33
6. Techniques available for checking central and	
arterial stiffness parameters	33

6.1. Methods for indirect measurement of CBP
7. Protocols for CBP, PWV, and Alx measurements
7.1. Protocol for measuring central parameters using tonometry
7.2. Protocol for the triple-trigger procedure (in-office measurement)
using the oscillometric method
7.3. Protocol for 24-hour central BP parameter measurements
using the oscillometric method
8. Reference values
8.1 Reference values for PWV
8.2. Reference values for cSBP
8.3. Reference values for PWV, CBP, and Alx using the
oscillometric method in the Brazilian population
9. Prognostic value of BP measurements derived from
central parameters
10. Measurement of central parameters
over 24 hours
<b>11.</b> Perspectives
References

## Updates and modifications to the Brazilian Guidelines for In-Office and Out-of-Office Blood Pressure Measurement

These Guidelines revise and update the previous Guidelines for Ambulatory Blood Pressure Monitoring (ABPM) and Home Blood Pressure Monitoring (HBPM). Several relevant modifications have been made, focusing on fundamental aspects of in-office and out-of-office blood pressure (BP) measurement and monitoring, including ABPM, HBPM, self-measured blood pressure, and central blood pressure (CBP) measurement. Some of the main modifications are described below:

- The update of the 6th Brazilian ABPM Guidelines and the 4th Brazilian HBPM Guidelines, published in 2018, is now called "Brazilian Guidelines for In-Office and Out-of-Office Blood Pressure Measurement". This updated nomenclature reflects the current scope and relevance of these Guidelines, highlighting their substantial contribution to clinical practice.
- Emphasis is placed on the accuracy and quality of inoffice BP measurement.
- 3. New recommendations are provided on unattended automated in-office BP measurement.
- 4. A rigorous assessment of postural hypotension is described.
- 5. The use of BP measurements in pharmacies and public spaces to screen for hypertension is expanded.
- 6. The clinical indications for in-office and out-of-office BP measurements are updated.
- 7. The importance of BP measurements during physical exercise is acknowledged.
- Mandatory certification and validation procedures are stipulated for monitors, according to www.stridebp.org and INMETRO.

- 9. Normality threshold values for HBPM are updated.
- New behaviors identified in patients receiving antihypertensive treatment are described.
- 11. The flowchart for the assessment and management of masked and white-coat hypertension is revised.
- 12. The indications, limitations, advantages, and disadvantages of ABPM and HBPM are updated.
- 13. A new classification of normal BP values obtained by ABPM in children and adolescents is introduced.
- 14. The HBPM protocol is updated.
- 15. Updated values are introduced for determining whitecoat and masking effects on HBPM.
- 16. A new HBPM protocol is provided for patients undergoing hemodialysis.
- 17. A new chapter on CBP, pulse wave velocity (PWV), and augmentation index (Alx) is introduced, which addresses possible indications, definition of specific protocols, and reference values for PWV, CBP, and Alx measurements.

These modifications support the commitment to diagnostic accuracy and improvement of BP care, promoting clinical practices that are based on and aligned with the most recent advances in the area.

## Part 1 – Blood pressure measurement

## **1.** Introduction

Hypertension is one of the primary modifiable risk factors for morbidity and mortality worldwide. It ranks among the leading risk factors for conditions such as coronary artery disease (CAD), stroke, and renal failure. Moreover, it is highly prevalent, affecting over a third of the world's population.<sup>1-9</sup>

Blood pressure (BP) measurement is an ESSENTIAL procedure in any medical setting and can be performed by different health care professionals. However, it is still commonly performed without the necessary technical care.<sup>1-9</sup> The diagnosis of hypertension relies on accurate BP readings, emphasizing the need for meticulous attention to measurement techniques, methods, and the use of adequate equipment.<sup>1-9</sup>

Following a diagnosis of hypertension, the course of action, including short-, medium-, and long-term treatments, is decided based on the results of BP measurements. Thus, poor technique and/or the use of inadequate equipment can lead to misdiagnosis, with either underestimation or overestimation of BP values, which in turn can lead to ineffective management, potentially causing significant harm to the health and economies of patients and nations.<sup>1-11</sup>

As recognition of the importance of adequate treatment increases, characterized by the adoption of more detailed normality thresholds and meticulous treatment objectives aimed at achieving stringent BP goals, the significance of taking accurate BP measurements becomes increasingly evident.<sup>1-11</sup>

BP measurement is commonly performed at the doctor's office using the traditional method, and this is referred to as "inoffice BP measurement". Over the years, alternative methods have emerged, allowing patients to use semiautomated or automated monitors to measure BP in the waiting room or out of the office, such as in their homes or public spaces. A notable advancement occurred with the introduction of memory-equipped semiautomated monitors that take sequential out-of-office measurements (self-measured blood pressure [SMBP] and home blood pressure monitoring [HBPM]) and automated monitors that take programmed measurements for longer periods of time (ambulatory blood pressure monitoring [ABPM]).<sup>1,2,4,12,13</sup>

Some factors related to BP measurement can affect the accuracy of results, potentially complicating decision-making regarding the appropriate approach. These include the importance of using average values, BP variability throughout the day, and short-term BP variability. As a result, an increased frequency of measurements at different times of the day has been encouraged, and various guidelines have recommended the use of devices that facilitate this process. The use of HBPM and ABPM monitors is becoming increasingly common. In addition to providing more accurate measurements, they can identify white-coat hypertension (WCH), masked hypertension (MH), variations in BP during sleep, and resistant hypertension (RH), as defined in Chapter 2 of these Guidelines, if used together.<sup>1-9,14-20</sup>\_

However, it should be noted that, despite these advancements, diagnosis, classification, and goal-setting still primarily rely on in-office BP measurements. Therefore, the utmost importance should be given to this procedure.<sup>15,16,21</sup>

## 2. In-office BP measurement

## 2.1. Auscultatory BP measurement2,12,22-25

- The mercury sphygmomanometer is still considered the reference standard device for BP measurement, in addition to being useful for validating oscillometric and aneroid devices. However, in Brazil, its use in the health care setting has been banned by the Ministry of Labor (Regulatory Standard 15 125.001-9/I4).
- In many countries, mercury devices have been largely replaced by aneroid manometers. However, they are easily damaged and require frequent recalibration (at least every 12 months) to ensure their accuracy.
- Auscultatory BP measurement remains a common practice, with the use of aneroid sphygmomanometers and stethoscopes.
- The sphygmomanometer consists of a cuff, an inflatable rubber bladder, a manometer for BP measurement, and a system of valves, tubes, and an inflation bulb.
- The cuff is placed over the brachial artery and inflated, interrupting blood flow. The cuff is then gradually deflated and, as cuff pressure is lowered further, pressure generated by left ventricular contraction will pump blood into the artery and characteristic sounds known as Korotkoff sounds (Chart 1) will be heard through the stethoscope.

• The auscultatory technique requires a combination of good hearing and the ability to visually track the manometer's values to accurately identify sounds corresponding to systolic and diastolic blood pressure.

## 2.2. Oscillometric BP measurement with automated and semiautomated devices<sup>4,13,24-27</sup>

- Oscillometric BP measurement with automated or semiautomated monitors offers several advantages over the auscultatory method, mainly by eliminating or reducing observer errors and systematic rounding errors, as well as poor technique (Chart 2).
- Another advantage of these devices is that patients can take their own BP measurements without the presence of a health care professional; this is referred to as "unattended automated office BP measurement" (Chart 3). This approach improves measurement reproducibility and helps minimize the white-coat effect.
- Automated and semiautomated monitors should be validated by specific protocols. A list of validated devices can be found at the following websites: British and Irish Hypertension Society (www.bihsoc.org/bp-monitors); European Society of Hypertension – International Society of Hypertension – World Hypertension League (www.stridebp.org); and Hypertension Canada (www. hypertension.ca/bpdevices). Most devices available on the market have not been validated.
- All devices, including those validated for use in adults, should be validated for use in special populations, including children, pregnant women, older adults, patients with an arm circumference greater than 42 cm, and patients with arrhythmias.
- Automated and semiautomated monitors should be calibrated every 12 months.
- Cuffs of different dimensions should be from the same manufacturer and model as the device.

## 2.3. Steps for in-office BP measurement<sup>1,10,11,16,28,29</sup>

Special care should be taken to correctly prepare the patient and execute the procedure when taking BP measurements using either the auscultatory or oscillometric method, as detailed in Chart 4.

Assessing postural hypotension is an important part of patient evaluation, particularly for older adults, those with dysautonomia, and patients taking antihypertensive medication. In this case, BP should be measured after the patient has been in the supine position for 5 minutes, and then after the patient has been in the standing position for 1 minute and again after 3 minutes. When measuring standing BP, the patient's arm should preferably be supported by the examiner at the heart level. Postural hypotension is defined as a drop of at least 20 mm Hg in systolic BP or a drop of at least 10 mm Hg in diastolic BP in the first and/or third minute after standing from a supine position.

#### 2.4. Wrist and finger BP measurement

As previously discussed, the most commonly used and validated devices for BP measurement consist of an inflatable arm cuff used with either the auscultatory or oscillometric method, the latter including semiautomated and automated monitors. However, some devices are designed to wrap the

#### Chart 1 – Korotkoff sounds

PHASES	SOUNDS
Phase I	Appearance of a first, weak sound, followed by repetitive tapping sounds corresponding to systolic BP
Phase II	Sounds become softer and longer, like an intermittent murmur
Phase III	Sounds become crisper
Phase IV	Sounds become muffled
Phase V	Sounds corresponding to systolic BP completely disappear

## Chart 2 – Disadvantages of the auscultatory method compared with the oscillometric method

- Rounding off of the last digit of BP values to 0 or 5
- Incorrect positioning of the aneroid manometer in relation to the eye
- Excessive stethoscope pressure causing artery deformation
- · Excessive cuff inflation causing pain
- Rapid cuff deflation leading to underestimation of systolic BP and/ or overestimation of diastolic BP
- · Incorrect identification of systolic and diastolic BP sounds
- Possibility of aneroid manometer being out of calibration, even when the pointer is at zero
- · Does not allow unattended automated office BP measurement

BP: blood pressure.

#### Chart 3 – Unattended automated office BP measurement

#### Instructions

- Perform BP measurement in a calm environment, preferably an empty room
- · Explain the importance of the procedure to the patient
- Follow the patient preparation steps for BP measurement using automated monitors (Chart 4)
- · Ask everyone to leave the room
- Instruct the patient to press the Start button to begin
  measurements when alone in the room
- Instruct the patient to wait approximately 1 minute between each
  measurement
- · Instruct the patient to take 3 consecutive measurements
- Leave an illustrative leaflet with instructions on the procedure in a visible place

BP: blood pressure.

cuff around the wrist, and these may also be used with the oscillometric method (automated devices). Compared with other devices, wrist BP monitors are smaller, easier to carry, and have been increasingly used by patients for out-of-office BP monitoring. These monitors are particularly indicated for patients with severe obesity, as errors in arm BP measurement and difficulty finding appropriately sized cuffs are more common in this population. Nevertheless, wrist monitors may introduce systematic errors, as their reliability is affected by the wrist's position (height in relation to the heart) at the time of BP measurement and the frequent occurrence of artifacts. Although these devices have been improved to

#### Chart 4 – Steps for office BP measurement

#### Patient preparation

Have the patient rest for 5 minutes in a calm and comfortable environment and advise him/her not to talk or move during measurements

Make sure the patient has:

- · Emptied his/her bladder
- · Not practiced physical activity in the past 90 minutes
- Not smoked or consumed alcohol, coffee, or food in the past 30 minutes

Have the patient sit with the feet flat on the floor and legs uncrossed, back relaxed and supported by chair

Position the patient's arm at the heart level, supported, with the palm facing up and remove any restrictive clothing around the patient's arm

If this is the patient's first visit, record BP in both arms (preferably simultaneously), then use the arm with the higher reading for all measurements. Record which arm should be used for BP measurement

#### **Measurement steps**

Wrap the cuff snugly around the arm, 2 to 3 cm above the antecubital fossa, positioning the center of the cuff bladder directly over the brachial artery

#### Estimate systolic BP level\* (Chart 5)

Palpate the brachial artery on the antecubital fossa and place the stethoscope's bell or diaphragm over it without applying too much pressure.\* Do not place the stethoscope over the cuff

Rapidly inflate the cuff to 20-30 mm Hg greater than the estimated systolic value  $\!\!\!\!*$ 

Slowly deflate the cuff (approximately 2 mm Hg/s)\*

Determine systolic BP upon hearing the first sound (Korotkoff phase I)

Determine diastolic BP upon disappearance of sounds (Korotkoff phase V)\*

Continue to auscultate as you deflate the cuff for another 20-30 mm Hg below the last sound to confirm it has disappeared, then proceed to complete and rapid deflation. If the tapping sound persists after the pointer has reached the zero mark, determine diastolic BP upon muffling of sounds (Korotkoff phase IV) and record zero/diastolic/systolic BP values\*

Take 3 measurements, 1 minute apart, and use the average of the last 2 measurements. If there is a difference of > 10 mm Hg, take more measurements.

BP: blood pressure. \*Applied to the auscultatory technique

take measurements only when the position of the wrist is adequate, more consistent validation and correlation studies are still scarce.  $^{\rm 30\cdot32}$ 

Recently, new technologies for measuring BP without the use of a cuff have emerged. These devices, called "wearables", can be attached to bracelets or watches and use different technologies to measure BP, such as photoplethysmography and applanation tonometry. Although there is a lack of studies validating wearables in relation to traditional BP measurement methods, numerous devices are already available on the market. Advantages such as ease of use, nearly continuous BP monitoring, and ease of data sharing and transmission of values (which are obtained almost in real-time), in addition to the fact that some do not require calibration, have attracted a significant number of users. However, current clinical practice lacks specific recommendations for the use of these new technologies and devices in patient monitoring. We will await the conclusion and publication of clinical studies that provide scientific evidence supporting the use of these monitoring devices.<sup>30-32</sup> As for finger monitors, they are inaccurate and should be avoided.

#### 2.5. BP measurement in older patients<sup>33-35</sup>

- BP measurement in older patients may be affected by changes associated with the aging process, such as pseudohypertension, auscultatory gap, arrhythmia, and postural hypotension.
- Pseudohypertension occurs when indirect BP measurement is overestimated compared with direct BP measurement, often due to excessive atheromatosis in association or not with medial hypertrophy. In such cases, calcification causes such pronounced stiffening of the arterial wall that cuff inflation cannot collapse the brachial artery. It should be noted that the diagnosis of pseudohypertension is suspected when systolic BP is very high in the absence of target organ impairment or when the patient presents signs of hypotension. The presence of calcium on radiography can further support this diagnosis.
- Osler's maneuver may help assess pseudohypertension. It involves inflating the arm cuff until the radial pulse disappears. If the artery remains palpable after the procedure, the patient is considered Osler-positive.
- Auscultatory gap refers to the disappearance of Korotkoff sounds between the end of phase I and the beginning of phase II during cuff deflation. This gap may lead to underestimation of systolic BP or overestimation of diastolic BP. To identify and correct for an auscultatory gap, systolic BP must be estimated by the palpatory method.
- Postural, or orthostatic, hypotension is common in older adults with symptoms such as dizziness, blurred vision, scotoma, asthenia, or syncope when standing from a supine position. BP measurement in older patients should be performed with the patient in the sitting, lying, and standing position. Atherosclerotic changes in the carotid sinus region can reduce baroreceptor sensitivity, resulting in greater BP variability and impaired

postural reflexes, making these patients more prone to postural hypotension. The use of medications such as diuretics, antidepressants, vasodilators, and betablockers can also contribute to postural hypotension. Its prevalence in older adults over 75 years of age has been reported as 34%, and the condition becomes clinically significant when it manifests as postural dizziness, particularly in patients taking hypotensive medication.

 The presence of arrhythmias, such as atrial fibrillation and extrasystoles, can pose challenges when measuring BP with oscillometric devices, unless the devices are equipped with mechanisms to detect atrial fibrillation and other arrhythmias.

#### 2.6. BP classification according to in-office measurements

The classification is defined according to in-office BP measurements and the highest systolic or diastolic level. Isolated systolic hypertension is defined as systolic BP  $\geq$  140 mm Hg and diastolic BP < 90 mm Hg and is classified into stages 1, 2, and 3 (Chart 8).

It is important to emphasize that the recognition of hypertension—that is, the final diagnosis—should not be based on a single BP measurement, as BP levels may vary a lot. Therefore, in-office BP values that do not fall within the stage 3 range should be reassessed in subsequent measurements to confirm the diagnosis and determine the stage of hypertension.

For a more accurate assessment, it is recommended to perform multiple in-office BP measurements on different days, with an interval of 1 to 2 minutes between each measurement.<sup>36-39</sup>

Nonetheless, in-office (casual) measurements may sometimes be insufficient for characterizing hypertension, as they are subject to numerous biases (systematic errors) and provide fewer measurements. In cases of doubt, alternative measurement methods should be used for diagnosis and follow-up, which were mentioned in this chapter and will be further detailed in the following chapters.

## 3. Out-of-office BP measurement

## 3.1. Self-measured blood pressure (SMBP)

According to the 6th ABPM Guidelines and the 4th HBPM Guidelines, SMBP refers to BP measurements taken by the patient or a family member at home. This method does not follow any pre-established protocols—measurements are taken at the patient's discretion or at the physician's request.<sup>18</sup> Unlike ABPM and HBPM, which are performed using automated devices belonging to health institutions whose accuracy and reproducibility has been validated, SMBP is performed with the patient's own automated device.<sup>17</sup>

The 2020 Brazilian Guidelines for Hypertension made a substantial contribution to the concept of SMBP by recommending a minimum of 7 measurements to be taken over a period of 16-72 hours using quality, validated oscillometric devices. However, studies validating SMBP values in relation to cardiovascular (CV) and renal risk, as well as studies investigating the impact of random BP measurements

#### Chart 5 – How to estimate systolic blood pressure

#### **Estimation of systolic BP**

Place the cuff (Chart 6) 2 to 3 cm above the antecubital fossa, positioning the center of the cuff bladder directly over the brachial artery

#### Palpate the radial artery

Close the bulb's valve and inflate the cuff until the pulse disappears

Open the valve slowly to deflate the cuff

Identify systolic blood pressure by the palpatory method (pulse reappearance)

BP: blood pressure.

#### Chart 6 – How to measure arm circumference

#### Measurement of arm circumference

Bent the arm at the elbow at a 90-degree angle

Measure the distance between the acromion and the olecranon processes to determine the midpoint of the arm

Straighten the arm and measure the circumference at the midpoint

Choose the cuff according to arm circumference size. The width of the inflatable cuff bladder must cover 37%-50% of the arm circumference, and the length must cover 75%-100% (Chart 7).

Do not place the cuff over clothing.

#### Chart 7 – Cuff dimensions according to arm circumference

Circumference	Cuff category	Width of the inflatable cuff bladder	Length of the inflatable cuff bladder
$\leq$ 6 cm	Infant	3 cm	6 cm
6-15 cm	Small child	5 cm	15 cm
16-21 cm	Child	8 cm	21 cm
22-26 cm	Small adult	10 cm	24 cm
27-34 cm	Adult	13 cm	30 cm
35-44 cm	Large adult	16 cm	38 cm
45-52 cm	Thigh	20 cm	42 cm

Chart 8 – Classification of blood pressure (BP) according to in-office measurements in patients aged 18 years and older (GR: I – LE: C)

Classification	Systolic BP (mm Hg)	Diastolic BP (mm Hg)
Excellent	< 120 and	< 80
Normal	120-129 and/or	80-84
Prehypertension	130-139 and/or	85-89
Stage 1 hypertension	140-159 and/or	90-99
Stage 2 hypertension	160-179 and/or	100-109
Stage 3 hypertension	$\geq$ 180 and/or	≥ 110

*GR:* grade of recommendation; *LE:* level of evidence. Adapted from the Brazilian Guidelines for Hypertension (2020).<sup>1</sup>

taken without methodological rigor on medical decision-making, are lacking.<sup>1</sup>

Given the essential role of accurate BP measurements in decision-making, these Guidelines recommend applying the same care and procedures described in Chart 4 to SMBP. Nevertheless, it is important to acknowledge that there is no conclusive evidence supporting the adoption of specific protocols (regarding number of measurements, monitoring schedules, and days) or the establishment of normality thresholds for this method. Therefore, these Guidelines recommend using SMBP only for screening purposes, and confirmatory tests should be requested (HBPM or ABPM) when necessary (Chart 9).

#### 3.2. BP measurement in pharmacies

BP measurement in pharmacies is a common practice in Brazil and many other countries. This approach, which is inexpensive for patients, may be useful for hypertension screening and treatment follow-up. However, it lacks established measurement protocols that ensure the validation of devices and measurement methods. Additionally, there is a scarcity of validation studies (Chart 9) and no defined criteria for abnormality thresholds.<sup>1,5</sup>

#### 3.3. BP measurement in public spaces

Often used in educational campaigns, BP measurement in public spaces has the main advantage of screening for hypertension in the general population for subsequent diagnostic confirmation with in-office BP measurements (Chart 9). Similar to pharmacy measurements, there are no defined criteria for abnormality thresholds.<sup>1,4</sup> Therefore, individuals identified as hypertensive who were unaware of their condition, or those who are hypertensive and have not reached their BP goal, should be referred for medical follow-up.

#### 3.4. Ambulatory blood pressure monitoring (ABPM)

See Chapters 2 and 3.

3.5. Home blood pressure monitoring (HBPM)

See Chapters 2 and 4.

## 4. Central BP measurement and derived parameters

See Chapter 5.

## 5. BP measurement during exercise

In patients with poorly controlled hypertension (CH) and/ or an exaggerated BP response to exercise, it is recommended to monitor BP before and during exercise.<sup>1,40</sup>

Before initiating exercise, BP measurements should be conducted with the patient in either a seated or standing position, depending on the type of exercise that will be performed. These measurements should be performed using either the auscultatory or oscillometric method, following the previously mentioned

Clinical use	Office	НВРМ	ABPM	SMBP	Pharmacy	Public spaces
Screening	+++	+	_	++	++	+
Initial diagnosis	+	++	+++	-	-	-
Treatment titration	+	++	++	+ (?)	-	-
Follow-up	++	+++	+	+ (?)	+ (?)	-
Main indication	Follow-up of treated patients	Follow-up	Initial diagnosis	Screening	Follow-up of treated patients (?)	Opportunistic screening
Values, mm Hg	≥ 140 × 90	≥ 130 × 80	≥ 130 × 80	?	?	?

Chart 9 – Clinical indications for in-office and out-of-office BP measurement (GR: I – LE: C)

*GR:* grade of recommendation; *LE:* level of evidence; *HBPM:* home blood pressure monitoring; *ABPM:* ambulatory blood pressure monitoring; *SMBP:* self-measured blood pressure. Adapted from Stergiou et al.<sup>5</sup>

recommendations regarding body and arm positioning, prior rest time, cuff dimensions, and measurement technique.<sup>2,5</sup> Of note, exercise testing should only be conducted if systolic/diastolic BP values are equal to or lower than 160/105 mm Hg.<sup>1,40</sup>

Measuring BP during aerobic exercises may pose challenges in some instances, as accurate readings can only be obtained when the patient can maintain their arm stable at heart level. Ideally, measurements should be taken during metabolic balance, that is, after maintaining intensity for at least 3 minutes. Given the scarcity of automated monitors validated for this purpose, the auscultatory method is recommended.<sup>41</sup> If systolic/diastolic BP values during aerobic exercise are greater than 180/ 105 mm Hg, exercise intensity should be reduced.<sup>1,40</sup>

In exercise testing, due to the progressive increase in intensity at different intervals, BP measurement should be performed as recommended in each protocol. $^{40,41}$ 

It is not recommended to measure BP during dynamic resistance training, as neither the auscultatory nor oscillometric method has been validated for this purpose, potentially leading to inaccurate measurements.<sup>41</sup>

# Part 2 – Aspects and concepts common to ABPM and HBPM

# **1**. Essential aspects for establishing an ABPM and HBPM service

To create or continue an ABPM and HBPM service, regardless of its management or location, some basic principles must be met, as defined in Chart 10.

ABPM and/or HBPM devices must be automated, digital, and use a validated oscillometric method, with data storage that allows issuing a report. These monitors must have a certificate of validation (see www.stridebp.org), corroborated by the Brazilian National Institute of Metrology, Standardization and Industrial Quality (INMETRO, for the acronym in Portuguese).<sup>27,42</sup> For both methods, arm BP monitors are recommended. Exceptionally in HBPM, in patients with an arm circumference greater than 42 cm, the use of a validated wrist BP monitor may be considered, or preference may be given to ABPM using an appropriate cuff size (42 to 50 cm). Furthermore, BP monitors should be checked and calibrated at least every 12 months or whenever decalibration is suspected.

# 2. Abnormality thresholds for in-office and out-of-office BP measurements

BP values considered abnormal are shown in Table 1. With the advent of out-of-office BP measurement, 8 patterns of BP behavior were defined: normotension (NT), CH, sustained hypertension (SH), sustained uncontrolled hypertension (SUH), WCH, white-coat uncontrolled hypertension (WCUH), MH, and masked uncontrolled hypertension (MUH) (Figures 1 and 2).<sup>1,5,43</sup> The use of ABPM added a ninth pattern: nocturnal hypertension.

#### 2.1. Normotension and controlled hypertension

NT is defined as in-office BP < 140/90 mm Hg and average 24-hour ABPM or HBPM < 130/80 mm Hg, without antihypertensive medication use. Individuals with antihypertensive medication use are defined as having CH.<sup>5,46</sup>

## Chart 10 – Essential conditions for creating ABPM and/or HBPM services

The BPM-responsible physician is familiar with the method and has technical and scientific knowledge of the examination

The team has a technician qualified to install the BP monitor and provide the appropriate and necessary guidance to the patient

Validated, calibrated automated oscillometric arm BP monitors with memory function; all cuff sizes; charged batteries

Preparation of standardized reports in spreadsheets, software, or online platforms

Appropriate place or site

HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.

## 2.2. Sustained hypertension and sustained uncontrolled hypertension

SH is defined as abnormal in-office BP ( $\geq$  140/90 mm Hg) and abnormal average 24-hour ABPM or HBPM ( $\geq$  130/80 mm Hg). Individuals with antihypertensive medication use are defined as having SUH.<sup>5,46</sup>

## 2.3. White-coat hypertension and white-coat uncontrolled hypertension

WCH is characterized by abnormal in-office BP ( $\geq$  140/90 mm Hg) and normal 24-hour ABPM (< 130/80 mm Hg) or HBPM (< 130/80 mm Hg) in untreated individuals. When occurring in patients receiving treatment, it is called WCUH.

## 2.3.1. White-coat effect

The white-coat effect is characterized by elevated BP in the presence of a physician, which can occur within the range of NT or hypertension. The presence of this effect does not change the diagnosis of the patient's pattern of BP behavior.<sup>47-49</sup> In ABPM, a white-coat effect has been empirically considered significant for systolic BP  $\geq$  20 mm Hg and/or diastolic BP  $\geq$  10 mm Hg. In HBPM, a white-coat effect, also called alarm reaction, is considered significant for systolic BP  $\geq$  15 mm Hg and/or diastolic BP  $\geq$  9 mm Hg.<sup>50</sup>

## 2.3.2. Investigation

In the absence of pathognomonic data, the characteristics that guide the investigation for the diagnosis of WCH are as follows: office isolated systolic or diastolic hypertension, older people, women, pregnant women, non-smokers, individuals without hypertension-mediated organ damage (HMOD), and particularly, patients with a diagnosis of stage 1 hypertension.<sup>50-53</sup>

Table 1 – Abnormality thresholds for in-office (casual) BPmeasurements, ABPM (24-hour, daytime, and nighttime),and HBPM to define diagnoses (GR: I – LE: B)<sup>1,18,43</sup>

	SBP (mm Hg)		DBP (mm Hg)
Office	≥ 140	and/or	$\geq 90$
24-hour ABPM	≥ 130	and/or	≥ 80
Daytime ABPM	≥ 135	and/or	≥ 85
Nighttime ABPM	≥ 120	and/or	≥ 70
HBPM – 5-day ABPM*	≥ 130	and/or	≥ 80

*GR:* grade of recommendation; LE: level of evidence; BP: blood pressure; HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring; SBP: systolic blood pressure; DBP: diastolic blood pressure. \*On May 8, 2019, HBPM was introduced into the Brazilian Hierarchical Classification of Medical Procedures (CBHPM for short, in Portuguese) and called 5-day ABPM, code: 2.01.02.16-0.<sup>44</sup>

## 2.3.3. Prognosis

The risk attributable to patients with WCH has long been debated. Some studies indicate that patients with WCH have an intermediate CV risk between NT and SH, but closer to the risk attributable to normotensive patients.<sup>54-56</sup> However, patients with WCUH do not appear to have greater CV risk than those with CH.<sup>57</sup>

## 2.3.4. Follow-up and treatment

Patients with WCH are at increased risk of developing SH compared with normotensive patients. Therefore, it is recommended that the diagnosis of WCH be confirmed and patients be followed annually, or more frequently in high-risk patients, using ABPM and/or HBPM to detect progression to SH, as they are more likely to become hypertensive.<sup>54</sup> There is no evidence of benefit from drug therapy, and non-drug treatment should be considered for all patients with WCH.<sup>49</sup>




Figure 1 – BP patterns and their prevalence in individuals without antihypertensive medication use.<sup>43,45</sup> HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.




Figure 2 – BP patterns and their prevalence in individuals with antihypertensive medication use.<sup>43,45</sup> HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.

## 2.4. Masked hypertension and masked uncontrolled hypertension

MH is characterized by normal in-office BP (<140/90 mm Hg) and abnormal 24-hour ABPM ( $\geq$ 130/80 mm Hg) or HBPM ( $\geq$ 130/80 mm Hg). When occurring in patients with antihypertensive medication use, it is called MUH. It is important to emphasize that, in MH, there is a change in diagnosis from NT in the office to hypertension outside the office.

## 2.4.1. Masking effect

A significant masking effect, or masking reaction, is defined as a difference  $\leq -1$  mm Hg between the average systolic BP and/or diastolic BP measured in the clinic and average HBPM. However, the presence of this effect does not change the diagnosis of the patient's pattern of BP behavior.<sup>18,58,59</sup>

## 2.4.2. Investigation

The characteristics that may suggest the diagnosis of MH and, therefore, deserve investigation are as follows: reports of elevated out-of-office BP measurements and individuals with office prehypertension, HMOD (left ventricular hypertrophy, hypertensive retinopathy, microalbuminuria, altered renal function), or high CV risk, including diabetes and chronic kidney disease (CKD).<sup>52</sup> Individuals with prehypertension have a 3-fold higher risk of developing MH than those without prehypertension.<sup>60</sup> However, the strategy of selecting patients with prehypertension in the office has only modest accuracy in predicting the presence of MH.<sup>60</sup>

## 2.4.3. Prognosis

Compared with normotensive individuals, those with MH have a worse prognosis, which is similar to that of SH. Likewise, MUH has a worse prognosis than CH, tending to be similar to SUH.<sup>53,61</sup>

## 2.4.4. Treatment

At first, it can be assumed that the worse prognosis associated with MH may support its treatment, such as in SH.<sup>62</sup> However, to date, there are no results from prospective clinical trials demonstrating an effect of MH treatment on the risk of CV events and mortality.

Given the presence of CV risk similar to that of SH, recommendations on lifestyle changes may be appropriate.<sup>9</sup> Even in the absence of conclusive evidence, if drug treatment is initiated, especially in patients with established HMOD, it is necessary to evaluate the response based on out-of-office BP measurements.<sup>9,63</sup>

A flowchart adapted from Huang et al.<sup>63</sup> is suggested in these Guidelines in Figure 3 for evaluation, diagnosis, and management of MH and WCH if ABPM or HBPM are available.

## 2.5. Resistant hypertension

Hypertension is defined as resistant to treatment when BP remains above the recommended targets with the use of 3 antihypertensives from different classes, including a reninangiotensin system blocker (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker), a long-acting calcium channel blocker (at optimal or best-tolerated doses), and a diuretic (preferably a long-acting thiazide diuretic).64 Resistant hypertension (RH) is a well-defined indication for out-of-office BP measurement.<sup>5,18</sup> HBPM and ABPM are mandatory in the diagnosis and monitoring of RH due to the great magnitude of the white-coat effect found in these clinical conditions, becoming essential to rule out pseudo-RH and, therefore, define the 4 patterns of RH behavior: true RH, white-coat RH, masked RH, and controlled RH.<sup>5,18,64</sup> Although most studies are based on ABPM, there is good agreement between HBPM and ABPM in these patients, with HBPM being the preferred method for monitoring patients with RH, especially those with more elevated in-office BP levels.65




Figure 3 – Flowchart for evaluation, diagnosis, and management of masked hypertension and white-coat hypertension. Adapted from Huang et al.<sup>63</sup> HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.

# 3. Indications, advantages, and disadvantages of ABPM and HBPM

Indications for ABPM and HBPM are shown in Chart 11, while the advantages and disadvantages of both methods are shown in Chart 12.

The diagnosis and treatment of hypertension are currently based on in-office and out-of-office BP measurements. Figure 4 presents an algorithm to guide the interpretation of BP patterns in this scenario.

# Part 3 – Ambulatory blood pressure monitoring (ABPM)

## 1. Definition

The 24-hour ABPM is a method that allows BP to be measured indirectly and intermittently for 24 hours or more when patients are engaged in their usual activities while awake and during sleep.<sup>18</sup>

ABPM was described more than 50 years ago and is currently performed using fully automated monitors.<sup>66</sup>

## 2. ABPM protocols

It is recommended that the monitor be programmed to record BP at 15- to 20-minute intervals for daytime and 20- to 30-minute intervals for nighttime.<sup>5,9,18,67</sup> The nighttime period can be programmed in advance according to the patient's usual sleep schedule or defined later as recorded on the activity diary. An appropriately sized arm cuff should be placed always on the nondominant arm, except in special situations or if there is a marked difference in BP between arms (> 10 mm Hg).

#### 2.1. ABPM reproducibility

ABPM has good reproducibility as long as it is performed in short time intervals under the same technical and clinical conditions. Average 24-hour, daytime, and nighttime systolic BP and diastolic BP readings present similar values in consecutive measurements performed in short time intervals.<sup>68,69</sup>

Nighttime BP dipping also has good reproducibility, with no significant difference between the first and second measurements. The reproducibility of BP pattern between the daytime and nighttime periods is questioned in the literature because of the probability that 30% to 50% of individuals will change status in subsequent recordings, especially in the presence of variables that may interfere with the measurements, such as stress, pharmacological changes, and sleep quality.<sup>18</sup>

# 3. Instructions for patients and health professionals

#### 3.1. Activity diary during BP measurements

Patients should be instructed to write brief notes on the activity diary to allow a correlation between activities, symptoms, and medication use during the monitoring period. To ensure the correct completion of the diary, the instructions should be explained to the patient upon removing the BP monitor. An activity diary template is suggested in Figure 5, and the instructions for completion are shown in Chart 13.

#### 3.2. General instructions

For successful BP measurements, some essential instructions must be explained to the patient when scheduling (Chart 14) and fitting the BP monitor (Chart 15). The activities of the health professional in charge of fitting and removing the monitor are shown in Chartss 16 and 17, respectively.

## Chart 11 – Indications for ABPM and HBPM (GR: I – LE: C)

Indications	ABPM	HBPM
Suspected WCH – white-coat effect	Х	Х
Stage 1 hypertension (140-159 and/or 90-99 mm Hg) in the office	Х	х
BP > 140/90 mm Hg in the office without HMOD and low CVR	Х	х
Isolated systolic or isolated diastolic hypertension in the office	Х	х
Suspected MH – masking effect	Х	Х
BP in the prehypertension range (130-139 and/or 85-89 mm Hg)	х	х
BP < 140/90 mm Hg in the office with HMOD and high CVR	х	х
Suspected white-coat effect	Х	Х
Elevated in-office BP or suspected pre-eclampsia in pregnant women	Х	Х
Identifying UH, RH, and excessive decline in BP	Х	Х
Adjusting antihypertensive medication	Х	Х
Ensuring adequate BP control	Х	Х
Evaluating BP control over 24 hours, during sleep and daily activities	Х	
Identifying postural, postprandial, and siesta hypotension	Х	
Evaluating BP variations in dysautonomia	Х	
Evaluating symptoms, especially hypotension	Х	
Monitoring long-term treatment efficacy and improving adherence		х

*GR:* grade of recommendation; *LE:* level of evidence; *WCH:* white-coat hypertension; *BP:* blood pressure; *HMOD:* hypertension-mediated organ damage; *MH:* masked hypertension; *UH:* uncontrolled hypertension; *RH:* resistant hypertension.

## 4. Interpretation of results

#### 4.1. Criteria for interpreting BP measurements

A minimum of 16 valid daytime and 8 nighttime BP measurements are required for a valid ABPM session.<sup>18</sup> Ideally, the monitoring period should not have time intervals between measurements longer than 2 hours or total duration less than 22 hours. Depending on the purpose of ABPM and in special situations, based on clinical judgment, fewer measurements than recommended may be accepted or the period with an appropriate number of measurements may be analyzed separately, whether daytime or nighttime.

## 4.2. Abnormality thresholds

Despite the continuous relationship between BP measured by ABPM and CV risk, in clinical practice, it is necessary to establish abnormality thresholds. Hypertension diagnostic thresholds for BP

#### Chart 12 - Limitations and advantages of ABPM and HBPM

Limitations	ABPM	HBPM
Difficulty fitting the cuff properly to the patient's arm	Х	х
Clinical conditions associated with movement disorders, such as Parkinson's disease	Х	Х
Cardiac arrhythmias such as atrial fibrillation, atrial flutter, and frequent ventricular extrasystoles	Х	х
Very high SBP values	Х	
Patient's and/or caregiver's difficulty performing the measurements		Х
Advantages	ABPM	HBPM
Out-of-office BP measurement without the presence of a physician	Х	Х
Correlation with better prognosis than in-office BP measurement	Х	х
Potential reduction in health care costs	Х	Х
Current gold standard for BP assessment	Х	
Evaluation of BP control over 24 hours, during sleep and daily activities	Х	
Evaluation of morning BP surge	Х	
Best method for long-term monitoring		Х
Promotion of BP control and adherence to treatment		Х
Less expensive than ABPM		Х
Disadvantages	ABPM	HBPM
Availability is occasionally limited	Х	Х
Some patients are reluctant to use and repeat the measurement	Х	Х
It may be uncomfortable, especially while sleeping	Х	
Often, nighttime BP is not calculated according to the patient's sleep schedule	Х	
BP measurement only at rest during daytime		Х
Guidance and training are required; potential for measurement error: measurement at inappropriate times, excessive number of measurements, induction of anxiety, change of medication by the patient, patient underreports the BP values		Х

HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring; SBP: systolic blood pressure; BP: blood pressure.

measured by ABPM are currently defined by few cohort studies and international guidelines (see Table 2 in Part 2).<sup>54,56,70,71</sup>

## 4.3. BP patterns in transition periods between daytime and nighttime

Among the BP measurement methods, ABPM has the unique characteristic of recording BP during sleep. The sleep-wake pattern is characterized by evaluating the percentage difference between daytime and nighttime average BP values (Table 2).<sup>72</sup> There is no evidence that these patterns of BP dipping have any therapeutic value, thus being considered only a risk marker.




Figure 4 – Interpretation of the patterns of in-office and out-of-office blood pressure behavior (GR: IIa – LE: C). GR: grade of recommendation; LE: level of evidence; HBPM: home blood pressure monitoring; ABPM: ambulatory blood pressure monitoring.

<b>T</b> '	1	device until lunch time (included)	
Time	Activities	Symptoms	Medications
	Notes from after lunch u	ntil dinner time (included)	
Time	Activities	Symptoms	Medications
Notes from after di	nner until the time of removing the o	device (do not forget the time of go	ing to bed and rising)
Time	Activities	Symptoms	Medications

Figure 5 – Diary template to record activities during BP measurements.

#### Chart 13 – Instructions for completion of the activity diary

#### **General instructions**

- All entries on the activity diary must be synchronized with the time on the device's display.
- Record the times and activities performed over 24 hours: professional, domestic, school, and physical activities and rest time.
- 3. Specific instructions

#### Record:

- a) Name, dose, and time of administration of medications used during the monitoring period.
- b) The time of meals, including coffee consumption.
- c) If consuming alcohol, cigarettes, and other drugs; record the time and quantity.
- d) Time spent in traffic and means of transportation.
- e) Occurrence and the time of stressful events.
- f) Presence of symptoms, preferably with start and end times, intensity (strong, medium, or weak), type (dizziness, pain, shortness of breath, etc.), and measures taken to resolve them.
- g) The time of going to bed and rising, including daytime naps (siesta), and perceived quality of sleep, rating it as good, regular, or poor and comparing the quality of sleep on the recording day with your usual quality of sleep.

## Chart 15 – Instructions for the patient when fitting the ABPM monitor

#### Patients must be instructed about the aspects described below:

- 1. Instruct patients not to take a shower or bath during the monitoring period.
- Instruct patients not to engage in physical training during the monitoring period.
- **3.** Instruct patients how to activate the monitor manually if necessary or in the presence of symptoms.
- 4. Instruct patients to remain still during measurement with the arm hanging relaxed along the body.
- Instruct patients how to refit the cuff if it becomes loose during the day and to place the monitor beneath the pillow at night.
- Instruct patients how to switch off the monitor in case of malfunctioning or an urgent need.
- 7. Warn patients not to lie down on the arm with the cuff.
- Instruct patients how to correctly complete the diary, highlighting its importance.

#### **Recommendations:**

- 1. The monitor should not be removed, and the cuff should not be switched between arms.
- 2. The monitor should not be exposed to water, ice, excessive dust, or heat.
- Patients should follow their usual daily activities during the monitoring period.
- 4. Patients should contact the clinic in case of emergency.

#### Chart 14 – Instructions for the patient when scheduling ABPM

On the day of ABPM scheduling, patients must receive the instructions described below:

- Instruct patients to schedule ABPM preferably on a day representative of their usual activities.
- Instruct patients to wear a wide-sleeved or sleeveless shirt to avoid limiting arm movement and interfering with cuff fitting; women should avoid wearing dresses.
- Instruct patients to follow their doctor's advice about long-term medications.
- Instruct patients to bring a list of their regular medications with the prescribed dose and time of administration.
- Instruct patients to take a shower before coming to the clinic, as they will not be allowed to do so during the monitoring period.
- 6. Instruct patients to bring a belt to facilitate fitting the monitor around their waist.

## Chart 16 – Activities of the health professional in charge of fitting the ABPM monitor

On the ABPM day, the health professional in charge of fitting the monitor must follow the instructions described below:

- 1. Provide detailed explanation of the procedure to patients and tell patients to follow their usual daily activities during the monitoring period.
- 2. Tell patients to follow their doctor's advice about medication use.
- Tell patients not to engage in physical activity during the monitoring period.
- 4. Measure weight and height.
- 5. Measure the arm circumference and select the appropriate cuff size (width and length).
- Before fitting the monitor, measure BP in the sitting position, after a 5-minute rest, in both arms, preferably simultaneously, using the auscultatory or oscillometric method.
- 7. Apply the cuff to the nondominant arm if systolic BP difference between arms is <10 mm Hg. If  $\geq$  10 mm Hg, apply the cuff to the arm with the higher BP values.
- Place the cuff 2 to 3 cm above the cubital fossa, following the specific device manufacturer's instructions.
- Program the monitor following the patient's information to define daytime and nighttime periods. Follow the guidelines provided under the item "HBPM protocol."
- 10. After fitting the monitor, compare the BP measurement obtained by ABPM with that obtained by the auscultatory or oscillometric method, ensuring that the difference is no greater than 5 mm Hg.
- 11. Ensure that patients have clearly understood all instructions and are confident to contribute appropriately to the monitoring.
- **12.** Perform at least 2 trial measurements before releasing the patient.

ABPM: ambulatory blood pressure monitoring; BP: blood pressure.

Patients considered to be at highest risk are those whose nighttime average BP does not fall by 10% to 20% of daytime values.<sup>73</sup>

## Chart 17 – Activities of the health professional in charge of removing the ABPM monitor

- Check the completion of the activity diary with patients, particularly regarding the time of drug intake, duration and quality of sleep, and reporting of "occasional events."
- 2. Perform at least 2 trial measurements.
- 3. Subjectively analyze the quality of the activities performed by patients during the monitoring period, for example: whether patients followed their usual daily activities, whether they felt limited in their activities due to discomfort caused by cuff inflations, among others. These events must be considered when interpreting the results and issuing the report.
- Check the number of valid readings during daytime and nighttime measurements. If minimum requirement is not met, inform the patient that measurement should be repeated.
- 5. Download the data from the monitor to the computer and enter information such as: weight, height, medications (with dose and number of doses), and the time of main activities (going to bed, rising, breakfast, lunch, dinner).

ABPM: ambulatory blood pressure monitoring.

## Table 2 – Classification of blood pressure patterns in transition periods between daytime and nighttime (GR: I – LE: B)

Blood pressure (BP) pattern	BP dipping (%)
Present dipping	$\geq 10 \leq 20$
Absent dipping or BP surge	$\leq 0$
Attenuated dipping	> 0 < 10
Blunted dipping	>20

GR: grade of recommendation; LE: level of evidence.

## 4.4. Morning BP surge

Morning BP surge reflects an increase in BP in early morning hours as a result of sympathetic activity. Several methods to determine morning BP surge have been proposed in different studies.<sup>74-77</sup> However, difficulty in standardizing the calculation of this parameter and its poor reproducibility indicate that it should not be used in clinical practice.<sup>72</sup>

## $\ensuremath{\textbf{4.5.BP}}$ load, areas under the curves, $\ensuremath{\textbf{BP}}$ variability, and heart rate

## 4.5.1. BP load

This index is defined as the percentage of abnormal readings in a given measurement period (daytime, nighttime, or 24-hour). Figure 6 exemplifies the calculation of BP load. Because its calculation only indicates that there were readings with elevated BP values (without quantifying them), there may be patients with the same BP load but completely different average BP values. The weak correlation of BP load with clinical outcomes makes its use irrelevant to clinical practice.<sup>78</sup>

## 4.5.2. Areas under the curves

This index is defined as the area under the recorded BP curve that exceeds the BP normality threshold in a given measurement period.  $^{79}\,$ 

This parameter can be considered to have greater clinical relevance than BP load alone because it takes into account, in addition to the number of readings exceeding the normality threshold value, the level of the recorded values.<sup>79</sup> This two-dimensional assessment provides a more accurate estimate of the impact of 24-hour BP. However, this planimetric measurement is not available in commercial software packages used for generating ABPM reports. BP load and average 24-hour, daytime, and nighttime BP values have shown to be strongly correlated




Figure 6 – Example of how to calculate blood pressure (BP) load. SBP: systolic blood pressure; DBP: diastolic blood pressure; BP: blood pressure.

with the areas under the BP curves. Likewise, the areas under the curves have shown a good correlation with left ventricular hypertrophy. However, due to the lack of normality parameters and evidence of a correlation between this index and clinical outcomes, there is currently no indication for its use in clinical practice.

#### 4.5.3. BP variability

This index is defined as systolic and diastolic BP variations over the 24-hour recording period. It can be assessed individually over 24 hours, daytime, or nighttime. In clinical reports, BP variability is expressed as the standard deviation of BP values, although it can also be obtained by the coefficient of variance and "average real variability."<sup>80</sup>

Based on studies of continuous BP measurement, evidence has accumulated correlating increased BP variability with undesirable CV, renal, and neurological outcomes and with increased risk of WCH and MH.<sup>63</sup> However, because of the lack of reference values for normality in BP variability and the lack of data supporting that the treatment acting on variability would bring any clinical advantage, its application is impaired.

## 4.5.4 Heart rate

Heart rate (HR) is estimated from the value of heartbeat frequency derived from pulse rate acquired over the 24hour BP recording period.<sup>81</sup> This parameter is little studied in terms of clinical significance based on ABPM recordings, since conventional devices have poor sensitivity to estimate it.

Because HR obtained with ABPM is a highly error-prone indicator and lacks reference values for normality, it has no clinical application.

## 5. Interpretation of ABPM and technical report

## 5.1. Technical report

The ABPM report must contain the items listed in Chart 18.<sup>82</sup> The different patterns of BP behavior, such as NT, hypertension, WCH, or MH, should not be established, as they are clinical diagnoses.

## 5.2. Systolic and diastolic BP patterns over 24 hours, daytime, and nighttime

The report should include the average 24-hour, daytime, and nighttime systolic and diastolic BP values. In both treated and untreated patients with hypertension, there is a positive correlation of 24-hour, daytime, and nighttime systolic BP and/or diastolic BP values with CV morbidity and mortality as well as HMOD.<sup>71,83-85</sup>

## 5.3. Systolic and diastolic BP patterns in transition periods between daytime and nighttime

The classification of BP patterns in transition periods between daytime and nighttime is shown in Table 2. The report should describe the classification of the morning surge in systolic BP

# Chart 18 – I Required items in the ABPM report (GR: I – LE: C) Date with start and end time of the ABPM session Number and percentage of BP measurements recorded and valid BP readings Average 24-hour, daytime, and nighttime systolic BP values Average 24-hour, daytime, and nighttime diastolic BP values BP pattern between daytime and nighttime Hypotensive episodes Correlation between activities, symptoms, and medication use Conclusion

*GR:* grade of recommendation; *LE:* level of evidence; *ABPM:* ambulatory blood pressure monitoring.

and diastolic BP jointly when the classifications are the same, and separately when the classifications are different.<sup>86</sup>

It is essential to describe the time of going to bed and rising of each individual to define the daytime and nighttime periods. This information should be clearly recorded in the activity diary. Self-reported quality of sleep during the monitoring period should also be considered when interpreting the results.

It is worth noting that reverse dipping or rising, non-dipping, or BP surge may be related to certain conditions, such as sleep disturbances caused by the measurements, inadequate BP control in treated patients, some forms of secondary hypertension, individuals with sleep apnea, dysautonomia, and use of some medications such as cyclosporine.

#### 5.4. BP spikes and hypotension

BP spikes are defined as 2 or 3 progressive elevations in BP measurements, all of which are well above the average BP values observed before and after the event. However, in most cases, isolated elevated BP readings correspond to artifacts and should not be characterized as BP spikes. Due to the lack of prospective studies evaluating prognosis after BP spikes, their significance is unclear and, therefore, they should not be described in the report.

Hypotension is characterized by episodes of a marked fall in BP below the average BP values observed before and after the event, as long as they are accompanied by symptoms (Figure 7). BP falls that are not accompanied by symptoms should not be described as hypotension.

Symptomatic episodes of a BP fall may occur in the following situations: medication use, syncope, lipothymia, postural hypotension, and autonomic neuropathy. Isolated BP readings not accompanied by symptoms, even with a marked fall in BP, may also result from technical artifacts.

## 5.5. Correlation between activities, medication use, and symptoms

Correct completion of the activity diary by the patient is crucial to correlate changes in BP with medications used,




Figure 7 – Episode of a fall in blood pressure on ABPM.

activities performed, and symptoms experienced during the ABPM session. Medication doses, the time of administration, and the time of main activities (going to bed, rising, breakfast, lunch, and dinner) should be recorded.

Symptoms should be recorded along with the time they have occurred and their intensity. The report should inform whether the described symptom caused any variation in BP. It should be recorded in the diary whether the medication was taken on the day of ABPM, with a list of the antihypertensive medications used, the doses and time of drug intake.

#### 5.6. Conclusion

The conclusion should include the following information (GR: I – LE: C):

- a) When the patient reports good or regular sleep quality:
  - The pattern of systolic BP and/or diastolic BP was normal or abnormal over the 24-hour recording period.
  - 2 Nighttime systolic BP and/or diastolic BP dipping was present, absent, blunted, or attenuated.
  - 3. Systolic BP and/or diastolic BP was controlled or uncontrolled during the daytime and nighttime periods if antihypertensive medication use was reported.
- b) When the patient reports poor sleep quality, nighttime BP dipping should not be analyzed, and the pattern and control of BP should only be described for the daytime period:
  - The pattern of systolic BP and/or diastolic BP was normal or abnormal during the **daytime** period.
  - Systolic BP and/or diastolic BP was controlled or uncontrolled during the daytime period.

Example of how to write a conclusion when the patient reports good or regular sleep quality:

- 1. Abnormal systolic blood pressure pattern and normal diastolic blood pressure pattern based on the 24-hour average blood pressure value.
- 2. Absent dipping of nighttime systolic blood pressure and blunted dipping of nighttime diastolic blood pressure.
- 3. The reported medication controlled diastolic blood pressure but not systolic blood pressure during the daytime and nighttime periods.

Example of how to write a conclusion when the patient reports poor sleep quality:

- 1. Abnormal systolic and diastolic blood pressure patterns based on the daytime average blood pressure value.
- 2. The reported medication did not control systolic or diastolic blood pressure during the daytime period.

Example of how to describe night-to-day BP variations when the patient reports poor sleep quality.

1. Night-to-day blood pressure variations.

Patient reports poor sleep quality. Therefore, the analysis of nighttime blood pressure pattern cannot be performed.

The following note should be placed at the end of the report:

ABPM, as well as other complementary medical examinations, should be assessed at the discretion of the attending physician.

Finally, it is important to highlight that the report template suggested here is only a guide to what can be done. Physicians can create their own report template as long as it provides essential information for the physician ordering the ABPM.

Another important factor is that the report should be limited to the information provided by ABPM, without containing deductions or clinical conclusions that are not supported by the data from the ABPM session.

## 6. Clinical applications of ABPM

## 6.1. Assessment of prognosis in patients with hypertension

The different BP components obtained with ABPM provide relevant information for the assessment of CV risk and prognosis in patients with hypertension.

Average 24-hour, daytime, and nighttime BP values correlate more strongly with HMOD, morbidity, and mortality than in-office (casual) BP measurements.<sup>87</sup>

Nighttime BP pattern, a parameter only obtainable by ABPM among all indirect BP measurement methods, also determines CV risk, with an independent association between elevated nighttime systolic BP and CV mortality.<sup>88</sup> Patients with attenuated nighttime systolic BP dipping have shown a higher incidence of lacunar stroke than patients with normal BP dipping.<sup>89</sup>

Attenuated nighttime BP dipping is associated with an increased risk of CV events also in individuals with CKD, in older adults, and in patients with CAD.<sup>89-91</sup>

An independent association between BP dipping and CV events was also demonstrated in a cohort of patients with RH. A BP reduction of less than 10%, or nocturnal BP elevation, was associated with a composite endpoint of CV events and all-cause mortality after a mean follow-up of 4.8 years.<sup>92</sup>

## 6.2. Assessment of antihypertensive treatment efficacy

Guidelines have placed greater emphasis on the role of ABPM in diagnosis and its considerable prognostic power than on the evaluation of treatment efficacy. Some studies have demonstrated a discrepancy in response to treatment between ABPM and in-office BP.<sup>93,94</sup> BP control was demonstrated in only 12% of cases by in-office BP assessment, against 33% with ABPM. Furthermore, 38% of patients had their prescription changed by ABPM, 32% had to add another medication, and 14% of patients with newly diagnosed hypertension in the office were maintained without medication after ABPM.<sup>93</sup> Longitudinal studies using ABPM, specifically designed to evaluate treatment efficacy, are needed before generalizing the method's indications to all patients with hypertension.

## 7. ABPM in special situations

## 7.1. Children and adolescents

Substantial data exist that link elevated BP levels measured in childhood and adolescence to current and future HMOD.  $^{\rm 95}$ 

Normative ambulatory definitions for ABPM values in the pediatric population are derived from studies of healthy populations, and recommendations for the use of ABPM in this population are based on expert opinions rather than on evidence arising from well-designed studies for this purpose.<sup>96</sup>

ABPM is mandatory to confirm the diagnosis of hypertension in children and adolescents with inoffice BP measurements in the elevated BP category for 1 year or more or with stage 1 hypertension over 3 consecutive clinic visits. ABPM is also mandatory to assess hypertension severity and determine if abnormal circadian BP patterns are present in children and adolescents with high-risk conditions, such as CKD, type 1 and 2 diabetes, preoperative and postoperative periods of aortic coarctation, solid-organ transplant, obstructive sleep apnea syndrome (OSAS), obesity, suspected MH or WCH, and genetic syndromes associated with hypertension (Williams syndrome, Turner syndrome, and neurofibromatosis).<sup>97</sup>

The recently published new normative data for pediatric ABPM presents an updated classification scheme for ABPM measurements, which, in addition to favoring the transition of care from adolescents to young adults, eliminates the use of BP load (Table 3).<sup>98</sup>

## 7.2. Pregnant women

The role of ABPM in pregnancy has not been clearly defined. ABPM is particularly useful in the first half of pregnancy.<sup>99</sup> WCH or MH can occur in up to one-third of pregnant women. Their identification is essential to avoid unnecessary and potentially harmful treatment to the fetus.<sup>99</sup>

WCH has a more favorable prognosis than gestational hypertension, persisting in 50% of cases throughout pregnancy without being associated with complications. However, 40% of pregnant women develop gestational hypertension, and 8% of pregnancies progress to pre-eclampsia.<sup>100</sup> On the other hand, a study showed that 22% of 158 pregnant women with hypertension confirmed by ABPM developed pre-eclampsia.<sup>100</sup> In this study, sleep hypertension occurred in 60% of cases, being more commonly associated with the risk of pre-eclampsia and fetal complications. A suspected diagnosis of MH is more challenging, and it should be investigated in the presence of HMOD in pregnant women.

These Guidelines suggest that:

- a) ABPM is indicated to evaluate suspected WCH and MH during pregnancy.
- b) The diagnostic threshold for gestational hypertension should be identical to that used for the general population (ABPM  $\geq$  130/80 mm Hg).<sup>101</sup>

## Table 3 – Classification for in-office BP by ABPM in pediatric patients (GR: IIa – LE: B)

	SBP/DBP office		SBP/DBP ABPM	
	<13 years of age	≥ 13 years of age	<13 years of age	≥ 13 years of age
Normal BP	< p95 ≥ p95	< 130/80 ≥ 130/80	< p95 OR adolescent cutoff points*	< 125/75 mm Hg 24 hours AND < 130/80 mm Hg daytime AND < 110/65 mm Hg nighttime
MH Ambulatory hypertension	< p95 ≥ p95	< 130/80 ≥ 130/80	≥ p95 OR adolescent cutoff points*	≥ 125/75 mm Hg 24 hours OR ≥ 130/80 mm Hg daytime OR ≥ 110/65 mm Hg nighttime

GR: grade of recommendation; LE: level of evidence; BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; WCH: white-coat hypertension; MH: masked hypertension; p95: 95th percentile. \*In children <13 years of age, select the lower of either the 24-hour 95th percentile or the respective adult cutoff point in the  $\geq$ 13 years of age column.

#### 7.3. Older people

ABPM can provide valuable clinical information in older patients, such as in cases of suspected postural, postprandial, drug-induced, and episodic hypotension, as well as in the assessment of dysautonomia and syncope. Some limitations should be highlighted in older patients: a) the same ABPM normality thresholds adopted for nonolder adults are accepted for older adults; and b) reduced nighttime BP dipping, increased pulse rate, and early morning BP surge, common in older people, are associated with increased CV risk.<sup>84,102,103</sup>

Patients with a blunted nocturnal fall in BP, with a > 20% fall in systolic BP, had a higher incidence of ischemic stroke, whereas a nocturnal rise in systolic BP was associated with a higher risk of hemorrhagic stroke.<sup>104</sup>

#### 7.4. Diabetes

The absence of nighttime BP dipping, an increase in nighttime BP relative to daytime BP, sleep hypertension, MH, and BP variability are highly prevalent in patients with type 2 diabetes, with or without a known history of hypertension.<sup>105</sup> In patients with diabetes, ABPM can contribute to the assessment of hypotension secondary to CV autonomic neuropathy, often related to symptoms such as syncope, dizziness, and sweating, thus assisting in the differential diagnosis with hypoglycemia.<sup>106</sup> Nighttime systolic hypertension stands out as a predictor of HMOD in patients with type 2 diabetes.<sup>105</sup> However, the absence of nighttime BP dipping has been associated with cardiovascular disease (CVD), neuropathy, and

retinopathy, whereas morning BP surge has been associated with neuropathy.  $^{\rm 107}$ 

#### 7.5. Chronic kidney disease

At any stage of CKD, ABPM can identify changes in the sleep-wake pattern and detect episodes of arterial hypotension, MH, and WCH.<sup>51</sup> Furthermore, in individuals with CKD, BP values obtained with ABPM are independently correlated with left ventricular mass, glomerular filtration rate, proteinuria, and other HMOD.<sup>108,109</sup> In hemodialysis patients, 24-hour ABPM may not encompass BP measurements throughout the dialysis cycle. Therefore, performing a 44-hour ABPM, fitting the device after a midweek dialysis session (between the second and third sessions of the week) and removing it immediately before the next session, provides a more adequate assessment.90 In practical terms, if the software used does not include the 44-hour protocol, we suggest performing two 22-hour ABPM sessions on two consecutive days. These Guidelines do not recommend the use of 24hour ABPM in hemodialysis patients. In this population, the cuff should not be placed on the arm with arteriovenous fistula. Patients treated with continuous or automated ambulatory peritoneal dialysis have also shown changes in the nighttime BP pattern.<sup>110</sup>

#### 7.6 Obstructive sleep apnea syndrome

In the pathophysiology of OSAS, episodes of micro-arousals and intermittent hypoxia trigger, among other events, the activation of the sympathetic nervous system, leading to an increase in BP, especially during sleep.<sup>111</sup>

These pathophysiological changes determine significant changes in the BP pattern measured by ABPM, significantly increasing the rate of patients with attenuated or absent nighttime BP dipping.<sup>112</sup>

A meta-analysis showed a prevalence of 59% of attenuated nighttime BP dipping measured by ABPM in patients with OSAS, and those with at least moderate OSAS (apnea/hypopnea index > 15 events/hour) were at least 1.67 times more likely to have attenuated dipping. This observation may explain, at least in part, the increased CV risk in patients with OSAS.<sup>113</sup>

A cross-sectional study including 153 patients showed that patients with absent nighttime systolic BP dipping on ABPM were 3.5 times more likely to have moderate OSAS when undergoing polysomnography, thus showing that ABPM data can screen patients who are more likely to be diagnosed with OSAS when undergoing polysomnography.<sup>114</sup>

#### 7.7. Heart failure

ABPM may be indicated to improve the treatment of patients with heart failure (HF) whose symptoms are related to changes in BP, such as in cases of paroxysmal nocturnal dyspnea or HF with preserved ejection fraction (EF). Likewise, ABPM can be useful to guide the treatment of patients with symptoms caused by hypotension, since many of those with advanced HF have fatigue, symptoms of coronary insufficiency, or cerebral manifestations. ABPM can also be

used to evaluate patients with HF who will undergo physical training programs.  $^{\scriptscriptstyle 115}$ 

The absence of nighttime BP dipping is more common in patients with HE.<sup>116</sup> Changes in the sleep-wake pattern have been associated with the severity of systolic dysfunction.<sup>117</sup>

More recently, a study evaluating all-cause and CV mortality in patients with HF with reduced EF, HF with mildly reduced EF, and HF with preserved EF showed that elevated systolic BP was associated with an increased risk among patients with HF with preserved EF, but not in patients with HF with reduced or mildly reduced EF.<sup>118</sup> In patients with HF with reduced EF, lower systolic/diastolic BP and the presence of nighttime BP dipping were predictors of high mortality compared with those with higher systolic/diastolic BP and nighttime non-dipping.<sup>119</sup>

## 7.8. Physical activity

Engaging in physical activity during ABPM may lead to inaccurate readings or missing measurements.<sup>120</sup> After a physical exercise session, BP decreases for several hours, which is more pronounced in patients with hypertension and can change the patient's average ambulatory BP values.<sup>121</sup> Therefore, physical activity should be avoided during ABPM, and also on the day before the ABPM session in patients who do not exercise regularly.

## 8. Cost-effectiveness

ABPM is the strategy of choice for diagnosis and initiation of treatment in most adults in primary care. The correct diagnosis of WCH and MH reduces the total cost of treating hypertension and future CV events.<sup>67</sup> The National Institute for Health and Care Excellence (NICE) conducted a rigorous cost-effectiveness analysis that demonstrated that ABPM would not only be a more effective means of diagnosing hypertension, but it would also provide a more cost-effective approach than in-office BP measurement or HBPM across all age and sex subgroups, leading to an improvement in quality health outcomes and cost savings when long-term costs were taken into account. The key costsaving factor in this analysis was that the cost of antihypertensive treatment would be avoided due to improved specificity in making a diagnosis with ABPM. The model suggested that antihypertensive therapy would be needed in approximately 25% fewer patients than if the diagnosis were made based on in-office BP alone. The drug cost savings outweighed the cost increases associated with the use of ABPM. The analyses were based on the United Kingdom model of health care delivery and may not be valid for use in other countries.<sup>122</sup> Using ABPM reduces the costs with drugs and medical appointments compared with using in-office BP measurements.<sup>123</sup> The benefits of ABPM are unquestionable, especially in primary care. ABPM has been implemented in the Brazilian public health system (SUS for short, in Portuguese) and is already fully incorporated into the private health insurance system. In Latin America, many scientific societies of hypertension and/or cardiology have given special attention in their guidelines to the use of ABPM for the diagnosis and control of hypertension in order to encourage health authorities to regulate access and allow more patients to have access to its benefits.

## 9. Perspectives

Since the introduction of 24-hour ABPM, in 1964, there has been great progress in the devices used for BP measurement. These technological advances have improved comfort for patients during monitoring and enabled cost savings.

Further advances are expected in the near future, as well as the development of devices capable of recording peripheral BP measurements, beat-to-beat monitoring, using a chip that can detect mechanical phenomena arising from hemodynamics and transform them into systolic and diastolic BP values.

Likewise, 24-hour recording of central hemodynamic parameters, including aortic BP, pulse wave velocity (PWV), and augmentation index, has become a reality.

Over time, we will be able to understand the broader applicability of the parameters obtained and, certainly, at that point, ABPM will have become widely accessible to the public in daily clinical practice.

Future applications and possibilities for using ABPM include:

- ABPM monitors with an attached actigraph.
- Adjustable cuffs.
- Assessment of parameters other than systolic BP and diastolic BP, such as HR, pulse rate, PWV and pulse waveform, BP variability over 24 hours or in subperiods, and morning BP surge.
- Reference values for 24-hour ABPM derived from studies of different populations worldwide.
- Prospective studies to evaluate the prognosis and effectiveness of antihypertensive treatment in populations followed by ABPM.
- Development of low-cost devices for noninvasive beatto-beat BP monitoring.

# Part 4 – Home blood pressure monitoring (HBPM)

## **1.** Introduction

HBPM assists in the diagnosis and monitoring of hypertension by taking multiple out-of-office BP readings over days in the individual's usual environment. It should be performed by a person trained in oscillometric BP measurement, preferably the patient himself/herself. In cases where self-measurement is not possible, another trained individual may assist. A fundamental aspect of HBPM is adherence to a previously validated, established, and standardized protocol.<sup>1,5</sup>

## 2. Instructions for patients

The effectiveness of HBPM fundamentally depends on the instructions provided to the patient, which should address factors that can influence BP levels or produce artifacts, such as the environment, patient preparation, and positioning.<sup>1,5</sup> Home measurements should follow the procedural steps

#### Chart 19 – General HBPM instructions for patients

#### Conditions

- Quiet room with comfortable temperature
- No smoking, caffeine, food, or exercise for 30 minutes before measurement
- Remain seated and relaxed for at least 3 minutes (ideally 5 minutes), with an empty bladder
- · No talking during or between measurements

#### Posture

- · Sitting with back supported by chair
- · Legs uncrossed and feet flat on floor
- Bare arm resting on table, palm facing up, mid-arm at heart level

Wrap the cuff around the arm according to the device instructions

Use the same arm to take all measurements—the arm with the highest in-office reading should be chosen (measurements should ideally be performed simultaneously)

Educate the patient on BP variability: "BP varies with each heartbeat"

Explain that, in some people, out-of-office BP may be lower, whereas others might present higher BP measurements at home

Instruct the patient to take measurements on the days and times recommended by the protocol, without changing daily routine

Emphasize that is not permitted to take BP readings of other people

Explain that the therapeutic regimen should not be altered as a result of BP measurements observed during HBPM—occasional high or low values are not a cause of concern

HBPM: home blood pressure monitoring; BP: blood pressure.

as in-office measurements and are also subject to transient variations (Chart 19).

## 3. HBPM protocol

The HBPM protocol aims to capture a patient's usual level of BP, assisting the physician in clinical decision-making.<sup>124</sup> HBPM reproducibility is directly associated with the number of measurements that are averaged.<sup>125</sup> Based on several studies and published evidence, our recommendations are as follows (GR: I – LE: C): <sup>1.5</sup>

- Number of measurements: ideally, the patient should take 24 to 36 valid readings.
- Monitoring period: 4 to 6 days.
- Day 0 or fitting day: on this day, BP measurements are initially taken at the doctor's office (ideally 3), with the average of the last 2 readings used to account for a masking or alarm reaction, then at home in the evening to correct for a potential white-coat effect. Home and in-office BP measurements taken on day 0 must be discarded, and the average should be calculated using measurements collected from day 1 onwards.
- Days 1-6: home readings are taken for 4 to 6 days. The patient should take 3 readings in the morning and another 3 in the evening/night, always after 5 minutes

of rest, before meals, with an empty bladder, and before intake of hypertensive medication (if applicable). If the patient has recently eaten, measurements should only be taken 2 hours after the meal.

 Discarded measurements: values that fall outside the following ranges should be excluded, unless there is clinical justification for their inclusion: diastolic BP 40-140 mm Hg, systolic BP 70-250 mm Hg, and pulse pressure 20-100 mm Hg, as well as systolic BP values lower than the previous or next diastolic BP reading and/or diastolic BP values higher than the previous or next systolic BP reading.

Keeping a record of BP measurements on a BP diary is extremely valuable. In addition, the diary should also include information on current medication. This helps the patient to correctly adhere to the protocol and facilitates the transcription of BP values (for devices lacking data transmission) to elaborate the technical report. A BP diary template is shown in Figure 8.

## 4. Abnormality thresholds

In the 2020 Brazilian Guidelines for Hypertension,<sup>1</sup> average HBPM measurements  $\geq 130$  mm Hg for systolic BP and/or  $\geq 80$  mm Hg for diastolic BP were considered abnormal.<sup>1,50,126-129</sup> These values differ from the ones recommended by the 7<sup>th</sup> Brazilian Guidelines for Hypertension<sup>130</sup> (published in 2016) and by the 4th HBPM Guidelines (published in 2018),<sup>18</sup> in which average HBPM  $\geq 135$  mm Hg for systolic BP and/ or  $\geq 85$  mm Hg for diastolic BP was considered abnormal. The estimated prevalence of hypertension in the Brazilian population based on these two thresholds is shown in Table 4, while the estimated correspondence between HBPM and inoffice BP values is presented in Table 5.

The normality thresholds are defined based on the average BP values obtained in the entire HBPM period. however, calculating separate averages for the morning and evening periods may be useful for establishing more individual strategies for drug therapy.

# 5. Technical report and interpretation of results

The HBPM report should include the following information (GR: I – LE: C):

- Reason for requesting HBPM: state the indication for HBPM.
- Protocol description: state the number of valid monitoring days, times, and number of measurements per day.
- Session quality: the HBPM session will only be considered valid when at least 14 readings have been taken in the 4-day protocol, 15 readings in the 5-day protocol, and 18 readings in the 6-day protocol, every day, in the morning and in the evening.
- BP averages: report the overall, daily, and morning and evening averages, especially for patients on antihypertensive medication. The averages should be

Name:			Date: / //	Phone: (	)
Weight:	Height:	Age:			
Indication:			Prescribing physician and	d clinic:	
		using the technique them in this diary <ul> <li>Take readings in the before meals and b medication (if appli)</li> <li>Remember to emplify</li> </ul>	ninute interval between then a you were taught and record e morning and in the evening efore taking hypertensive cable) ty your bladder dings of another person	Í	:
		I		1	
FITTING DAY					
	ANY TIME			N THE EVENING AT HOM	
HOUR:		HOUR:		HOUR:	HOUR:
BP: /	BP: /	BP: /	BP: /	BP: /	BP: /
PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:
DAY 1					
	MORNING			EVENING	
HOUR:	HOUR:	HOUR:	HOUR:	HOUR:	HOUR:
BP: /	BP: /	BP: /	BP: /	BP: /	BP: /
PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:
DAY 2					
	MORNING			EVENING	
HOUR:		HOUR:	HOUR:	HOUR:	HOUR:
BP: /			BP: /	BP: /	BP: /
PULSE RATE:				PULSE RATE:	PULSE RATE:
DAY 3					
	MORNING			EVENING	
HOUR:			HOUR:	HOUR:	HOUR:
BP: /				BP: /	BP: /
PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:
DAY 4					
	MORNING			EVENING	
HOUR:	HOUR:	HOUR:	HOUR:	HOUR:	HOUR:
BP: /	BP: /	BP: /	BP: /	BP: /	BP: /
PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:
DAY 5					
	MORNING			EVENING	
HOUR:		HOUR:	HOUR:	HOUR:	HOUR:
BP: /		BP: /	BP: /	BP: /	BP: /
PULSE RATE:			PULSE RATE:	PULSE RATE:	PULSE RATE:
			. 5101 10111.		. 5101 10111.
DAY 6					
	MORNING			EVENING	
HOUR:	HOUR:	HOUR:	HOUR:	HOUR:	HOUR:
BP: /	BP: /	BP: /	BP: /	BP: /	BP: /
PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:	PULSE RATE:

Figure 8 – Diary for home blood pressure monitoring (HBPM).

calculated from valid readings obtained over at least 4 days (ideally 6). Readings taken on day 0 should be discarded, as they were taken in the office and the device was handed to the patient.

- White-coat and masking effects: calculate by subtracting HBPM from in-office BP.
- Abnormality thresholds: averages ≥ 130 mm Hg and/or ≥ 80 mm Hg should be considered abnormal.
- Conclusion:
  - I. BP behavior during HBPM was normal or abnormal (according to the overall HBPM average).
  - II. A masking and/or alarm reaction was observed, as indicated by the difference between in-office BP and HBPM (asses systolic and diastolic BP separately).
  - III. The use of hypertensive medication was reported (or not).

The following note should be placed at the end of the report:

HBPM, as well as other complementary medical examinations, should be assessed at the discretion of the attending physician.

## 6. Applications of HBPM

## 6.1. Determination of in-office and out-of-office BP behavior

BP varies continuously in response to internal and external factors, which may lead to misdiagnosis of hypertension, resistance to treatment, or NT.<sup>131</sup> HBPM is superior to in-office BP measurement in the evaluation of BP behavior, particularly as it allows the diagnosis of WCH and MH.<sup>132-134</sup> Furthermore, HBPM can evaluate day-to-day and seasonal BP variability, in addition to separately determining BP behavior in the morning and in the evening/night. However, the incremental value of these measurements compared with the average BP value in predicting CV and renal risk remains uncertain.<sup>135-137</sup>

## 6.2. Assessment of prognosis

Several studies have consistently demonstrated that HBPM is strongly associated with HMOD prediction, particularly left ventricular hypertrophy, and has a greater capacity to predict CV and renal events than in-office BP.<sup>138-140</sup> Results from a meta-analysis including approximately 18,000 patients showed that home BP was superior to in-office BP in predicting CV mortality: the hazard ratio for home BP was 1.29 (95% CI = 1.02-1.64) per 10 mm Hg increase in systolic BP compared with 1.15 (95% CI = 0.91-1.46) for in-office BP.<sup>138</sup>

HBPM also proved to be similarly reliable in predicting HMOD as ABPM.<sup>139</sup> Moreover, a meta-analysis of studies that exclusively performed HBPM or ABPM showed that MH and MUH detected by these methods had similar predictive value for CV events and mortality, irrespective of the diagnostic method.<sup>141</sup> Taken together, these findings suggest that ABPM and HBPM may be equally effective in predicting CV risk. However, studies directly comparing Table 4 – Prevalence of hypertension and hypertensionphenotypes based on the abnormality thresholds recommendedby the 4th HBPM Guidelines and the 2020 Brazilian Guidelinesfor Hypertension<sup>1,18</sup>

Hypertension	HBPM ≥ 135/85 mm Hg*	HBPM ≥ 130/80 mm Hg**
Diagnosis	37%	57%
Normotension	47%	36%
WCH	16%	7%
MH	10%	22%
SH	27%	35%
Control	40%	58%
Controlled hypertension	45%	34%
White-coat uncontrolled hypertension	15%	8%
Masked uncontrolled hypertension	11%	22%
Uncontrolled SH	29%	36%

HBPM: home blood pressure monitoring; WHC: white-coat hypertension; MH: masked hypertension; SH: systolic hypertension.

## Table 5 – Estimated correspondence between HBPM and in-office BP values (GR: IIa – LE: B)<sup>128</sup>

In-office Systolic/diastolic BP (mm Hg)	HBPM Systolic/diastolic BP (mm Hg)
< 120/< 80	< 120/< 75
120-129/80-84	120-124/< 75
130-139/85-89	125-129/75-79
140-159/90-99	130-139/80-89
160-179/100-109	140-149/90-95
≥ 180/≥ 110	≥ 150/≥ 95

*GR:* grade of recommendation; *LE:* level of evidence; *HBPM:* home blood pressure monitoring. \*The classification is defined according to in-office *BP* measurements or *HBPM* and the highest systolic or diastolic value (depending on the technique of choice).

the capacity of HBPM and ABPM to predict CV events in the same population are scarce, precluding more definitive conclusions on this topic.<sup>142</sup> A recent analysis of the PAMELA study showed that HBPM and ABPM were superior to in-office BP measurement in predicting CV risk and even suggested that HBPM could be more accurate than ABPM in predicting CV and total mortality.<sup>143</sup> Furthermore, the day-to-day variability of home BP has been shown to have predictive value for cerebrovascular, renal, and CV diseases.<sup>140</sup>

## 6.3. Assessment of antihypertensive treatment

The main contributions of HBPM to the treatment of hypertension are the characterization of hypertension

phenotypes, particularly WCUH and MUH, and the confirmation of controlled, uncontrolled, and resistant hypertension.<sup>1,5,18,144</sup> Identifying these phenotypes allows a more personalized approach, with individualized therapeutic adjustments.<sup>5,18,144</sup>

Because of its wide accessibility, affordability, and user-friendliness, HBPM is well-tolerated by both the patient and physician. Therefore, HBPM is the preferred method for monitoring treated hypertensive patients, allowing drug titration to achieve BP control and long-term monitoring.<sup>5,144-146</sup>

Regarding BP goals to be achieved in HBPM with treatment, systolic BP values < 130 mm Hg and diastolic BP values < 80 mm Hg are recommended.<sup>145,147</sup> Studies have shown that performing HBPM can increase patient engagement and adherence to long-term treatment, and it can be used for BP telemonitoring. The combination of these factors can help improve BP control, particularly when combined with patient education and counseling.<sup>148-150</sup>

#### 6.4. In special populations and situations

#### 6.4.1. Children and adolescents

The practice of out-of-office BP measurement is also encouraged in children and adolescents, as they may also present with WCH and MH. Measurements should be taken using appropriately sized cuffs and devices validated for use in this population. Studies investigating reference values for HBPM in children and adolescents are scarce. In adolescents, these Guidelines recommend using values  $\geq$  95th percentile of the normality thresholds obtained from a Brazilian population to diagnose hypertension with HBMP.<sup>151,152</sup>

#### 6.4.2. Pregnant women

In pregnant women, it is recommended to measure BP during each prenatal care visit. However, even regular prenatal checkups may not be sufficient to identify conditions such as pre-eclampsia or WCH, the latter which is common at the end of pregnancy.<sup>144,153</sup> The use of HBPM during pregnancy has some advantages, as it is wellaccepted by women and facilitates treatment monitoring, thereby reducing the number of medical appointments. When performing HBPM during pregnancy, the patient should be in a sitting position<sup>144,153,154</sup> and use devices that were specifically validated for this population.

During pregnancy, we recommend the use of ABPM and HBPM to assess WCH and MH, in order to avoid unnecessary and potentially harmful treatment to the fetus.<sup>155</sup> ABPM should be used before 20 weeks of pregnancy and HBPM after 20 weeks.<sup>153</sup>

#### 6.4.3. Older patients

HBPM is an extremely important tool in the initial assessment and periodic therapeutic monitoring of older patients, contributing to a better prognosis.<sup>156,157</sup> This population usually has a high CV risk, greater BP variability,

and less tolerance to inadequate treatment, such as antihypertensive use for WCH.<sup>158</sup>

There is no consensus on whether age is a risk factor for a higher prevalence of WCH and MH.<sup>50,159</sup> HBPM is feasible with minimal training in older patients, but extra care should be taken when initially training those over 80 years old, with low educational level, cognitive decline, or physical restrictions requiring assistance from others.<sup>160</sup> An alternative for achieving better BP control among older patients with hypertension is the use of telemonitoring.<sup>161</sup>

#### 6.4.4 Diabetes

Diabetes is a disease with different pathophysiological mechanisms that, in general, doubles the risk of CV and renal outcomes, including stroke, CAD, CKD, and CV death.<sup>162,163</sup> Patients with diabetes, particularly due to visceral fat and insulin resistance, are more prone to having MH than those without diabetes.<sup>43</sup> In a small observational study involving 170 patients with type 2 diabetes, HBPM was superior to in-office BP in identifying microvascular complications.<sup>164</sup> This finding suggests that HBPM has great potential in the clinical management of patients, emphasizing the need for clinical trials to further investigate its clinical relevance in this population.

#### 6.4.5. Chronic kidney disease

WCH and MH are very common in patients with CKD.<sup>165,166</sup> The usefulness of HBPM is indisputable in patients with CKD undergoing conservative treatment, peritoneal dialysis (PD), or hemodialysis (HD) and in patients who received a kidney transplant, as it predicts disease progression and the risk of CV events and death.<sup>167</sup> However, the main limitation of HBPM lies in its inability to assess changes in the nocturnal BP pattern, which are common in patients with CKD. Nighttime telemonitoring might be an alternative and is currently under consideration for patients with CKD or who received a kidney transplant.<sup>168</sup>

In patients undergoing conservative treatment and in those who received a kidney transplant, HBPM should be performed according to the usual recommendations.<sup>169</sup> In patients undergoing dialysis, we recommend the following protocol:

- Number of measurements: ideally, the patient should take 36 readings.
- Monitoring period: 6 days.
- Day 0 or fitting day: on this day, BP measurements are initially taken at the office or hemodialysis clinic (ideally 3), with the average of the last 2 readings used to account for a masking/alarm reaction, then at home in the evening to correct for a possible white-coat effect. BP should never be measured on the fistula arm. Home and in-office BP measurements taken on day 0 must be discarded from the average calculation.
- **HBPM days:** at home, BP readings are taken for 6 days. The patient should take 3 readings in the

morning and another 3 in the evening/night, always after 5 minutes of rest, before meals, with an empty bladder, and before taking hypertensive medication (if applicable). If the patient has eaten, measurements should be taken only 2 hours after the meal. In patients undergoing typical hemodialysis (2 to 3 times a week), measurements taken on these days should also be excluded from the average calculation; in cases of daily hemodialysis and PD, all measurements will be included.

#### 6.4.6. Obesity

The assessment of BP in patients with obesity presents challenges in clinical practice, as BP variability and the prevalence of WCH and MH is higher in this population than in patients without obesity. Therefore, HBPM is a fundamental tool for identifying hypertension phenotypes in these patients.<sup>170,171</sup> However, accurate BP measurement is often hindered by factors such as large arm circumference and/or conical arm shapes, as well as limited availability of appropriately sized cuffs. In this setting, the use of inadequate cuffs may lead to overestimation of BP.<sup>172</sup> In the absence of appropriately sized or shaped cuffs, validated and calibrated wrist devices may serve as an alternative for HBPM in patients with obesity.<sup>144</sup>

#### 6.4.7. Arrhythmias

HBPM devices, especially those currently available on the market, are validated for BP measurement in patients with cardiac arrhythmias, particularly atrial fibrillation.<sup>173</sup> Some automated oscillometric devices are equipped with a specific algorithm that can identify the presence of atrial fibrillation, assisting in the diagnosis of these conditions, especially in older adults.<sup>168,174,175</sup>

## 7. Cost-effectiveness

Health care costs are a global concern, prompting widespread efforts to contain them. Cost-effectiveness analysis assesses cost (monetary value) in relation to outcomes (effectiveness, eg, lives saved) using various intervention methods.<sup>176,177</sup>

A recent cost-effectiveness analysis concluded that HBPM is more effective than conventional in-office BP measurement and requires less financial and human investment than ABPM.<sup>123,178</sup>

## 8. Perspectives

In recent years, numerous cuffless devices claiming to accurately measure BP have been made available for use. In general, these devices are equipped with a sensor that assesses arterial pulse and estimates BP mostly through pulse wave analysis (PWA).<sup>179</sup>

This new method is believed to have great potential for allowing multiple or even continuous BP measurements over days or weeks without the discomfort associated with cuff inflation. However, the accuracy and usefulness of cuffless devices are uncertain and require validation in large randomized clinical trials in different clinical settings compared with the gold standard, such as ABPM or invasive measurements. Therefore, at the moment, these devices should not be used for diagnostic or treatment decisions in Brazil.

Nighttime HBPM is already a reality in some countries around the world. This method measures BP during sleep and records nocturnal dipping for a period of days or weeks.<sup>180</sup> However, no such equipment validated by the Brazilian National Health Surveillance Agency is available in Brazil.

# Part 5 – Central blood pressure, pulse wave velocity, and augmentation index

## **1.** Introduction

BP values differ significantly between the central and peripheral regions of the arterial tree. SBP is higher in peripheral arteries than in central arteries, while DBP and mean BP differ only slightly. Age and genetics greatly influence the difference between peripheral and central BP curves, and this difference can reach 20 mm Hg for SBP in young individuals. This effect is known as SBP augmentation or PP augmentation. PP augmentation is lower in older people due to increased arterial stiffness (AS) and the early return of the reflected waves, so that central SBP (cSBP) may be close to peripheral SBP. Therefore, the time interval relative to the forward and backward pressure waves in the aorta is considered an important parameter for defining central blood pressure (CBP).<sup>181,182</sup>

## 2. Definitions

An increase in BP is directly related to an increase in CV risk due to endothelial dysfunction and damage and increased AS resulting from aggression in the vascular media.<sup>183-187</sup> AS is defined as a set of vessel properties that determine their biophysical characteristics, including distensibility, elasticity, and compliance, which interfere with the dynamics of blood flow in each cardiac cycle.<sup>183</sup> Changes in microvessels, arteriosclerosis, and endothelial dysfunction as well as increased AS are injuries resulting from hypertension and other diseases, such as diabetes, obesity, and dyslipidemia, being also influenced by genetic factors and age.<sup>184,185,188-192</sup> Increased AS is the main cause of increased SBP observed with aging.<sup>193</sup>

#### 2.1. Pulse wave velocity

Defined as the ratio of the distance traveled between two points in the arterial system to the ventricular ejection wave generated in a unit of time, PWV is measured in meters per second (m/s).<sup>184,194,195</sup> PWV is the gold standard method for quantifying AS, and an increasing intensity of AS is associated with an increasing PWV.<sup>196</sup> PWV measurement is simple, noninvasive and can be performed in an outpatient setting.<sup>183,197</sup> The current reference method in clinical research is carotid-femoral PWV (cfPWV).

#### 2.2. Augmentation index

The augmentation index (Alx) is defined as the ratio of the pressure caused by the reflected wave to the ejection wave. This measure is directly related to PWV and inversely related to HR,<sup>192,198</sup> and it has the advantage of taking into account the timing of the forward and backward waves, which are the main determinants of CBP.<sup>199,200</sup> Alx describes the relationship between CBP and the reflected pulse wave, incorporating the magnitude and velocity of the reflected waves. Consequently, this index can be defined as a measure of the intensity of pulse wave reflections.<sup>201,202</sup>

HR should be taken into account to correct Alx, so Alx@75 is the Alx corrected for HR of 75 beats per minute (bpm). This index is reported by AS measurement devices, as a result of applying the following formula: Alx@75 = Alx - 0.39 × (75 - HR).<sup>203</sup>

#### 2.3. Central blood pressure

CBP is the pressure exerted by the blood column, at each beat, on the aorta and carotid arteries, approximating the BP exerted on the heart and brain. For this reason, this marker is often more closely related to CV morbidity and mortality than peripheral BP.<sup>204,205</sup> Currently, CBP can be measured noninvasively using several validated methods and devices.<sup>206</sup>

## **3. Indications**

Possible indications for CBP, PWV, and AIx are summarized in Table 6.

## 4. Advantages of measuring CBP, Alx, and PWV

• Identification of subclinical HMOD: PWV  $\geq 10 \text{ m/s}.^{207,208}$ 

**Prognostic assessment:** an increase of 1 m/s in PWV is associated with a 14% increase in the occurrence of CV events and a 15% increase in mortality.<sup>205</sup>

- Alx is a predictor of outcomes and HMOD.<sup>209,210</sup>
- These measures can improve precision in the diagnosis of hypertension, safety in therapeutic decisions, and definition of prognosis.<sup>211</sup>

## 5. Limitations of measuring CBP, Alx, and PWV

- Poor availability in health centers.
- High-cost devices.
- Measurements obtained by the oscillometric method still require further epidemiological studies, especially regarding their prognostic value.

# 6. Techniques available for checking central and arterial stiffness parameters

Applanation tonometry, as well as piezoelectric mechanoreceptors, sensitive to intravascular pressure, can be used as a substitute for CBP due to the anatomical proximity to the ascending aorta. Applanation tonometry in the radial

artery can measure CBP from a generalized mathematical transfer function, but a major drawback of the method is operator dependence. The brachial oscillometric technique has the advantage of being practical for use in the office, in addition to being operator independent. However, it has been criticized for how these devices are calibrated, as they tend to underestimate the true brachial intra-arterial pressure and, consequently, CBP.<sup>1,212-219</sup>

#### 6.1. Methods for indirect measurement of CBP

- **Direct arterial tonometry**: method used in the Complior Analyse® device. This method directly measures pressure waveform in common carotid artery by applanation tonometry and corresponds to the pressure waveform of the ascending aorta.<sup>212,213</sup>
- Indirect arterial tonometry: method used in the SphygmoCor® device based on brachial artery BP measurement and radial artery applanation tonometry. This method indirectly reconstructs pressure waveform using an algorithm.<sup>212,213</sup>
- Brachial oscillometric method: method used in the Mobil-O-Graph®, Dyna-MAPA AOP®, and Arteris® devices based on brachial artery BP measurement using an algorithm and transfer function. This method indirectly reconstructs pressure waveform.

Although indirect arterial tonometry is considered the gold standard for the evaluation of AS assessed by cfPWV, oscillometric measurement is a simpler method that provides more reproducible and reliable results.<sup>214,215,220,221</sup>

# 7. Protocols for CBP, PWV, and Alx measurements

## 7.1. Protocol for measuring central parameters using tonometry

In the direct method, piezoelectric sensors are placed in the carotid and femoral arteries to record arterial diameter change curves secondary to changes in intra-arterial pressure with simultaneous recording of central and peripheral signals. CBP is obtained directly from the carotid pressure waveform. It is also possible to evaluate PWV in 3 different arterial segments from a single-point measurement for the study of peripheral arteries.<sup>183,219</sup>

In the indirect method, the system consists of an applanation tonometer and an ECG, PWV is measured at 2 points and aligned with the R wave of the ECG QRS complex as a reference point. The central pressure waveform and ascending aortic pressure values are defined using a transfer function.<sup>183,219</sup>

## 7.2. Protocol for the triple-trigger procedure (in-office measurement) using the oscillometric method

Depending on the device used, central BP measurements (CBP, PWV, and AIx) obtained by the oscillometric method can be performed at preset time intervals. The preparation steps for in-office BP measurement should be followed, including the choice of appropriate cuff size and arm, as recommended by the 2020 Brazilian Guidelines for Hypertension.<sup>1</sup>

After choosing the arm, a cuff connected to the device programmed to perform a 15-minute monitoring should be applied to the arm, with triggers that assess brachial pressure and central parameters every 3 minutes, considering the last 3 measurements or 3 valid measurements – protocol known as triple PWA. Some devices have a built-in triple PWA function, without the need for presetting.

## 7.3. Protocol for 24-hour central BP parameter measurements using the oscillometric method

The same preparation protocol, patient guidance, and choice of arm/cuff proposed for the 24-hour ABPM should be followed to perform the 24-hour central BP parameter measurements. For improved patient comfort during monitoring, it is recommended that the device be programmed to record BP at 30-minute intervals (daytime and nighttime). A minimum of 16 valid daytime and 8 nighttime BP readings are required. Furthermore, patients should be warned about double cuff inflation during measurements, thus preventing patients from suspecting that an error has occurred during BP measurements.

## 8. Reference values<sup>216,218,222-225</sup>

#### 8.1. Reference values for PWV

As age and BP have a major influence on AS, reference values for PWV are usually presented in categories derived from these variables. In Tables 7 and 8, reference values are suggested for PWV, whose measurements were obtained mainly using a tonometer or piezoelectric sensors.<sup>226</sup>

#### 8.2. Reference values for cSBP

The reference values for cSBP using the SphygmoCor, Omron HEM-9000AI, PulsePen, and direct carotid artery tonometry devices and categorized by age, sex, and risk factors and for peripheral BP are shown in Tables 9 and 10.<sup>227</sup>

## 8.3. Reference values for PWV, CBP, and Alx using the oscillometric method in the Brazilian population

A Brazilian multicenter study, including 6499 individuals from 4 centers, described reference values for PWV, cSBP, and Alx in the Brazilian population measured using the oscillometric method.<sup>212</sup> Tables 11 and 12 show the reference values for these measurements according to age group, sex, and CV risk factors.<sup>214</sup>

In view of the foregoing, we can conclude that there are currently reference values for the different AS and CBP measurement devices, including for the Brazilian population. However, little is still known about the abnormality thresholds for the measurement of central BP parameters capable of predicting CV events, especially when obtained using the oscillometric method. The suggested abnormality thresholds for the measurement of central BP parameters are shown in Table 13. 
 Table 6 – Possible indications for measuring central blood pressure, augmentation index, and pulse wave velocity (GR: IIa – LE: C)

Parameter	Possible indications
Central systolic blood pressure (cSBP)	Evaluation of spurious hypertension in isolated systolic hypertension in young people
Pulse wave velocity (PWV)	Re-stratification of patients with prehypertension and low-to-intermediate risk hypertension Patients evaluated by SAGE score $\geq 8$
Augmentation index (Alx)	Reserved for clinical research setting only

GR: grade of recommendation; LE: level of evidence.

## Tabela 7 – PWV reference values categorized by age in a healthy population $^{\rm 226}$

Age (years)	Mean (+2 SD)	Median (p10- p90)
30	6.2 (4.7-7.6)	6.1 (5.3-7.1)
30-39	6.5 (3.8-9.2)	6.4 (5.2-8.0)
40-49	7.2 (4.6-9.8)	6.9 (5.9-8.6)
50-59	8.3 (4.5-12.1)	8.1 (6.3-10.0)
60-69	10.3 (5.5-15.0)	9.7 (7.9-13.1)
≥70	10.9 (5.5-16.3)	10.6 (8.0-14.6)

*PWV:* pulse wave velocity; SD: standard deviation; p10: upper 10th percentile; p90: lower 90th percentile.

# 9. Prognostic value of BP measurements derived from central parameters

Evidence indicates that CBP is more closely associated with traditional CV risk factors and HMOD. AS is one of the main determinants of CBP and has been considered to have high predictive value for CV events. Likewise, prospective observational studies have demonstrated the predictive value of central hemodynamic parameters for CV events in the general population, in older people, and in patients with coronary disease and CKD.<sup>228</sup>

In the Strong Heart Study, central PP (cPP) was superior to peripheral PP as a predictor of fatal and non-fatal CV events.<sup>229</sup> Other studies have found equal superiority in normotensive or hypertensive older people and in Asian individuals.<sup>227,228</sup>

In the Multiethnic Study of Atherosclerosis (MESA), pulse wave reflection parameters were associated with new-onset CV events and incidence of HF in individuals without evidence of prior CVD.<sup>229,230</sup>

In a meta-analysis involving more than 5000 normotensive and hypertensive individuals, some with coronary disease or CKD, for every 10 mm Hg increase in cPP and in cSBP, there was a 14% increase in CV risk and a 9% increase in CVD risk, respectively.<sup>231</sup> Average 24-hour ambulatory BP values have also been considered better predictors of CV risk than peripheral BP measurements in normotensive and hypertensive patients.<sup>232</sup>

Age (years)	Optimal BP	Normal BP	High-normal BP	Stage 1 hypertension	Stage 2/3 hypertension	
Mean PWV (+2 SD)						
< 30	6.1 (4.6-7.5)	6.6 (4.9-8.2)	6.8 (5.1-8.5)	7.4 (4.6-10.1)	7.7 (4.4-11.0)	
30-39	6.6 (4.4-8.9)	6.8 (4.2-9.4)	7.1 (4.5-9.7)	7.3 (4.0-10.7)	8.2 (3.3-13.0)	
40-49	7.0 (4.5-9.6)	7.5 (5.1-10.0)	7.9 (5.2-10.7)	8.6 (5.1-12.0)	9.8 (3.8-15.7)	
50-59	7.6 (4.8-10.5)	8.4 (5.1-11.7)	8.8 (4.8-12.8)	9.6 (4.9-14.3)	10.5 (4.1-16.8)	
60-69	9.1 (5.2-12.9)	9.7 (5.7-13.6)	10.3 (5.5-15.1)	11.1 (6.1-16.2)	12.2 (5.7-18.6)	
≥ 70	10.4 (5.2-15.6)	11.7 (6.0-17.5)	11.8 (5.7-17.9)	12.9 (6.9-18.9)	14.0 (7.4-20.6)	
Median PWV (p10- p90)\						
< 30	6.0 (5.2-7.0)	6.4 (5.7-7.5)	6.7 (5.8-7.9)	7.2 (5.7-9.3)	7.6 (5.9-9.9)	
30-39	6.5 (5.4-7.9)	6.7 (5.3-8.2)	7.0 (5.5-8.8)	7.2 (5.5-9.3)	7.6 (5.8-11.2)	
40-49	6.8 (5.8-8.5)	7.4 (6.2-9.0)	7.7 (6.5-9.5)	8.1 (6.8-10.8)	9.2 (7.1-13.2)	
50-59	7.5 (6.2-9.2)	8.1 (6.7-10.4)	8.4 (7.0-11.3)	9.2 (7.2-12.5)	9.7 (7.4-14.9)	
60-69	8.7 (7.0-11.4)	9.3 (7.6-12.2)	9.8 (7.9-13.2)	10.7 (8.4-14.1)	12.0 (8.5-16.5)	
≥ 70	10.1 (7.6-13.8)	11.1 (8.6-15.5)	11.2 (8.6-15.8)	12.7 (9.3-16.7)	13.5 (10.3-18.2)	

#### Table 8 – PWV reference values categorized by age and blood pressure<sup>226</sup>

PWV: pulse wave velocity; BP: blood pressure; SD: standard deviation; p10: upper 10th percentile; p90: lower 90th percentile.

#### Table 9 – VCBP reference values categorized by age, sex, and risk factors<sup>227</sup>

Age	Healthy po	opulation	Population with cardiovascular risk factors		
(years)	Female	Male	Female	Male	
< 20	97 (86, 91, 102, 109)	105 (95, 99, 109, 113)	99 (88, 93, 105, 120)	109 (96, 102, 117, 127)	
(n = 1104)	n = 350	n = 290	n = 182	n = 282	
20-29	95 (80, 88, 102, 110)	103 (92, 97, 109, 115)	101 (88, 91, 110, 124)	110 (95, 102, 120, 130)	
(n = 4157)	n = 1411	n = 880	n = 888	n = 974	
30-39	98 (84, 90, 108, 119)	103 (88, 95, 112, 120)	111 (92, 100, 127, 141)	114 (95, 103, 129, 144)	
(n = 6386	n = 1860	n = 1259	n = 1373	n = 1889	
40-49	102 (87, 93, 113, 123)	106 (90, 97, 114, 123)	116 (95, 104, 133, 146)	118 (97, 106, 132, 144)	
(n = 9595)	n = 2318	n = 2068	n = 2196	n = 2995	
50-59	110 (93, 100, 119, 127)	110 (96, 102, 118, 126)	120 (100, 109, 134, 148)	123 (102, 111, 137, 150)	
(n = 11950)	n = 2002	n = 1997	n = 4251	n = 3646	
60-69	114 (97, 105, 122, 129)	114 (97, 105, 122, 128)	128 (105, 115, 141, 154)	128 (105, 115, 142, 155)	
(n = 7779)	n = 1057	n = 1410	n = 2656	n = 2629	
> 70	118 (100, 109, 126, 131)	116 (99, 107, 124, 130)	138 (113, 126, 152, 164)	135 (113, 124, 147, 160)	
(n = 4445)	n = 530	n = 747	n = 1567	n = 1592	

Values described in the 50th percentiles (10th, 25th, 75th, and 90th).

In patients with earlier stage CKD, cPP was able to predict progression to end-stage renal disease and, in stages 2 to 4, an independent relationship between cSBP and overall mortality was demonstrated.<sup>233</sup> The adverse effect of increased arterial pulse wave reflection on the CV system of patients with endstage renal disease has also been demonstrated.<sup>234</sup>

The clinical value of CBP measurement was initially demonstrated in the Anglo-Scandinavian Cardiac Outcomes Trial – Conduit Artery Function Evaluation (ASCOT-CAFE). The main ASCOT study had already reported a more favorable CV outcome in hypertensive patients treated with a combination treatment regimen of an angiotensin-converting enzyme inhibitor (ACEI) with a calcium channel blocker (CCB) compared with therapy based on beta-blockers and diuretics.<sup>235,236</sup>

In the CAFE substudy, although there was no difference in peripheral BP levels between the two groups, treatment with ACEI + CCB promoted a greater reduction in CBP.<sup>45</sup>

The REASON study was able to demonstrate that a favorable effect of the combination of ACEI + diuretics on the reflection coefficient was present even after 9

Blood pressure	Healthy population		Population with cardiovascular risk factors	
category\	Female	Male	Female	Male
Optimal (n = 17678) 108 (96, 102, 114, 117)	97 (84, 90, 104, 110) n = 6415	100 (88, 94, 106, 111) n = 4035	102 (89, 95, 108, 112) n = 4082	101 (90, 96, 107, 112) n = 3146
Normal (n = 9313) 123 (120, 121, 126, 128)	116 (104, 110, 121, 125) n = 1902	112 (102, 106, 117, 122) n = 2669	116 (107, 111, 120, 123) n = 2281	113 (103, 108, 118, 122) n = 2461
High-normal (n = 7148) 133 (128, 130, 136, 138)	126 (115, 120, 131, 135) n = 1212	122 (110, 115, 128, 132) n = 1947	125 (116, 120, 130, 133) n = 1861	123 (111, 116, 128,132) n = 2128
Stage 1 (n = 3288) 143 (130, 137, 150, 155)			137 (122, 129, 144, 150) n = 1276	133 (119, 126, 142, 148) n = 2012
Stage 2 (n = 1930) 161 (146, 154, 168, 174)			154 (128, 142, 161, 168) n = 798	148 (128, 138, 158, 165) n = 1132
Stage 3 (n = 701) 183 (162, 178, 193, 206)			173 (153, 164, 183, 194) n = 312	171 (143, 158, 183, 192) n = 389
ISH (n = 5255) 147 (141, 143, 155, 163)			140 (128, 134, 148, 156) n = 2507	137 (122, 129, 144, 152) n = 2748

## Table 10 – BP reference values according to BP classification and cardiovascular risk factors<sup>227</sup>

Values described in the 50th percentiles (10th, 25th, 75th, and 90th). Blood pressure (BP) categories refer to brachial artery blood pressure.

## Table 11 – CBP reference values according to sex and age in a healthy population and to cardiovascular risk factors<sup>214</sup>

Age	Healthy p	opulation	Population with cardiovascular risk factors			
(years)	Female	Male	Female	Male		
Variable: Central systolic blood pressure						
< 30	101 (90, 93, 113, 119)	113 (104, 109, 120, 123)	118 (102, 109, 127, 131)	123 (107, 114, 132, 144)		
30-39	109 (96, 102, 117, 123)	114 (102,110,121, 127)	120 (102, 110, 130, 143)	125 (108, 116, 133, 141)		
40-49	110 (99, 103, 117, 122)	116 (102,109, 122, 126)	121 (104, 112, 134, 146)	123 (108, 115, 131, 141)		
50-59	110 (97, 104, 120, 124)	112 (100, 106, 118, 124)	124 (106, 114, 135, 146)	124 (105, 114, 134, 144)		
60-69	114 (100, 105, 120, 125)	112 (96, 101, 120, 127)	127 (105, 115, 141, 154)	123 (103, 112, 136, 149)		
≥70	113 (100, 103, 121, 126)	116 (94, 104, 125, 129)	131 (108, 118, 146, 165)	125 (102, 111, 140, 156)		
		Variable: Central diastolic bloc	od pressure			
< 30	73 (60, 66, 77, 85)	76 (66, 71, 82, 87)	82 (68, 73, 90, 97)	83 (72, 77, 93, 100)		
30-39	77 (67, 71, 83, 88)	80 (71, 75, 85, 88)	86 (71, 77, 95, 105)	88 (75, 80, 96, 103)		
40-49	79 (67, 73, 84, 88)	81 (74, 77, 86, 89)	86 (71, 78, 94, 103)	90 (75, 82, 97, 104)		
50-59	76 (64, 70, 82, 85)	82 (70, 77, 86, 88)	84 (71, 77, 92, 100)	88 (75, 80, 97, 103)		
60-69	76 (66, 71, 81, 87)	80 (68, 72, 83, 87)	81 (67, 74, 90, 98)	85 (71, 77, 93, 101)		
≥ 70	76 (60, 70, 79, 83)	79 (60, 70, 84, 90)	81 (66, 72, 89, 97)	82 (68, 74, 91, 98)		
Variable: Central pulse pressure						
< 30	29 (23, 27, 37, 43)	36 (26, 32, 43, 53)	34 (24, 28, 41, 48)	38 (26, 31, 46, 52)		
30-39	30 (22, 26, 37, 44)	35 (25, 29, 42, 50)	34 (24, 28, 38, 46)	36 (25, 31, 41, 48)		
40-49	31 (22, 27, 36, 42)	32 (25, 28, 38, 45)	35 (25, 29, 43, 53)	33 (23, 28, 37, 46)		
50-59	34 (25, 28, 42, 49)	30 (25, 27, 35, 42)	39 (28, 32, 47, 58)	34 (25, 28, 41, 49)		
60-69	35 (28, 31, 43, 52)	31 (24, 28, 36, 49)	44 (30, 36, 55, 66)	37 (25, 31, 46, 58)		
≥ 70	39 (28, 34, 45, 52)	37 (19, 27, 41, 51)	50 (33, 41, 63, 77)	42 (28, 34, 52, 66)		

CBP: central blood pressure. Values described in the 50th percentiles (10th, 25th, 75th, and 90th).

Age (years)	Healthy po	pulation	Population with cardiovascular risk factors			
	Female	Male	Female	Male		
Variable: PWV						
< 30	4.9 (4.4, 4.5, 5.0, 5.3)	5.2 (4.9, 5.1, 5.4, 5.7)	5.3 (4.7, 5.0, 5.6, 6.0)	5.5 (5.0, 5.3, 5.8, 6.3)		
30-39	5.4 (5.0, 5.2, 5.8, 6.1)	5.7 (5.3, 5.5, 5.9, 6.1)	5.8 (5.3, 5.5, 6.2, 6.7)	6.1 (5.5, 5.8, 6.4, 6.7)		
40-49	6.4 (5.7, 6.0, 6.7, 6.9)	6.5 (5.9, 6.2, 6.8, 7.0)	6.8 (6.0, 6.4, 7.2, 7.7)	6.8 (6.2, 6.4, 7.1, 7.5)		
50-59	7.5 (6.7, 7.0, 7.8, 8.2)	7.4 (6.9, 7.2, 7.9, 8.0)	7.9 (7.1, 7.5, 8.3, 8.8)	7.9 (7.1, 7.5, 8.3, 8.7)		
60-69	8.9 (8.1, 8.5, 9.2, 9.4)	8.9 (8.2, 8.6, 9.1, 9.6)	9.3 (8.4, 8.8, 9.8, 10.4)	9.2 (8.4, 8.7, 9.7, 10.2)		
≥ 70	11.3 (10.2, 10.4, 12.5, 13.2)	11.0 (10.1, 10.6, 11.6, 12.3)	11.8 (10.2, 10.8, 12.9, 14.0)	11.2 (9.9, 10.4, 12.1, 13.2)		
		Variable: Alx				
< 30	20 (11, 13, 27, 33)	16 (04, 10, 23, 27)	28 (11, 20, 34, 38)	16 (02, 08, 23, 30)		
30-39	22 (12, 16, 28, 34)	14 (01, 07, 18, 24)	26 (11, 18, 32, 37)	15 (03, 09, 21, 27)		
40-49	23 (09, 15, 29, 35)	15 (00, 06, 21, 25)	25 (10, 17, 34, 38)	15 (02, 08, 23, 30)		
50-59	22 (07, 12, 33, 39)	12 (02, 04, 19, 22)	24 (08, 14, 33, 39)	15 (03, 07, 24, 32)		
60-69	23 (09, 14, 34, 42)	17 (01, 05, 27, 43)	28 (11, 18, 37, 44)	17 (03, 09, 26, 34)		
≥ 70	28 (11, 20, 39, 42)	22 (05, 10, 33, 41)	33 (17, 25, 42, 48)	22 (04, 12, 31, 41)		

#### Table 12 – PWV and Alx reference values according to sex and age in a healthy population and to cardiovascular risk factors<sup>214</sup>

PWV: pulse wave velocity; Alx: augmentation index. Values described in the 50th percentiles (10th, 25th, 75th, and 90th).

## Table 13 – Abnormality thresholds for CBP, PWV, and Alx (GR: IIa – LE: C).<sup>216,218,222-225</sup>

Parameters	In-office measurement	24-hour ABPM	Daytime ABPM	Nighttime ABPM
Central SBP	$\geq$ 130 mm Hg	$\geq$ 120 mm Hg	$\geq$ 125 mm Hg	$\geq$ 110 mm Hg
Central DBP	$\geq$ 90 mm Hg	$\geq$ 80 mm Hg	$\geq$ 85 mm Hg	$\geq$ 70 mm Hg
vPWV	$\geq$ 10 m/s	$\geq$ 10 m/s	$\geq$ 10 m/s	$\geq$ 10 m/s
Alx	Not available			

GR: grade of recommendation; LE: level of evidence; ABPM: ambulatory blood pressure monitoring; CBP: central blood pressure; PWV: pulse wave velocity; Alx: augmentation index; vPWV: venous pulse wave velocity.

months of treatment, although without additional effect on peripheral  $BP^{\rm 237}$ 

The prediction of CV events and all-cause mortality through the analysis of central hemodynamics measured with noninvasive methods allowed the calculation of the predictive value of central pressures and central hemodynamic indexes for CV events and all-cause mortality by measuring PWV, cSBP, cPP, and Alx.<sup>205</sup> The following could be stated: for an increase in aortic PWV of 1 m/s, the risk of total CV events, CV mortality, and all-cause mortality increases by 14%, 15%, and 15%, respectively; an increase of 10 mm Hg in cSBP determines a relative risk (RR) of 8.8% for CV events; an increase of 10 mm Hg in cPP determines an RR of 12.9% for CV events; an increase of 10% in Alx determines an RR of 29.4% for total CV events and an RR of 38.4% for all-cause mortality.<sup>205</sup>

PWV has predictive value in CV morbidity and mortality and is currently considered the gold standard method in the assessment of AS and arterial aging, with good correlation with the risk of CV death, CV events, and all-cause mortality. $^{197,205}$ 

To allow a practical identification of individuals at greater risk of developing increased PWV, a clinical score that evaluates easily available variables, called SAGE score, was developed and validated: (S) systolic blood pressure, (A) age, (G) fasting plasma glucose, and (E) estimated glomerular filtration rate (estimated by CKD-EPI), summarized in Figure 9.<sup>242</sup> This score was also applied to Brazilian hypertensive patients evaluated with the oscillometric method, and a SAGE score of  $\geq 8$  was effective in identifying patients with a high risk of PWV  $\geq 10$  m/s, with a sensitivity of 67.19% (95% Cl, 60.1-73.8) and a specificity of 93.95% (95% Cl, 91.8-95.7).<sup>239</sup>

# 10. Measurement of central parameters over 24 hours

The assessment of CBP and AS indicators over 24 hours is still little used in clinical practice, even with growing evidence worldwide of their predictive validity.<sup>217</sup> There is a need to expand scientific knowledge of 24-hour monitoring. However, evidence indicates that monitoring these parameters in daily life conditions can favor the assessment and clinical prognosis of CVD, the possibility of categorizing hypertension phenotypes, especially WCH and MH, and the specific investigation of daytime and nighttime BP.<sup>1,45,214,217</sup>

The International 24-Hour Aortic Blood Pressure Consortium (20 centers, 14 countries, and 5 continents), with central parameters obtained using a Mobil-O-Graph® monitor, conducted a pooled analysis of part of its database (2092 adults) and showed that 24-hour cSBP was more closely associated with hypertensive cardiac organ damage (left




Figure 9 – SAGE score chart.<sup>238,239</sup> In orange (SAGE  $\geq$  8): high probability of elevated arterial stiffness (PWV  $\geq$  10 m/s). In green (SAGE < 8): low probability of elevated arterial stiffness; PWV: pulse wave velocity.

ventricular mass and hypertrophy) than 24-hour brachial cSBP. The same group, in a recent publication, using 130,804 valid cSBP measurements from 2423 untreated adults, pragmatically proposed 120 mm Hg as the upper normal limit for 24-hour cSBP (C1 calibration = systolic/diastolic).<sup>222,240</sup>

A recent meta-analysis reviewed current 24-hour noninvasive technologies for cSBP, PWV, and AIx and the evidence supporting their use in the clinical treatment of patients with hypertension or at risk of CV complications and concluded that the studies performed to date suggest that 24-hour central parameters may represent a promising tool for assessing vascular function, structure, and damage in daily life conditions and promoting early screening in individuals at increased risk.<sup>217</sup> There is still a paucity of studies evaluating the predictive value of 24-hour PWV. Furthermore, the precision of measurements may vary from device to device, affecting the generalization of study results. Longitudinal studies are still needed to validate the predictive value of 24-hour central parameters.

## **11.** Perspectives

The assessment of AS in the range of recommendations for CV risk stratification as a way of identifying the presence of still subclinical HMOD has already been incorporated into the main guidelines.<sup>1,216,217</sup> In this context, the analysis of AS by PWV and central hemodynamic indexes (SBP, cPP, and Alx) are useful for clinical monitoring of patients with hypertension and low-to-intermediate CV risk, young patients with hypertension, patients with prehypertension, diabetes, or CKD, patients with a family history of early CVD, and other risk factors.<sup>205,207,241-245</sup> Although the use of PWV for the identification of HMOD is well established in the literature, as well as its cutoff point of > 10 m/s, values that define the

normality threshold for PWV, corrected for sex and age, remain to be better explored.  $^{1,216,218,223\cdot225}$ 

Based on the interactions of genetics and epigenetics and the ability of the biological system to deal with the results of these combinations, there may be a difference between chronological and biological age. This is the basis for new concepts in vascular aging. Accelerated vascular aging occurs in individuals whose biological vascular age is greater than their chronological age, and these individuals will present earlier disease manifestations. The term SUPERNOVA (supernormal vascular aging) is reserved for individuals who present a vascular age in which arterial injury/stiffness is significantly lower than that expected for a healthy individual of the same age. However, even though this ability to age slowly might be genetically predetermined, lifestyle and pharmaceutical interventions can slow vascular senescence and improve prognosis.<sup>206,219,246</sup>

Studies that guide drug treatment using cSBP, to date, have only demonstrated a reduction in the number of

## References

- Barroso WKS, Rodrigues CIS, Bortolotto LA, Mota-Gomes MA, Brandão AA, Feitosa ADM, et al. Brazilian Guidelines of Hypertension - 2020. Arq Bras Cardiol. 2021;116(3):516-658. doi: 10.36660/abc.20201238.
- Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, et al. The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2014;30(5):485-501. doi: 10.1016/j.cjca.2014.02.002.
- Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017;33(5):557-76. doi: 10.1016/j.cjca.2017.03.005.
- 4. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697-716. doi: 10.1161/01. CIR.0000154900.76284.F6.
- Stergiou GS, Palatini P, Parati G, O'Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension Practice Guidelines for Office and Out-Of-Office Blood Pressure Measurement. J Hypertens. 2021;39(7):1293-302. doi: 10.1097/HJH.00000000002843.
- Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. J Hypertens. 2020;38(6):982-1004. doi: 10.1097/ HJH.00000000002453.
- Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16(1):14-26. doi: 10.1111/jch.12237.
- Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association

antihypertensive drugs, with no effect on left ventricular function.<sup>247-249</sup> In a study evaluating the use of free-dose vs fixed-dose drug combinations to achieve central and brachial SBP goals, ACEIs in a fixed-dose combination were more effective in achieving BP goals. Based on the repercussions of the CAFE study, it became clear that drugs have different effects on BP values (central and peripheral), which result in different clinical outcomes.<sup>250,251</sup>

All these aspects allow us to conclude that there is considerable potential for a true evolution toward precision medicine in its purest concept: identifying damage early or even preventing it from occurring and treating each individual with the most appropriate strategy for their clinical characteristics, thus further reducing CV outcomes.

In conclusion, these Guidelines do not recommend the routine use of cSBP, PWV, and Alx assessment. To this end, further studies with robust clinical outcomes are still required to define the normality thresholds and prognosis for these measurements.

Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. doi: 10.1161/HYP.00000000000066.

- 9. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339.
- 10. Palatini P, Asmar R. Cuff Challenges in Blood Pressure Measurement. J Clin Hypertens. 2018;20(7):1100-103. doi: 10.1111/jch.13301.
- Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of Blood Pressure in the Office: Recognizing the Problem and Proposing the Solution. Hypertension. 2010;55(2):195-200. doi: 10.1161/ HYPERTENSIONAHA.109.141879.
- Myers MG. A Short History of Automated Office Blood Pressure 15 Years to SPRINT. J Clin Hypertens. 2016;18(8):721-4. doi: 10.1111/jch.12820.
- Muntner P, Einhorn PT, Cushman WC, Whelton PK, Bello NA, Drawz PE, et al. Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(3):317-35. doi: 10.1016/j.jacc.2018.10.069.
- Imai Y, Kario K, Shimada K, Kawano Y, Hasebe N, Matsuura H, et al. The Japanese Society of Hypertension Guidelines for Self-monitoring of Blood Pressure at Home (Second Edition). Hypertens Res. 2012;35(8):777-95. doi: 10.1038/hr.2012.56.
- Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018;115(33-34):557-68. doi: 10.3238/arztebl.2018.0557.
- Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guideline for the Diagnosis and Management of Hypertension in Adults - 2016. Med J Aust. 2016;205(2):85-9. doi: 10.5694/mja16.00526.
- 17. Mota-Gomes MA, Gus M, Costa LS, Feitosa ADM. Conceituação, Diagnóstico e Métodos de Medida da Pressão Arterial. Barueri: Manole; 2015.
- Nobre F, Mion D Jr, Gomes MAM, Barbosa ECD, Rodrigues CIS, Neves MFT, et al. 6a Diretrizes de Monitorização Ambulatorial Da Pressão Arterial E 4a Diretrizes De Monitorização Residencial da Pressão Arterial (Sociedade Brasileira de Cardiologia). Arq Bras Cardiol. 2018;110(5 Suppl 1):1-29. doi: 10.5935/abc.20180074.
- Fagard RH, Cornelissen VA. Incidence of Cardiovascular Events in White-Coat, Masked and Sustained Hypertension versus True Normotension:

A Meta-Analysis. J Hypertens. 2007;25(11):2193-8. doi: 10.1097/ HJH.0b013e3282ef6185.

- Clark LA, Denby L, Pregibon D, Harshfield GA, Pickering TG, Blank S, et al. A Quantitative Analysis of the Effects of Activity and Time of Day on the Diurnal Variations of Blood Pressure. J Chronic Dis. 1987;40(7):671-81. doi: 10.1016/0021-9681(87)90103-2.
- Kaczorowski J, Myers MG, Gelfer M, Dawes M, Mang EJ, Berg A, et al. How do Family Physicians Measure Blood Pressure in Routine Clinical Practice? National Survey of Canadian Family Physicians. Can Fam Physician. 2017;63(3):e193-e199.
- Segall HN. How Korotkoff, the Surgeon, Discovered the Auscultatory Method of Measuring Arterial Pressure. Ann Intern Med. 1975;83(4):561-2. doi: 10.7326/0003-4819-83-4-561.
- Brasil. Ministério do Desenvolvimento, Indústria e Comércio Exterior. Instituto Nacional de Metrologia Q e T– P n. 4. Esfigmomanometros [Internet]. Brasília: Ministério do Desenvolvimento, Indústria e Comércio Exterior; 2016 [cited 2016 Jan 22]. Available from: http://www.inmetro.gov. br/legislacao/rtac/ pdf/RTAC002373.pdf.
- Ostchega Y, Prineas RJ, Nwankwo T, Zipf G. Assessing Blood Pressure Accuracy of an Aneroid Sphygmomanometer in a National Survey Environment. Am J Hypertens. 2011;24(3):322-7. doi: 10.1038/ajh.2010.232.
- Serafim TS, Toma GA, Gusmão JL, ColósimoIII FC, Silva SSBE, Pierin AMG. Evaluation of the Conditions of Use of Sphygmomanometers in hospital SERVICes. Acta Paul Enferm. 2012;25(6):940-6. doi: 10.1590/S0103-21002012000600018.
- Quan X, Liu J, Roxlo T, Siddharth S, Leong W, Muir A, et al. Advances in Non-Invasive Blood Pressure Monitoring. Sensors. 2021;21(13):4273. doi: 10.3390/s21134273.
- 27. Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al. A Universal Standard for the Validation of Blood Pressure Measuring Devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. Hypertension. 2018;71(3):368-74. doi: 10.1161/HYPERTENSIONAHA.117.10237.
- Picone DS, Schultz MG, Otahal P, Aakhus S, Al-Jumaily AM, Black JA, et al. Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. J Am Coll Cardiol. 2017;70(5):572-86. doi: 10.1016/j. jacc.2017.05.064.
- Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a Difference in Systolic Blood Pressure between Arms with Vascular Disease and Mortality: A Systematic Review and Meta-Analysis. Lancet. 2012;379(9819):905-14. doi: 10.1016/S0140-6736(11)61710-8.
- Leblanc MÈ, Auclair A, Leclerc J, Bussières J, Agharazii M, Hould FS, et al. Blood Pressure Measurement in Severely Obese Patients: Validation of the Forearm Approach in Different Arm Positions. Am J Hypertens. 2019;32(2):175-85. doi: 10.1093/ajh/hpy152.
- Senarclens O, Feihl F, Giusti V, Engelberger RP, Rodieux F, Gomez P, et al. Brachial or Wrist Blood Pressure in Obese Patients: Which is the Best? Blood Press Monit. 2008;13(3):149-51. doi: 10.1097/MBP.0b013e3282fd16e3.
- Irving G, Holden J, Stevens R, McManus RJ. Which Cuff Should I Use? Indirect Blood Pressure Measurement for the Diagnosis of Hypertension in Patients with Obesity: A Diagnostic Accuracy Review. BMJ Open. 2016;6(11):e012429. doi: 10.1136/bmjopen-2016-012429.
- Messerli FH, Schmieder RE. Blood Pressure Measurement. New York: Elsevier; 1991.
- Saedon NI, Tan MP, Frith J. The Prevalence of Orthostatic Hypotension: A Systematic Review and Meta-Analysis. J Gerontol A Biol Sci Med Sci. 2020;75(1):117-22. doi: 10.1093/gerona/gly188.
- Fagard RH, De Cort P. Orthostatic Hypotension is a More Robust Predictor of Cardiovascular Events Than Nighttime Reverse Dipping in Elderly. Hypertension. 2010;56(1):56-61. doi: 10.1161/ HYPERTENSIONAHA.110.151654.

- Gazibara T, Rancic B, Maric G, Radovanovic S, Kisic-Tepavcevic D, Pekmezovic T. Medical Students, do You Know How to Measure Blood Pressure Correctly? Blood Press Monit. 2015;20(1):27-31. doi: 10.1097/ MBP.000000000000085.
- 37. Ibiyemi O, Ogunbodede O, Gbolahan OO, Ogah OS. Knowledge and Practices of Blood Pressure Measurement among Final Year Students, House Officers, and Resident Dental Surgeons in a Dental Hospital, South West Nigeria. Niger J Clin Pract. 2020;23(6):848-56. doi: 10.4103/njcp. njcp\_416\_19.
- Rakotz MK, Townsend RR, Yang J, Alpert BS, Heneghan KA, Wynia M, et al. Medical Students and Measuring Blood Pressure: Results from the American Medical Association Blood Pressure Check Challenge. J Clin Hypertens. 2017;19(6):614-9. doi: 10.1111/jch.13018.
- González-López JJ, Ramírez JG, García RT, Esteban SA, del Barrio JA, Rodríguez-Artalejo F. Knowledge of Correct Blood Pressure Measurement Procedures among Medical and Nursing Students. Rev Esp Cardiol. 2009;62(5):568-71. doi: 10.1016/s1885-5857(09)71840-7.
- 40. American College of Sports Medicine. Guidelines for Exercise Testing and Prescription. 10th ed. Philadelphia: Wolters Kluwer; 2018.
- Queiroz ACC, Brito LC, Souza DR, Tinucci T, Forjaz CLM. Medida da Pressão Arterial e Exercício Físico. Rev Hipertens. 2022;14(3):21-32. doi: 10.1590/ S1517-86922004000600008.
- Bergel E, Carroli G, Althabe F. Ambulatory versus Conventional Methods for Monitoring Blood Pressure During Pregnancy. Cochrane Database Syst Rev. 2002;(2):CD001231. doi: 10.1002/14651858.CD001231.
- Feitosa ADM, Mota-Gomes MA, Barroso WS, Miranda RD, Barbosa ECD, Brandão AA, et al. The Impact of Changing Home Blood Pressure Monitoring Cutoff from 135/85 to 130/80 mmHg on Hypertension Phenotypes. J Clin Hypertens. 2021;23(7):1447-451. doi: 10.1111/jch.14261.
- Associação Médica Brasileira. Resolução Normativa CNHM n. 040/2019 [Internet]. São Paulo: AM | B; 2019 [cited 2023 Aug 17]. Available from: https:// amb.org.br/wp-content/uploads/2019/05/RN-CNHM-040\_2019-nova.pdf.
- 45. Paiva AMG, Gomes MICM, Campana ÉMG, Feitosa ADM, Sposito AC, Mota-Gomes MA, et al. Impact of Hypertension Phenotypes on the Office and 24-h Pulse Wave Velocity and Augmentation Index in Individuals with or without Antihypertensive Medication Use. Hypertens Res. 2019;42(12):1989-95. doi: 10.1038/s41440-019-0323-6.
- Nobre F, Mion D Jr. Ambulatory Blood Pressure Monitoring: Five Decades of More Light and Less Shadows. Arq Bras Cardiol. 2016 Jn;106(6):528-37. doi: 10.5935/abc.20160065.
- Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, Ferrari A, et al. Effects of Blood-Pressure Measurement by the Doctor on Patient's Blood Pressure and Heart Rate. Lancet. 1983;2(8352):695-8. doi: 10.1016/s0140-6736(83)92244-4.
- Pierin AM, Souza V, Lima JC, Mano GM, Ortega K, Ignês EC, et al. White Coat Effect and White Coat Hypertension and Office Blood Pressure Measurement Taken by Patients, Nurses, and Doctors Compared with Ambulatory Blood Pressure Monitoring. J Hypertens. 2002;20(4 Suppl):S975.
- Franklin SS, Thijs L, Hansen TW, O'Brien E, Staessen JA. White-Coat Hypertension: New Insights from Recent Studies. Hypertension. 2013;62(6):982-7. doi: 10.1161/HYPERTENSIONAHA.113.01275.
- Feitosa ADM, Mota-Gomes MA, Barroso WS, Miranda RD, Barbosa ECD, Pedrosa RP, et al. Relationship between Office Isolated Systolic or Diastolic Hypertension and White-Coat Hypertension Across the Age Spectrum: A Home Blood Pressure Study. J Hypertens. 2020;38(4):663-70. doi: 10.1097/ HJH.00000000002320.
- Manios ED, Koroboki EA, Tsivgoulis GK, Spengos KM, Spiliopoulou IK, Brodie FG, et al. Factors Influencing White-Coat Effect. Am J Hypertens. 2008;21(2):153-8. doi: 10.1038/ajh.2007.43.
- 52. Barroso WKS, Feitosa ADM, Barbosa ECD, Miranda RD, Brandão AA, Vitorino PVO, et al. Prevalence of Masked and White-Coat Hypertension

in Pre-Hypertensive and Stage 1 Hypertensive patients with the use of TeleMRPA. Arq Bras Cardiol. 2019;113(5):970-5. doi: 10.5935/abc.20190147.

- Pierdomenico SD, Cuccurullo F. Prognostic Value of White-Coat and Masked Hypertension Diagnosed by Ambulatory Monitoring in Initially Untreated Subjects: An Updated Meta Analysis. Am J Hypertens. 2011;24(1):52-8. doi: 10.1038/ajh.2010.203.
- O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension position paper on Ambulatory Blood Pressure Monitoring. J Hypertens. 2013;31(9):1731-68. doi: 10.1097/ HJH.0b013e328363e964.
- Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Friz HP, et al. Long-Term Risk of Sustained Hypertension in White-Coat or Masked Hypertension. Hypertension. 2009;54(2):226-32. doi: 10.1161/ HYPERTENSIONAHA.109.129882.
- Ugajin T, Hozawa A, Ohkubo T, Asayama K, Kikuya M, Obara T, et al. White-Coat Hypertension as a Risk Factor for the Development of Home Hypertension: The Ohasama Study. Arch Intern Med. 2005;165(13):1541-6. doi: 10.1001/archinte.165.13.1541.
- 57. Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, et al. White-Coat Hypertension is a Risk Factor for Cardiovascular Diseases and Total Mortality. J Hypertens. 2017;35(4):677-88. doi: 10.1097/HJH.000000000001226.
- Feitosa ADM, Mota-Gomes MA, Barroso WS, Miranda RD, Barbosa ECD, Pedrosa RP, et al. Blood Pressure Cutoffs for White-Coat and Masked Effects in a Large Population Undergoing Home Blood Pressure Monitoring. Hypertens Res. 2019;42(11):1816-23. doi: 10.1038/ s41440-019-0298-3.
- Thakkar HV, Pope A, Anpalahan M. Masked Hypertension: A Systematic Review. Heart Lung Circ. 2020;29(1):102-11. doi: 10.1016/j. hlc.2019.08.006.
- Alves MAM, Feitosa ADM, Mota-Gomes MA, Paiva AMG, Barroso WS, Miranda RD, et al. Accuracy of Screening Strategies for Masked Hypertension: A Large-Scale Nationwide Study Based on Home Blood Pressure Monitoring. Hypertens Res. 2023;46(3):742-50. doi: 10.1038/ s41440-022-01103-y.
- Bangash F, Agarwal R. Masked Hypertension and White-Coat Hypertension in Chronic Kidney Disease: A Meta-Analysis. Clin J Am Soc Nephrol. 2009;4(3):656-64. doi: 10.2215/CJN.05391008.
- Palla M, Saber H, Konda S, Briasoulis A. Masked Hypertension and Cardiovascular Outcomes: An Updated Systematic Review and Meta-Analysis. Integr Blood Press Control. 2018;11:11-24. doi: 10.2147/IBPC. S128947.
- 63. Huang QF, Yang WY, Asayama K, Zhang ZY, Thijs L, Li Y, et al. Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension. 2021;77(2):254-64. doi: 10.1161/ HYPERTENSIONAHA.120.14591.
- Yugar-Toledo JC, Moreno H Jr, Gus M, Rosito GBA, Scala LCN, Muxfeldt ES, et al. Brazilian Position Statement on Resistant Hypertension - 2020. Arq Bras Cardiol. 2020;114(3):576-96. doi: 10.36660/abc.20200198.
- 65. Muxfeldt ES, Barros GS, Viegas BB, Carlos FO, Salles GF. Is Home Blood Pressure Monitoring Useful in the Management of Patients with Resistant Hypertension? Am J Hypertens. 2015;28(2):190-9. doi: 10.1093/ajh/hpu145.
- Pickering TG, Shimbo D, Haas D. Ambulatory Blood-Pressure Monitoring. N Engl J Med. 2006;354(22):2368-74. doi: 10.1056/NEJMra060433.
- 67. Gijón-Conde T, Gorostidi M, Banegas JR, de la Sierra A, Segura J, Vinyoles E, et al. Position Statement on Ambulatory Blood Pressure Monitoring (ABPM) by the Spanish Society of Hypertension (2019). Hipertens Riesgo Vasc. 2019;36(4):199-212. doi: 10.1016/j.hipert.2019.05.002.
- Eguchi K, Hoshide S, Hoshide Y, Ishikawa S, Shimada K, Kario K. Reproducibility of Ambulatory Blood Pressure in Treated and Untreated Hypertensive Patients. J Hypertens. 2010;28(5):918-24. doi: 10.1097/ HJH.0b013e3283378477.

- 69. Bo Y, Kwok KO, Chung VC, Yu CP, Tsoi KK, Wong SY, et al. Short-Term Reproducibility of Ambulatory Blood Pressure Measurements: A Systematic Review and Meta-Analysis of 35 Observational Studies. J Hypertens. 2020;38(11):2095-109. doi: 10.1097/HJH.00000000002522.
- Kikuya M, Hansen TW, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al. Diagnostic Thresholds for ambulatory Blood Pressure Monitoring Based on 10-Year Cardiovascular Risk. Circulation. 2007;115(16):2145-52. doi: 10.1161/CIRCULATIONAHA.106.662254.
- Pickering TG, White WB; American Society of Hypertension Writing Group. ASH Position Paper: Home and Ambulatory Blood Pressure Monitoring. When and How to Use Self (Home) and Ambulatory Blood Pressure Monitoring. J Clin Hypertens. 2008;10(11):850-5. doi: 10.1111/j.1751-7176.2008.00043.x.
- Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive Role of the Nighttime Blood Pressure. Hypertension. 2011;57(1):3-10. doi: 10.1161/ HYPERTENSIONAHA.109.133900.
- Tadic M, Cuspidi C, Sljivic A, Pencic B, Mancia G, Bombelli M, et al. Do Reverse Dippers Have the Highest Risk of Right Ventricular Remodeling? Hypertens Res. 2020;43(3):213-9. doi: 10.1038/s41440-019-0351-2.
- 74. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning Surge in Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in Elderly Hypertensives: A Prospective Study. Circulation. 2003;107(10):1401-6. doi: 10.1161/01. cir.0000056521.67546.aa.
- Cheng HM, Wu CL, Sung SH, Lee JC, Kario K, Chiang CE, et al. Prognostic Utility of Morning Blood Pressure Surge for 20-Year All-Cause and Cardiovascular Mortalities: Results of a Community-Based Study. J Am Heart Assoc. 2017;6(12):e007667. doi: 10.1161/JAHA.117.007667.
- Kario K, Weber MA, Böhm M, Townsend RR, Mahfoud F, Schmieder RE, et al. Effect of Renal Denervation in Attenuating the Stress of Morning Surge in Blood Pressure: Post-Hoc Analysis from the SPYRAL HTN-ON MED Trial. Clin Res Cardiol. 2021;110(5):725-31. doi: 10.1007/ s00392-020-01718-6.
- Mokwatsi GG, Schutte AE, Mels CMC, Kruger R. Morning Blood Pressure Surge in Young Black and White Adults: The African-PREDICT Study. J Hum Hypertens. 2019;33(1):22-33. doi: 10.1038/s41371-018-0089-3.
- Li Y, Thijs L, Boggia J, Asayama K, Hansen TW, Kikuya M, et al. Blood Pressure Load Does Not Add to Ambulatory Blood Pressure Level for Cardiovascular Risk Stratification. Hypertension. 2014;63(5):925-33. doi: 10.1161/ HYPERTENSIONAHA.113.02780.
- Nobre F, Mion D Jr. Is the Area Under Blood Pressure Curve the Best Parameter to Evaluate 24-h Ambulatory Blood Pressure Monitoring Data? Blood Press Monit. 2005;10(5):263-70. doi: 10.1097/01. mbp.0000180669.38161.6e.
- Mena LJ, Felix VG, Melgarejo JD, Maestre GE. 24-hour Blood Pressure Variability Assessed by Average Real Variability: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6(10):e006895. doi: 10.1161/ JAHA.117.006895.
- Lauder L, Scholz SS, Ewen S, Lettner C, Ukena C, Böhm M, et al. Accuracy of Pulse Rate Derived from 24-h ambulatory Blood Pressure Monitoring Compared with Heart Rate from 24-h Holter-ECG. J Hypertens. 2020;38(12):2387-92. doi: 10.1097/HJH.000000000002566.
- Mion D Jr., Nobre F OW. Monitorização Ambulatorial da Pressão Arterial de 24h. 2nd ed. São Paulo: Atheneu; 1998.
- Clement DL, Buyzere ML, Bacquer DA, Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension. N Engl J Med. 2003;348(24):2407-15. doi: 10.1056/NEJMoa022273.
- Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension: Prognostic Implications. Hypertension. 2012;60(1):34-42. doi: 10.1161/ HYPERTENSIONAHA.112.191858.

- Perloff D, Sokolow M, Cowan R. The Prognostic Value of Ambulatory Blood Pressures. JAMA. 1983;249(20):2792-8. doi: 10.1001/ jama.1983.03330440030027.
- Bilo G, Grillo A, Guida V, Parati G. Morning Blood Pressure Surge: Pathophysiology, Clinical Relevance and Therapeutic Aspects. Integr Blood Press Control. 2018;11:47-56. doi: 10.2147/IBPC.S130277.
- Banegas JR, Ruilope LM, de la Sierra A, Vinyoles E, Gorostidi M, de la Cruz JJ, et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. N Engl J Med. 2018;378(16):1509-20. doi: 10.1056/NEJMoa1712231.
- Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, Buyzere ML, et al. Daytime and Nighttime Blood Pressure as Predictors of Death and Cause-Specific Cardiovascular Events in Hypertension. Hypertension. 2008;51(1):55-61. doi: 10.1161/HYPERTENSIONAHA.107.100727.
- Zhang H, Cui Y, Zhao Y, Dong Y, Wang J, Duan D, et al. Association of Circadian Rhythm of Blood Pressure and Cerebral Small Vessel Disease in Community-Based Elderly Population. J Gerontol A Biol Sci Med Sci. 2019;74(8):1322-30. doi: 10.1093/gerona/gly212.
- Viazzi F, Cappadona F, Leoncini G, Ratto E, Gonnella A, Bonino B, et al. Two-Day ABPM-Derived Indices and Mortality in Hemodialysis Patients. Am J Hypertens. 2020;33(2):165-174. doi: 10.1093/ajh/hpz166.
- Wirtwein M, Gruchala M, Sobiczewski W. Diurnal Blood Pressure Profile and Coronary Atherosclerosis Extent are Related to Cardiovascular Complications. Blood Press. 2017;26(2):81-6. doi: 10.3109/08037051.2016.1160498.
- Muxfeldt ES, Cardoso CR, Salles GF. Prognostic Value of Nocturnal Blood Pressure Reduction in Resistant Hypertension. Arch Intern Med. 2009;169(9):874-80. doi: 10.1001/archinternmed.2009.68.
- Uallachain GN, Murphy G, Avalos G. The RAMBLER Study: The Role of Ambulatory Blood Pressure Measurement in Routine Clinical Practice: A Cross-Sectional Study. Ir Med J. 2006;99(9):276-9.
- Banegas JR, de la Cruz JJ, Graciani A, López-García E, Gijón-Conde T, Ruilope LM, et al. Impact of Ambulatory Blood Pressure Monitoring on Reclassification of Hypertension Prevalence and Control in Older People in Spain. J Clin Hypertens. 2015;17(6):453-61. doi: 10.1111/jch.12525.
- Koskinen JS, Kytö V, Juonala M, Viikari JSA, Nevalainen J, Kähönen M, et al. Childhood Risk Factors and Carotid Atherosclerotic Plaque in Adulthood: The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2020;293:18-25. doi: 10.1016/j.atherosclerosis.2019.11.029.
- Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, et al. Update: Ambulatory Blood Pressure Monitoring in Children and Adolescents: A Scientific Statement from the American Heart Association. Hypertension. 2014;63(5):1116-35. doi: 10.1161/ HYP.0000000000000007.
- Flynn JT, Kaelber DC, Baker-Smith CM, Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. Pediatrics. 2018;142(3):e20181739. doi: 10.1542/peds.2018-1739.
- Flynn JT, Urbina EM, Brady TM, Baker-Smith C, Daniels SR, Hayman LL, et al. Ambulatory Blood Pressure Monitoring in Children and Adolescents: 2022 Update: A Scientific Statement from the American Heart Association. Hypertension. 2022;79(7):e114-e124. doi: 10.1161/ HYP.00000000000215.
- Lowe SA, Bowyer L, Lust K, McMahon LP, Morton M, North RA, et al. SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55(5):e1-29. doi: 10.1111/ajo.12399.
- 100. Brown MA, Davis GK, McHugh L. The Prevalence and Clinical Significance of Nocturnal Hypertension in Pregnancy. J Hypertens. 2001;19(8):1437-44. doi: 10.1097/00004872-200108000-00012.
- 101. Feldman DM. Blood Pressure Monitoring During Pregnancy. Blood Press Monit. 2001;6(1):1-7. doi: 10.1097/00126097-200102000-00001.

- 102. Okada Y, Galbreath MM, Shibata S, Jarvis SS, Bivens TB, Vongpatanasin W, et al. Morning Blood Pressure Surge is Associated with Arterial Stiffness and Sympathetic Baroreflex Sensitivity in Hypertensive Seniors. Am J Physiol Heart Circ Physiol. 2013;305(6):H793-802. doi: 10.1152/ajpheart.00254.2013.
- Hoshide S, Kario K. Early Morning Hypertension: A Narrative Review. Blood Press Monit. 2013;18(6):291-6. doi: 10.1097/MBP0000000000000004.
- 104. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke Prognosis and Abnormal Nocturnal Blood Pressure Falls in Older Hypertensives. Hypertension. 2001;38(4):852-7. doi: 10.1161/hy1001.092640.
- 105. Gunawan F, Ng HY, Gilfillan C, Anpalahan M. Ambulatory Blood Pressure Monitoring in Type 2 Diabetes Mellitus: A Cross-sectional Study. Curr Hypertens Rev. 2019;15(2):135-43. doi: 10.2174/15734021146661806 07090205.
- 106. Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus Statement on the Definition of Neurogenic Supine Hypertension in Cardiovascular Autonomic Failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355-62. doi: 10.1007/s10286-018-0529-8.
- 107.Najafi MT, Khaloo P, Alemi H, Jaafarinia A, Blaha MJ, Mirbolouk M, et al. Ambulatory Blood Pressure Monitoring and Diabetes Complications: Targeting Morning Blood Pressure Surge and Nocturnal Dipping. Medicine. 2018;97(38):e12185. doi: 10.1097/MD.00000000012185.
- 108. Wang C, Zhang J, Deng W, Gong W, Liu X, Ye Z, et al. Nighttime Systolic Blood-Pressure Load Is Correlated with Target-Organ Damage Independent of Ambulatory Blood-Pressure Level in Patients with Non-Diabetic Chronic Kidney Disease. PLoS One. 2015;10(7):e0131546. doi: 10.1371/journal. pone.0131546.
- 109. Rahman M, Wang X, Bundy JD, Charleston J, Cohen D, Cohen J, et al. Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2020;31(11):2609-21. doi: 10.1681/ASN.2020030236.
- 110. Vareta G, Georgianos PI, Vaios V, Sgouropoulou V, Roumeliotis S, Georgoulidou A, et al. Epidemiology of Hypertension among Patients on Peritoneal Dialysis Using Standardized Office and Ambulatory Blood Pressure Recordings. Am J Nephrol. 2022;53(2-3):139-47. doi: 10.1159/000521861.
- 111. Rundo JV. Obstructive Sleep Apnea Basics. Cleve Clin J Med. 2019;86(9 Suppl 1):2-9. doi: 10.3949/ccjm.86.s1.02.
- 112.Hoshide S, Kario K, Chia YC, Siddique S, Buranakitjaroen P, Tsoi K, et al. Characteristics of Hypertension in Obstructive Sleep Apnea: An Asian Experience. J Clin Hypertens. 2021;23(3):489-95. doi: 10.1111/ jch.14184.
- 113. Cuspidi C, Tadic M, Sala C, Gherbesi E, Grassi G, Mancia G. Blood Pressure Non-Dipping and Obstructive Sleep Apnea Syndrome: A Meta-Analysis. J Clin Med. 2019;8(9):1367. doi: 10.3390/jcm8091367.
- 114. Genta-Pereira DC, Furlan SF, Omote DQ, Giorgi DMA, Bortolotto LA, Lorenzi-Filho G, et al. Nondipping Blood Pressure Patterns Predict Obstructive Sleep Apnea in Patients Undergoing Ambulatory Blood Pressure Monitoring. Hypertension. 2018;72(4):979-85. doi: 10.1161/ HYPERTENSIONAHA.118.11525.
- 115. Carvalho VO, Ciolac EG, Guimarães GV, Bocchi EA. Effect of Exercise Training on 24-hour Ambulatory Blood Pressure Monitoring in Heart Failure Patients. Congest Heart Fail. 2009;15(4):176-80. doi: 10.1111/j.1751-7133.2009.00093.x.
- 116. Goyal D, Macfadyen RJ, Watson RD, Lip GY. Ambulatory Blood Pressure Monitoring in Heart Failure: A Systematic Review. Eur J Heart Fail. 2005;7(2):149-56. doi: 10.1016/j.ejheart.2004.05.010.

- 117. Canesin MF, Giorgi D, Oliveira MT Jr, Wajngarten M, Mansur AJ, Ramires JA, et al. Ambulatory Blood Pressure Monitoring of Patients with Heart Failure. A New Prognosis Marker. Arq Bras Cardiol. 2002;78(1):83-9. doi: 10.1590/ s0066-782x2002000100007.
- 118. Ueda T, Kawakami R, Nakada Y, Nakano T, Nakagawa H, Matsui M, et al. Differences in Blood Pressure Riser Pattern in Patients with Acute Heart Failure with Reduced Mid-Range and Preserved Ejection Fraction. ESC Heart Fail. 2019;6(5):1057-67. doi: 10.1002/ehf2.12500.
- 119. Kotti K, Bagarhatta R, Rathore M, Bagarhatta P. Is Ambulatory Blood Pressure Measurement a New Indicator for Survival among Advanced Heart Failure Cases. Indian Heart J. 2018;70(Suppl 1):S73-S78. doi: 10.1016/j. ihj.2017.08.028.
- 120. Brito LC, Fecchio RY, Peçanha T, Andrade-Lima A, Halliwill JR, Forjaz CLM. Postexercise Hypotension as a Clinical Tool: A "Single Brick" in the Wall. J Am Soc Hypertens. 2018;12(12):e59-e64. doi: 10.1016/j.jash.2018.10.006.
- 121. Beyhaghi H, Viera AJ. Comparative Cost-Effectiveness of Clinic, Home, or Ambulatory Blood Pressure Measurement for Hypertension Diagnosis in US Adults. Hypertension. 2019;73(1):121-31. doi: 10.1161/ HYPERTENSIONAHA.118.11715.
- 122. Bloch MJ, Basile JN. New British Guidelines Mandate Ambulatory Blood Pressure Monitoring to Diagnose Hypertension in All Patients: Not Ready for Prime Time in the United States. J Clin Hypertens. 2011 Nov;13(11):785-6. doi: 10.1111/j.1751-7176.2011.00532.x.
- 123. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, et al. Cost-Effectiveness of Options for the Diagnosis of High Blood Pressure in Primary Care: A Modelling Study. Lancet. 2011;378(9798):1219-30. doi: 10.1016/S0140-6736(11)61184-7.
- 124. Stergiou GS, Parati G. The Optimal Schedule for Self-Monitoring of Blood Pressure by Patients at Home. J Hypertens. 2007;25(10):1992-7. doi: 10.1097/HJH.0b013e3282efc17d.
- 125. Feitosa AD, Gomes MA, Mion D Jr. How Many Days, Which Period of the Day and How Many Measurements Per Day are Recommended in Home Blood Pressure Monitoring?. Arq Bras Cardiol. 2005;85(3):210-1. doi: 10.1590/s0066-782x2005001600012.
- 126. Park JS, Rhee MY, Namgung J, Lee SY, Cho DK, Choi TY, et al. Comparison of Optimal Diagnostic Thresholds of Hypertension with Home Blood Pressure Monitoring and 24-hour Ambulatory Blood Pressure Monitoring. Am J Hypertens. 2017;30(12):1170-6. doi: 10.1093/ajh/hpx115.
- 127. Niiranen TJ, Asayama K, Thijs L, Johansson JK, Ohkubo T, Kikuya M, et al. Outcome-Driven Thresholds for Home Blood Pressure Measurement: International Database of Home Blood Pressure in Relation to Cardiovascular Outcome. Hypertension. 2013;61(1):27-34. doi: 10.1161/ HYPERTENSIONAHA.111.00100.
- 128. Feitosa ADM, Mota-Gomes MA, Barroso WS, Miranda RD, Barbosa ECD, Pedrosa RP, et al. Correlation between Office and Home Blood Pressure in Clinical Practice: A Comparison with 2017 American College of Cardiology/American Heart Association Hypertension Guidelines recommendations. J Hypertens. 2020;38(1):179-81. doi: 10.1097/ HJH.00000000002265.
- 129. Yasui D, Asayama K, Ohkubo T, Kikuya M, Kanno A, Hara A, et al. Stroke Risk in Treated Hypertension Based on Home Blood Pressure: The Ohasama Study. Am J Hypertens. 2010;23(5):508-14. doi: 10.1038/ajh.2010.15.
- 130. Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brandão AA, Neves MFT, et al. 7th Brazilian Guideline of Arterial Hypertension: Presentation. Arq Bras Cardiol. 2016;107(3 Suppl 3):1-83. doi: 10.5935/abc.20160140.
- 131. Niiranen TJ, Hänninen MR, Johansson J, Reunanen A, Jula AM. Home-Measured Blood Pressure is a Stronger Predictor of Cardiovascular Risk Than Office Blood Pressure: The Finn-Home Study. Hypertension. 2010;55(6):1346-51. doi: 10.1161/HYPERTENSIONAHA.109.149336.
- 132. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of "Masked" Hypertension and "White-Coat" Hypertension Detected by 24-h Ambulatory Blood Pressure Monitoring 10-Year Follow-

Up from the Ohasama Study. J Am Coll Cardiol. 2005;46(3):508-15. doi: 10.1016/j.jacc.2005.03.070.

- 133. Feitosa ADM, Mota-Gomes MA, Miranda RD, Barroso WS, Barbosa ECD, Pedrosa RP, et al. Impact of 2017 ACC/AHA Hypertension Guidelines on the Prevalence of White-Coat and Masked Hypertension: A Home Blood Pressure Monitoring Study. J Clin Hypertens. 2018;20(12):1745-47. doi: 10.1111/jch.13422.
- 134. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic Value of Ambulatory and Home Blood Pressures Compared with Office Blood Pressure in the General Population: Follow-Up Results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Circulation. 2005;111(14):1777-83. doi: 10.1161/01. CIR.0000160923.04524.5B.
- 135. Hashimoto T, Kikuya M, Ohkubo T, Satoh M, Metoki H, Inoue R, et al. Home Blood Pressure Level, Blood Pressure Variability, Smoking, and Stroke Risk in Japanese Men: The Ohasama Study. Am J Hypertens. 2012;25(8):883-91. doi: 10.1038/ajh.2012.62.
- 136. Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and Evening Home Blood Pressure and Risks of Incident Stroke and Coronary Artery Disease in the Japanese General Practice Population: The Japan Morning Surge-Home Blood Pressure Study. Hypertension. 2016;68(1):54-61. doi: 10.1161/HYPERTENSIONAHA.116.07201.
- 137. Kollias A, Ntineri A, Stergiou GS. Association of Night-Time Home Blood Pressure with Night-Time Ambulatory Blood Pressure and Target-Organ Damage: A Systematic Review and Meta-Analysis. J Hypertens. 2017;35(3):442-52. doi: 10.1097/HJH.000000000001189.
- 138. Ward AM, Takahashi O, Stevens R, Heneghan C. Home Measurement of Blood Pressure and Cardiovascular Disease: Systematic Review and Meta-Analysis of Prospective Studies. J Hypertens. 2012;30(3):449-56. doi: 10.1097/HJH.0b013e32834e4aed.
- 139. Bliziotis IA, Destounis A, Stergiou GS. Home versus Ambulatory and Office Blood Pressure in Predicting Target Organ Damage in Hypertension: A Systematic Review and Meta-Analysis. J Hypertens. 2012;30(7):1289-99. doi: 10.1097/HJH.0b013e3283531eaf.
- 140.Kario K. Home Blood Pressure Monitoring: Current Status and New Developments. Am J Hypertens. 2021;34(8):783-94. doi: 10.1093/ajh/hpab017.
- 141.Zhang DY, Guo QH, An DW, Li Y, Wang JG. A Comparative Meta-Analysis of Prospective Observational Studies on Masked Hypertension and Masked Uncontrolled Hypertension Defined by Ambulatory and Home Blood Pressure. J Hypertens. 2019;37(9):1775-85. doi: 10.1097/ HJH.00000000002109.
- 142. Townsend RR. Out-of-Office Blood Pressure Monitoring: A Comparison of Ambulatory Blood Pressure Monitoring and Home (Self) Monitoring Of Blood Pressure. Hypertension. 2020;76(6):1667-73. doi: 10.1161/ HYPERTENSIONAHA.120.14650.
- 143. Mancia G, Facchetti R, Seravalle G, Cuspidi C, Corrao G, Grassi G. Adding Home and/or Ambulatory Blood Pressure to Office Blood Pressure for Cardiovascular Risk Prediction. Hypertension. 2021;77(2):640-9. doi: 10.1161/HYPERTENSIONAHA.120.16303.
- 144. Parati G, Stergiou GS, Bilo G, Kollias A, Pengo M, Ochoa JE, et al. Home Blood Pressure Monitoring: Methodology, Clinical Relevance and Practical Application: A 2021 Position Paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021;39(9):1742-67. doi: 10.1097/ HJH.00000000002922.
- 145. Feitosa ADM, Mota-Gomes MA, Nobre F, Mion D Jr, Paiva AMG, Argenta F, et al. What are the Optimal Reference Values for Home Blood Pressure Monitoring? Arq Bras Cardiol. 2021;116(3):501-3. doi: 10.36660/abc.20201109.
- 146.Agarwal R, Bills JE, Hecht TJ, Light RP. Role of Home Blood Pressure Monitoring in Overcoming Therapeutic Inertia and Improving Hypertension Control: A Systematic Review and

Meta-Analysis. Hypertension. 2011;57(1):29-38. doi: 10.1161/ HYPERTENSIONAHA.110.160911.

- 147. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-79. doi: 10.1056/NEJMoa2111437.
- 148. Tang O, Foti K, Miller ER, Appel LJ, Juraschek SP. Factors Associated with Physician Recommendation of Home Blood Pressure Monitoring and Blood Pressure in the US Population. Am J Hypertens. 2020;33(9):852-9. doi: 10.1093/ajh/hpaa093.
- 149. McManus RJ, Mant J, Franssen M, Nickless A, Schwartz C, Hodgkinson J, et al. Efficacy of Self-Monitored Blood Pressure, with or without Telemonitoring, for Titration of Antihypertensive Medication (TASMINH4): an Unmasked Randomised Controlled Trial. Lancet. 2018;391(10124):949-959. doi: 10.1016/S0140-6736(18)30309-X.
- 150. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and Self-Management in the Control of Hypertension (TASMINH2): A Randomised Controlled Trial. Lancet. 2010;376(9736):163-72. doi: 10.1016/S0140-6736(10)60964-6.
- 151. Feitosa FGAM, Feitosa ADM, Mota-Gomes MA, Paiva AMG, Barroso WS, Miranda RD, et al. Discrepancies in the Diagnosis of Hypertension in Adolescents According to Available Office and Home High Blood Pressure Criteria. J Clin Hypertens. 2022;24(1):83-7. doi: 10.1111/jch.14406.
- 152. Jardim TV, Rosner B, Bloch KV, Kuschnir MCC, Szklo M, Jardim PCV. Blood Pressure Reference Values for Brazilian Adolescents: Data from the Study of Cardiovascular Risk in Adolescents (ERICA Study). J Pediatr. 2020;96(2):168-76. doi: 10.1016/j.jped.2018.09.003.
- 153. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension. 2018;72(1):24-43. doi: 10.1161/HYPERTENSIONAHA.117.10803.
- 154. Hurrell A, Webster L, Chappell LC, Shennan AH. The Assessment of Blood Pressure in Pregnant Women: Pitfalls and Novel Approaches. Am J Obstet Gynecol. 2022;226(2S):S804-S818. doi: 10.1016/j.ajog.2020.10.026.
- 155. Avila WS, Alexandre ERG, Castro ML, Lucena AJG, Marques-Santos C, Freire CMV, et al. Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease - 2020. Arq Bras Cardiol. 2020;114(5):849-942. doi: 10.36660/abc.20200406.
- 156. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular Prognosis of "Masked Hypertension" Detected by Blood Pressure Self-Measurement in Elderly Treated Hypertensive Patients. JAMA. 2004;291(11):1342-9. doi: 10.1001/jama.291.11.1342.
- 157. Broege PA, James GD, Pickering TG. Management of Hypertension in the Elderly Using Home Blood Pressures. Blood Press Monit. 2001;6(3):139-44. doi: 10.1097/00126097-200106000-00004.
- 158. Feitosa-Filho GS, Peixoto JM, Pinheiro JES, Afiune A Neto, Albuquerque ALT, Cattani ÁCet al. Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. Arq Bras Cardiol. 2019;112(5):649-705. doi: 10.5935/abc.20190086.
- 159. Trudel X, Brisson C, Gilbert-Ouimet M, Duchaine CS, Dalens V, Talbot D, et al. Masked Hypertension Incidence and Risk Factors in a Prospective Cohort Study. Eur J Prev Cardiol. 2019;26(3):231-7. doi: 10.1177/2047487318802692.
- 160. Cacciolati C, Tzourio C, Dufouil C, Alpérovitch A, Hanon O. Feasibility of Home Blood Pressure Measurement in Elderly Individuals: Cross-Sectional Analysis of a Population-Based Sample. Am J Hypertens. 2012;25(12):1279-85. doi: 10.1038/ajh.2012.121.
- 161. Yue J, Yang X, Wang B, Hu H, Fu H, Gao Y, et al. Home Blood Pressure Telemonitoring for Improving Blood Pressure Control in Middle-Aged and Elderly Patients with Hypertension. J Clin Hypertens. 2021;23(9):1744-51. doi: 10.1111/jch.14341.
- 162. Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes Mellitus, Fasting Blood Glucose Concentration,

and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. Lancet. 2010;375(9733):2215-22. doi: 10.1016/ S0140-6736(10)60484-9.

- 163. Harris MI. Racial and Ethnic Differences in Health Care Access and Health Outcomes for Adults with Type 2 Diabetes. Diabetes Care. 2001;24(3):454-9. doi: 10.2337/diacare.24.3.454.
- 164. Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O. Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients. Diabetes Care. 2002;25(12):2218-23. doi: 10.2337/ diacare.25.12.2218.
- 165. Georgianos PI, Agarwal R. Hypertension in Chronic Kidney Disease (CKD): Diagnosis, Classification, and Therapeutic Targets. Am J Hypertens. 2021;34(4):318-26. doi: 10.1093/ajh/hpaa209.
- 166. Parati G, Ochoa JE, Bilo G. White Coat and Masked Hypertension in Chronic Kidney Disease: Importance of the Difference between Office and Out-of-Office Blood Pressure Measurements. J Am Heart Assoc. 2019;8(9):e012299. doi: 10.1161/JAHA.119.012299.
- 167.Ku E, Hsu RK, Tuot DS, Bae SR, Lipkowitz MS, Smogorzewski MJ, et al. Magnitude of the Difference between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients with Chronic Kidney Disease. J Am Heart Assoc. 2019;8(9):e011013. doi: 10.1161/ JAHA.118.011013.
- 168.Stergiou GS, Kyriakoulis KG, Bountzona I, Menti A, Destounis A, Kalogeropoulos P, et al. Automated Blood Pressure Measurement in Atrial Fibrillation: Validation Process Modification and Evaluation of a Novel Professional Device which Detects Atrial Fibrillation and Adapts its Blood Pressure Measurement Algorithm. J Hypertens. 2021;39(4):614-20. doi: 10.1097/HJH.00000000002684.
- 169. Sarafidis PA, Persu A, Agarwal R, Burnier M, Leeuw P, Ferro CJ, et al. Hypertension in Dialysis Patients: A Consensus Document by the European Renal and Cardiovascular Medicine (EURECA-m) Working Group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney Working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32(4):620-40. doi: 10.1093/ndt/gfw433.
- 170. Obara T, Ohkubo T, Funahashi J, Kikuya M, Asayama K, Metoki H, et al. Isolated Uncontrolled Hypertension at Home and in the Office among Treated Hypertensive Patients from the J-HOME Study. J Hypertens. 2005;23(9):1653-60. doi: 10.1097/01.hjh.0000178334.33352.56.
- 171. Lurbe E, Invitti C, Torro I, Maronati A, Aguilar F, Sartorio A, et al. The Impact of the Degree of Obesity on the Discrepancies between Office and Ambulatory Blood Pressure Values in Youth. J Hypertens. 2006;24(8):1557-64. doi: 10.1097/01.hjh.0000239291.32883.e3.
- 172. Halm MA. Arm Circumference, Shape, and Length: How Interplaying Variables affect Blood Pressure Measurement in Obese Persons. Am J Crit Care. 2014;23(2):166-70. doi: 10.4037/ajcc2014364.
- 173.Stergiou GS, Kyriakoulis KG, Stambolliu E, Destounis A, Karpettas N, Kalogeropoulos P, et al. Blood Pressure Measurement in Atrial Fibrillation: Review and Meta-Analysis of Evidence on Accuracy and Clinical Relevance. J Hypertens. 2019;37(12):2430-41. doi: 10.1097/HJH.00000000002201.
- 174. Verberk WJ, Omboni S, Kollias A, Stergiou GS. Screening for Atrial Fibrillation with Automated Blood Pressure Measurement: Research Evidence and Practice Recommendations. Int J Cardiol. 2016;203:465-73. doi: 10.1016/j. ijcard.2015.10.182.
- 175. Park SH, Choi YK. Measurement Reliability of Automated Oscillometric Blood Pressure Monitor in the Elderly with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Blood Press Monit. 2020;25(1):2-12. doi: 10.1097/MBP.00000000000414.
- 176. Billups SJ, Moore LR, Olson KL, Magid DJ. Cost-Effectiveness Evaluation of a Home Blood Pressure Monitoring Program. Am J Manag Care. 2014;20(9):e380-7.

- 177. Arrieta A, Woods JR, Qiao N, Jay SJ. Cost-Benefit Analysis of Home Blood Pressure Monitoring in Hypertension Diagnosis and Treatment: An Insurer Perspective. Hypertension. 2014;64(4):891-6. doi: 10.1161/ HYPERTENSIONAHA.114.03780.
- 178.Krakoff LR. Cost-Effectiveness of Ambulatory Blood Pressure: A Reanalysis. Hypertension. 2006;47(1):29-34. doi: 10.1161/01. HYP.0000197195.84725.66.
- 179. Stergiou GS, Mukkamala R, Avolio A, Kyriakoulis KG, Mieke S, Murray A, et al. Cuffless Blood Pressure Measuring Devices: Review and Statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2022;40(8):1449-60. doi: 10.1097/HJH.00000000003224.
- 180. Kario K, Kanegae H, Tomitani N, Okawara Y, Fujiwara T, Yano Y, et al. Nighttime Blood Pressure Measured by Home Blood Pressure Monitoring as an Independent Predictor of Cardiovascular Events in General Practice. Hypertension. 2019;73(6):1240-8. doi: 10.1161/ HYPERTENSIONAHA.118.12740.
- 181. Mendes ABB, Giollo LT Jr, Andrade DO, Gregório ML, Yugar-Toledo JC, Vilela-Martin JF. How to Investigate the Vascular Changes in Resistant Hypertension. Curr Hypertens Rev. 2016;12(2):139-47. doi: 10.2174/157 3402111666150812143349.
- 182. Torjesen AA, Wang N, Larson MG, Hamburg NM, Vita JA, Levy D, et al. Forward and Backward Wave Morphology and Central Pressure Augmentation in Men and Women in the Framingham Heart Study. Hypertension. 2014;64(2):259-65. doi: 10.1161/HYPERTENSIONAHA.114.03371.
- 183. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, et al. Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness: A Scientific Statement From the American Heart Association. Hypertension. 2015;66(3):698-722. doi: 10.1161/HYP.00000000000033.
- 184. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis. Lancet. 2016;387(10022):957-67. doi: 10.1016/S0140-6736(15)01225-8.
- 185. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation. 1998;97(18):1837-47. doi: 10.1161/01.cir.97.18.1837.
- 186. Yugar-Toledo JC, Buonalumi L, Yugar T, Helena L, Tácito B, Vilela-Martin JF. Disfunção Endotelial e Hipertensão Arterial Endothelium Dysfunction and Arterial Hypertension. Rev Bras Hipertens. 2015;22(3):84-92.
- 187.Bortolotto LA. Papel da Rigidez Arterial no Risco Cardiovascular do Hipertenso. Medicina. 2007;14(1):46-7.
- 188. Persu A, Plaen JF. Recent Insights in the Development of Organ Damage Caused by Hypertension. Acta Cardiol. 2004;59(4):369-81. doi: 10.2143/ AC.59.4.2005202.
- 189.Safar ME, Asmar R, Benetos A, Blacher J, Boutouyrie P, Lacolley P, et al. Interaction between Hypertension and Arterial Stiffness. Hypertension. 2018;72(4):796-805. doi: 10.1161/HYPERTENSIONAHA.118.11212.
- 190.Mendes-Pinto D, Rodrigues-Machado MDG. Applications of Arterial Stiffness Markers in Peripheral Arterial Disease. J Vasc Bras. 2019;18:e20180093. doi: 10.1590/1677-5449.009318.
- 191. Fan X, Zhu M, Chi C, Yu S, Xiong J, Lu Y, et al. Association of Arteriosclerosis and/or Atherosclerosis with Hypertensive Target Organ Damage in the Community-Dwelling Elderly Chinese: The Northern Shanghai Study. Clin Interv Aging. 2017;12:929-936. doi: 10.2147/CIA.S133691.
- 192.Laurent S, Boutouyrie P, Lacolley P. Structural and Genetic Bases of Arterial Stiffness. Hypertension. 2005;45(6):1050-5. doi: 10.1161/01. HYP.0000164580.39991.3d.
- 193. O'Rourke M. Arterial Stiffness, Systolic Blood Pressure, and Logical Treatment of Arterial Hypertension. Hypertension. 1990;15(4):339-47. doi: 10.1161/01.hyp.15.4.339.

- 194. Mikael LR, Paiva AMG, Gomes MM, Sousa ALL, Jardim PCBV, Vitorino PVO, et al. Vascular Aging and Arterial Stiffness. Arq Bras Cardiol. 2017;109(3):253-8. doi: 10.5935/abc.20170091.
- 195. van Sloten TT, Schram MT, van den Hurk K, Dekker JM, Nijpels G, Henry RM, et al. Local Stiffness of the Carotid and Femoral Artery is Associated with Incident Cardiovascular Events and All-Cause Mortality: The Hoorn Study. J Am Coll Cardiol. 2014;63(17):1739-47. doi: 10.1016/j.jacc.2013.12.041.
- 196. Laurent S, Marais L, Boutouyrie P. The Noninvasive Assessment of Vascular Aging. Can J Cardiol. 2016;32(5):669-79. doi: 10.1016/j.cjca.2016.01.039.
- 197. van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert Consensus Document on the Measurement of Aortic Stiffness in Daily Practice Using Carotid-Femoral Pulse Wave Velocity. J Hypertens. 2012;30(3):445-8. doi: 10.1097/HJH.0b013e32834fa8b0.
- 198. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The Influence of Heart Rate on Augmentation Index and Central Arterial Pressure in Humans. J Physiol. 2000;525(Pt 1):263-70. doi: 10.1111/j.1469-7793.2000.t01-1-00263.x.
- 199. Laurent S, Cockcroft J, van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert Consensus Document on Arterial Stiffness: Methodological Issues and Clinical Applications. Eur Heart J. 2006;27(21):2588-605. doi: 10.1093/eurhearti/ehl254.
- 200. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness. Arterioscler Thromb Vasc Biol. 2005;25(5):932-43. doi: 10.1161/01.ATV.0000160548.78317.29.
- 201. Gajdova J, Karasek D, Goldmannova D, Krystynik O, Schovanek J, Vaverkova H, et al. Pulse Wave Analysis and Diabetes Mellitus. A Systematic Review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161(3):223-33. doi: 10.5507/bp.2017.028.
- 202. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic Stiffness is an Independent Predictor of All-Cause and Cardiovascular Mortality in Hypertensive Patients. Hypertension. 2001;37(5):1236-41. doi: 10.1161/01.hyp.37.5.1236.
- 203. Nunan D, Wassertheurer S, Lasserson D, Hametner B, Fleming S, Ward A, et al. Assessment of Central Haemomodynamics from a Brachial Cuff in a Community Setting. BMC Cardiovasc Disord. 2012;12:48. doi: 10.1186/1471-2261-12-48.
- 204.Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, Hamburg NM, et al. Arterial Stiffness and Cardiovascular Events: The Framingham Heart Study. Circulation. 2010;121(4):505-11. doi: 10.1161/ CIRCULATIONAHA.109.886655.
- 205. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of Cardiovascular Events and All-Cause Mortality with Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2010;55(13):1318-27. doi: 10.1016/j. jacc.2009.10.061.
- 206. Dorobantu M, Mancia G, Grassi G. Hypertension and Heart Failure. New York: Springer; 2019.
- 207. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction: An Individual Participant Meta-Analysis of Prospective Observational Data from 17,635 Subjects. J Am Coll Cardiol. 2014;63(7):636-46. doi: 10.1016/j. jacc.2013.09.063.
- 208. Chirinos JA, Segers P, Hughes T, Townsend R. Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(9):1237-63. doi: 10.1016/j.jacc.2019.07.012.
- 209. Hashimoto J, Watabe D, Hatanaka R, Hanasawa T, Metoki H, Asayama K, et al. Enhanced Radial Late Systolic Pressure Augmentation in Hypertensive Patients with Left Ventricular Hypertrophy. Am J Hypertens. 2006;19(1):27-32. doi: 10.1016/j.amjhyper.2005.06.017.
- 210. Sibiya MJ, Norton GR, Hodson B, Redelinghuys M, Maseko MJ, Majane OH, et al. Gender-Specific Contribution of Aortic Augmentation Index to Variations in Left Ventricular Mass Index in a Community Sample of African Ancestry. Hypertens Res. 2014;37(11):1021-7. doi: 10.1038/hr.2014.113.

- 211. Wilkinson IB, Mäki-Petäjä KM, Mitchell GF. Uses of Arterial Stiffness in Clinical Practice. Arterioscler Thromb Vasc Biol. 2020;40(5):1063-7. doi: 10.1161/ATVBAHA.120.313130.
- 212. Yao Y, Wang L, Hao L, Xu L, Zhou S, Liu W. The Noninvasive Measurement of Central Aortic Blood Pressure Waveform. In: Blood Pressure - From Bench to Bed [Internet]. London: InTech; 2018 [cited 2023 Aug 18]. Available from: http://www.intechopen.com/books/blood-pressure-frombench-to-bed/the-noninvasive-measurement-of-central-aortic-bloodpressure-waveform.
- 213. Salvi P, Lio G, Labat C, Ricci E, Pannier B, Benetos A. Validation of a New Non-Invasive Portable Tonometer for Determining Arterial Pressure Wave and Pulse Wave Velocity: The PulsePen device. J Hypertens. 2004;22(12):2285-93. doi: 10.1097/00004872-200412000-00010.
- 214. Paiva AMG, Mota-Gomes MA, Brandão AA, Silveira FS, Silveira MS, Okawa RTP, et al. Reference Values of Office Central Blood Pressure, Pulse Wave Velocity, and Augmentation Index Recorded by Means of the Mobil-O-Graph PWA Monitor. Hypertens Res. 2020;43(11):1239-48. doi: 10.1038/ s41440-020-0490-5.
- 215. Brandão AA, Amodeo C, Alcântara C, Barbosa E, Nobre F, Pinto F, et al. I Luso-Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017;108(2):100-8. doi: 10.5935/abc.20170011.
- 216. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. doi: 10.1161/ HYP.0000000000000055.
- 217. Omboni S, Arystan A, Benczur B. Ambulatory Monitoring of Central Arterial Pressure, Wave Reflections, and Arterial Stiffness in Patients at Cardiovascular Risk. J Hum Hypertens. 2022;36(4):352-63. doi: 10.1038/ s41371-021-00606-4.
- 218. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi: 10.1097/HJH.000000000001940.
- 219. Barroso WKS, Barbosa ECD, Mota-Gomes MA, editors. Rigidez Arterial e Hemodinâmica Central: Do Endotélio à Camada Média. São Paulo: Atha Mais Editora; 2020.
- 220. Pereira EN, Vitorino PVO, Souza WKSB, Pinheiro MC, Sousa ALL, Jardim PCBV, et al. Assessment of Central Blood Pressure and Arterial Stiffness in Practicing Long-Distance Walking Race. Int J Cardiovasc Sci. 2017;30(6):510-6. doi: 10.5935/2359-4802.20170076.
- 221.Milan A, Zocaro G, Leone D, Tosello F, Buraioli I, Schiavone D, et al. Current Assessment of Pulse Wave Velocity: Comprehensive Review of Validation Studies. J Hypertens. 2019;37(8):1547-57. doi: 10.1097/ HJH.00000000002081.
- 222. Weber T, Protogerou AD, Agharazii M, Argyris A, Bahous SA, Banegas JR, et al. Twenty-Four-Hour Central (Aortic) Systolic Blood Pressure: Reference Values and Dipping Patterns in Untreated Individuals. Hypertension. 2022;79(1):251-60. doi: 10.1161/HYPERTENSIONAHA.121.17765.
- 223. Gómez-Sánchez M, Patino-Alonso MC, Gómez-Sánchez L, Recio-Rodríguez JI, Rodríguez-Sánchez E, Maderuelo-Fernández JA, et al. Reference Values of Arterial Stiffness Parameters and Their Association with Cardiovascular Risk Factors in the Spanish Population. The EVA Study. Rev Esp Cardiol. 2020;73(1):43-52. doi: 10.1016/j.rec.2019.04.016.
- 224. Stoner L, Kucharska-Newton A, Meyer ML. Cardiometabolic Health and Carotid-Femoral Pulse Wave Velocity in Children: A Systematic Review and Meta-Regression. J Pediatr. 2020;218:98-105.e3. doi: 10.1016/j. jpeds.2019.10.065.

- 225. Aristizábal-Ocampo D, Espíndola-Fernández D, Gallo-Villegas J. Pulse Wave Velocity Reference Values in 3,160 Adults Referred to a Hypertension Clinic for 24-hour Ambulatory Blood Pressure Monitoring. Clin Exp Hypertens. 2019;41(8):759-65. doi: 10.1080/10641963.2018.1545853.
- 226. Reference Values for Arterial Stiffness' Collaboration. Determinants of Pulse Wave Velocity In Healthy People and in the Presence of Cardiovascular Risk Factors: 'Establishing Normal and Reference Values'. Eur Heart J. 2010;31(19):2338-50. doi: 10.1093/eurheartj/ehq165.
- 227. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P; Reference Values for Arterial Measurements Collaboration. Establishing Reference Values for Central Blood Pressure and its Amplification in a General Healthy Population and According to Cardiovascular Risk Factors. Eur Heart J. 2014;35(44):3122-33. doi: 10.1093/eurheartj/ehu293.
- 228. Williams B, Brunel P, Lacy PS, Baschiera F, Zappe DH, Kario K, et al. Application of Non-Invasive Central Aortic Pressure Assessment in Clinical Trials: Clinical Experience and Value. Artery Res. 2017;17:1-15. doi: 10.1016/j.artres.2016.10.154.
- 229. Roman MJ, Devereux RB, Kizer JR, Okin PM, Lee ET, Wang W, et al. High Central Pulse Pressure is Independently Associated with Adverse Cardiovascular Outcome the Strong Heart Study. J Am Coll Cardiol. 2009;54(18):1730-4. doi: 10.1016/j.jacc.2009.05.070.
- 230. Chirinos JA, Kips JG, Jacobs DR Jr, Brumback L, Duprez DA, Kronmal R, et al. Arterial Wave Reflections and Incident Cardiovascular Events and Heart Failure: MESA (Multiethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012;60(21):2170-7. doi: 10.1016/j.jacc.2012.07.054.
- 231. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of Cardiovascular Events and All-Cause Mortality with Central Haemodynamics: A Systematic Review and Meta-Analysis. Eur Heart J. 2010;31(15):1865-71. doi: 10.1093/eurheartj/ehq024.
- 232. Jankowski P, Bednarek A, Olszanecka A, Windak A, Kawecka-Jaszcz K, Czarnecka D. Twenty-four-Hour Profile of Central Blood Pressure and Central-to-Peripheral Systolic Pressure Amplification. Am J Hypertens. 2013;26(1):27-33. doi: 10.1093/ajh/hps030.
- 233. Wassertheurer S, Baumann M. Assessment of Systolic Aortic Pressure and its Association to All Cause Mortality Critically Depends on Waveform Calibration. J Hypertens. 2015;33(9):1884-8. doi: 10.1097/ HJH.000000000000633.
- 234. London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial Wave Reflections and Survival in End-Stage Renal Failure. Hypertension. 2001;38(3):434-8. doi: 10.1161/01.hyp.38.3.434.
- 235. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial. Lancet. 2005;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1.
- 236. Greve AM, Olsen MH, Bella JN, Lønnebakken MT, Gerdts E, Okin PM, et al. Contrasting Hemodynamic Mechanisms of Losartan- vs. Atenolol-Based Antihypertensive Treatment: A LIFE Study. Am J Hypertens. 2012;25(9):1017-23. doi: 10.1038/ajh.2012.81.
- 237. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of Selective Systolic Blood Pressure Reduction after a Low-Dose Combination of Perindopril/Indapamide in Hypertensive Subjects: Comparison with Atenolol. J Am Coll Cardiol. 2004;43(1):92-9. doi: 10.1016/j.jacc.2003.07.039.
- 238.Xaplanteris P, Vlachopoulos C, Protogerou AD, Aznaouridis K, Terentes-Printzios D, Argyris AA, et al. A Clinical Score for Prediction of Elevated Aortic Stiffness: Derivation and Validation in 3943 Hypertensive Patients. J Hypertens. 2019;37(2):339-46. doi: 10.1097/ HJH.000000000001904.
- 239. Oliveira AC, Barroso WKS Vitorino PVO, Sousa ALL, Fagundes RR, Deus GD, et al. A SAGE Score Cutoff that predicts High-Pulse Wave Velocity as

Measured by Oscillometric Devices in Brazilian Hypertensive Patients. Hypertens Res. 2022;45(2):315-23. doi: 10.1038/s41440-021-00793-0.

- 240. Wassertheurer S, Protogerou A, Sharman J, Sala ER, Jankowski P, Muiesan ML, et al. P34 24-hour Ambulatory Brachial Versus Aortic Systolic Blood Pressure: Relationship with Left Ventricular Mass Significantly Differs. Pooled Results from the International 24 Hour Aortic Blood Pressure Consortium (i24ABC). Artery Res. 2020;25(Supplement 1):S75. doi: 10.2991/artres.k.191224.066.
- 241. Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al. The Role of Vascular Biomarkers for Primary and Secondary Prevention. A position Paper from the European Society of Cardiology Working Group on Peripheral Circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015;241(2):507-32. doi: 10.1016/j. atherosclerosis.2015.05.007.
- 242. Koivistoinen T, Lyytikäinen LP, Aatola H, Luukkaala T, Juonala M, Viikari J, et al. Pulse Wave Velocity Predicts the Progression of Blood Pressure and Development of Hypertension in Young Adults. Hypertension. 2018;71(3):451-6. doi: 10.1161/HYPERTENSIONAHA.117.10368.
- 243. Boutouyrie P, Chowienczyk P, Humphrey JD, Mitchell GF. Arterial Stiffness and Cardiovascular Risk in Hypertension. Circ Res. 2021;128(7):864-86. doi: 10.1161/CIRCRESAHA.121.318061.
- 244. Climie RE, van Sloten TT, Bruno RM, Taddei S, Empana JP, Stehouwer CDA, et al. Macrovasculature and Microvasculature at the Crossroads Between Type 2 Diabetes Mellitus and Hypertension. Hypertension. 2019;73(6):1138-49. doi: 10.1161/HYPERTENSIONAHA.118.11769.
- 245. Briet M, Collin C, Karras A, Laurent S, Bozec E, Jacquot C, et al. Arterial Remodeling Associates with CKD Progression. J Am Soc Nephrol. 2011;22(5):967-74. doi: 10.1681/ASN.2010080863.

- 246. Bruno RM, Nilsson P, Ensgrtom G, Wadstrom B, Empana J-P, Boutouyrie P, et al. 1.2 Chronological versus Vascular Age: Predictive Value for Cardiovascular Events and Identification of Patients with SUPERNOrmal Vascular Aging (SUPERNOVA). Artery Res. 2020;25(Supplement 1):S2. doi: 10.2991/artres.k.191224.002.
- 247. Sharman JE, Laurent S. Central Blood Pressure in the Management of Hypertension: Soon Reaching the Goal? J Hum Hypertens. 2013;27(7):405-11. doi: 10.1038/jhh.2013.23.
- 248. Sharman JE, Marwick TH, Gilroy D, Otahal P, Abhayaratna WP, Stowasser M, et al. Randomized Trial of Guiding Hypertension Management Using Central Aortic Blood Pressure Compared with Best-Practice Care: Principal Findings of the BP GUIDE Study. Hypertension. 2013;62(6):1138-45. doi: 10.1161/HYPERTENSIONAHA.113.02001.
- 249. Kosmala W, Marwick TH, Stanton T, Abhayaratna WP, Stowasser M, Sharman JE. Guiding Hypertension Management Using Central Blood Pressure: Effect of Medication Withdrawal on Left Ventricular Function. Am J Hypertens. 2016;29(3):319-25. doi: 10.1093/ajh/hpv108.
- 250. Sharma RK, Verma M, Tiwari RM, Joshi A, Trivedi CA, Chodankar DR. Prevalence and Real-World Assessment of Central Aortic Blood Pressure in Adult Patients with Essential Hypertension Uncontrolled on Single Anti-Hypertensive Agents. Indian Heart J. 2018;70(Suppl 3):S213-S220. doi: 10.1016/j.ihj.2018.11.013.
- 251. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006;113(9):1213-25. doi: 10.1161/CIRCULATIONAHA.105.595496.